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Histone deacetylase inhibitors (HDIs) are a group of chemo-preventive and 
chemo-therapeutic agents that have generated significant attention in clinical trials, 
given their ability to selectively induce cell cycle arrest, differentiation and/or apoptosis 
of tumor cells. Presently, these agents are proposed to function by altering gene 
expression levels, primarily by promoting histone hyperacetylation and gene 
transcription. However, in this thesis, HDIs are reported to control the expression of 
genes from the c-Src kinase family and p21WAF1 by means other than transcriptional 
activation.  
Overexpression and activation of c-Src, a 60kDa non-receptor tyrosine kinase, 
has been implicated in the development, growth, progression, and metastasis of several 
human cancers, especially those of the colon.  Butyrate and the more specific histone 
deacetylase inhibitor trichostatin A (TSA) were both found to effectively inhibit the 
expression of c-Src mRNA and protein in a number of tumor cell lines, including those 
of the colon, liver and breast. Expression of the SRC oncogene is alternatively regulated 
by the SRC1A and SRC1α promoters. HDIs were shown to repress c-Src expression by 
inhibiting transcription of both of these promoters, independent of any new protein 
synthesis. Furthermore, butyrate and TSA similarly regulated the expression of the c-
Src family kinase (SFK) members Yes, Fyn, Lyn and Lck in human colon cancer cell 
lines. In addition, TATA binding protein (TBP) associated factor 1 (TAF1) was shown 
to be necessary for basal transcription of the SRC1A, YES and LYN promoters, but was 
not required for HDI mediated repression.  
   Induction of the potent cyclin dependent kinase inhibitor p21WAF1 has been 
identified to be a key feature of HDI mediated cell cycle arrest. The level of p21WAF1 
expression has been extensively reported to be directly upregulated by HDIs in a p53 
independent manner that requires Sp family binding sites in the p21WAF1 proximal 
promoter to induce transcription. However, HDIs were shown to be capable of inducing 
p21WAF1 gene expression, dependent on new protein synthesis, by increasing mRNA 
stability. To date, p21WAF1 mRNA stability has been extensively studied and a 
number of cis-acting elements in the 3’ untranslated region (UTR) of the p21WAF1 
mRNA have been implicated in the regulation of mRNA stability, such as AU rich 
 iii
elements (AREs) and a 42 nucleotide HuD/Elav binding element. Similarly, in this 
work, two novel cis-acting elements were identified in the 3’ UTR of p21WAF1 and 
were shown to facilitate basal and HDI induced post-transcriptional regulation of 
p21WAF1 mRNA stability in HepG2 cells. Collectively, these studies highlight the 
intricacy of HDI mediated effects and challenge the preconceptions regarding the 
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1. REVIEW OF THE LITERATURE 
1.1. Introduction  
 Histone deacetylase inhibitors (HDIs) are exciting chemotherapeutic agents that 
have recently gained acceptance for clinical use, due to their ability to promote cell 
cycle arrest, differentiation and/or apoptosis. However, the mechanisms by which HDIs 
exhibit these effects are poorly understood. A large fraction of the literature has focused 
on the model that HDIs inhibit histone deacetylase enzymes and therefore shift the 
steady state balance toward elevated histone acetylation levels. This is proposed to 
relieve the compacted state of the DNA backbone, thereby enhancing transcription 
factor accessibility and promoting gene transcription. However, HDIs also repress a 
significant percentage of genes, suggesting that additional mechanisms must be 
responsible for this phenomena. There is increasing evidence that HDIs do, in fact, 
display supplementary functions beyond influencing histone acetylation and 
upregulating gene expression. Novel extensions of HDI regulatory events concerning 
the c-Src proto-oncogene and cyclin dependent kinase inhibitor p21WAF1 are presented 
in this thesis. c-Src is overexpressed and/or activated in a number of human 
malignancies and downregulation of c-Src expression levels have been hypothesized to 
decrease tumor cell growth. p21WAF1 is upregulated in a p53 dependent and p53 
independent manner to induce cell cycle arrest. The effects that HDIs impose on gene 
expression of the c-Src and p21WAF1 genes have been investigated at the 
transcriptional and post-transcriptional levels, respectively. The literature review will 
provide current knowledge related to chromatin structure, histone modifying enzymes 
and histone deacetylase inhibitors. In addition, a review of transcriptional and post-
transcriptional regulation will be touched upon. Finally, background will be presented 
on c-Src and p21WAF1.   
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1.2. Chromatin Structure and Remodeling  
1.2.1. Chromatin Structure  
Long double helix DNA molecules are efficiently packaged within a eukaryotic 
nucleus into distinct chromosome structures by increasing levels of DNA condensation. 
The nucleosome core particle is the primary unit of chromatin structural organization, 
consisting of 147 base pairs of DNA wrapped in 1.67 left-handed superhelical turns 
around a core histone octamer. The histone octamer is made up of two copies of each 
histone protein; H2A, H2B, H3 and H4 (Woodcock and Dimitrov, 2001 and Richmond 
and Davey, 2003). Two pairs of each of the histone dimers, H3-H4 and H2A-H2B, 
interact to form the histone core octamer (Eickbush and Moudrianakis, 1978 and 
Benbow, 1992). The octamer is assembled first by the association of two H3-H4 dimers, 
forming a H3-H4 tetramer bound to the center of the DNA, and secondly by the 
interaction of each H2A-H2B dimer with the tetramer, via associations between H2B 
and H4 (Luger et al., 1997). Each of these core histone proteins contains a structured 
globular domain that mediates histone - histone and histone - DNA interactions, and an 
unstructured amino-terminal domain or tail which emanates from the surface and serves 
as a substrate for histone modifying enzymes to introduce post-translational 
modifications such as acetylation, methylation, phosphorylation, ubiquitylation and 
sumoylation (Luger, 2006 and Cosgrove and Wolberger, 2005). 
 Chromatin is compacted into a higher order structure, known as the secondary 
or 30 nm structure, by repetitive folding of adjacent nucleosomes (Benbow, 1992). 
Condensation is primarily mediated by the linker histone, H1, which resides in a 1:1 
ratio with the histone core octamer and associates within 10-90 base pairs of linker 
DNA beyond the core nucleosome particle (Woodcock and Dimitrov, 2001; Adkins et 
al., 2004 and Richmond and Davey, 2003). As well, an unmodified region of the H4 N-
terminal tail, between amino acids 14-19, plays a pivotal role in assembling the 30 nm 
chromatin fiber, likely via its interaction with the H2A acidic patch of adjacent 
nucleosomes (Dorigo et al., 2003 and Luger and Hansen, 2005). More specifically, H4 
lysine (K) residue 16 has recently been implicated in chromatin compaction, as 
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acetylation of H4 K16 inhibits assembly of the 30 nm chromatin fiber (Shogen-Knaak et 
al., 2006 and Robinson and Rhodes, 2006).  
Further chromatin condensation into thick fibrous mitotic chromosomes or 
tertiary chromatin structures occurs by poorly defined long-range chromatin fiber 
interactions with chromatin associated proteins bound to nucleosomes (Woodcock and 
Dimitrov, 2001; Adkins et al., 2004; Luger and Hansen, 2005 and McBryant et al., 
2006). An example of this includes the association of human Methyl-CpG binding 
protein 2 (MeCP2) with unmethylated nucleosomal arrays, which guides chromatin 
condensation and generates a novel tertiary chromatin structure observed as oligomers 
of ellipsoidal particles (Georgel et al., 2003 and McBryant et al., 2006). Drosophila 
heterochromatin-associated protein 1 (HP1) and the polycomb group protein complex 
(PGC) represent additional examples of chromatin associated proteins involved in 
tertiary chromatin structure formation (Woodcock, 2006 and McBryant et al., 2006). 
While three distinct levels of chromatin structure organization have been 
outlined above, in reality the scale of chromatin condensation is rather dynamic and 
structurally heterogeneous, allowing numerous nuclear events such as transcription, 
repair, replication and recombination to occur (Luger, 2006). Even so, two principal 
forms of chromatin, heterochromatin and euchromatin, have been denoted at opposite 
ends of the spectrum. Heterochromatin is representative of a compact or inaccessible 
chromatin structure inherent to transcriptionally inactive regions of DNA and is present 
at the chromosome centromere and telomeric regions (Cosgrove and Wolberger, 2005). 
Euchromatin, on the other hand, is typical of uncondensed chromatin lacking histone 
H1, is amenable to gene activation and exists in gene rich environments (Benbow, 
1992). ATP-dependent chromatin remodeling complexes and histone modifying 
enzymes are two of the factors known to modulate the structure of chromatin, which 
will be discussed in further detail. 
 
1.2.2. ATP-Dependent Chromatin Remodeling Factors 
 Chromatin remodeling enzymes are part of large multi-subunit protein 
complexes that utilize the energy derived from ATP hydrolysis to mobilize 
nucleosomes, thereby altering the accessibility of binding proteins to DNA target sites 
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(Cosgrove et al., 2004). As a result, these factors play a role in regulating transcription. 
The best characterized ATPase subunits of these chromatin remodeling complexes 
belong to the Switch 2 (SWI2) and Imitation switch (ISWI) families (Eberharter and 
Becker, 2004). The SWI2 is the remodeling ATPase subunit of the yeast 
Switch/Sucrose non-fermenting (SWI/SNF) complex, and can be structurally described 
by a conserved ATPase and C-terminal bromodomain capable of binding acetylated 
lysine residues (Eberharter and Becker, 2004 and Saha et al., 2006). Human 
homologues of the SWI2 family include Brahma-related gene 1 (BRG1) and the human 
Brahma (hBRM) ATPase subunits (Lusser and Kadonaga, 2003). The ISWI–based 
chromatin remodeling complexes include the human chromatin-accessibility factor 
(hCHRAC) and human ATP-utilizing chromatin assembly and remodeling factor 
(hACF) complexes, which both contain the ISWI ATPase subunit Sucrose non 
fermenting 2 homologue (SNF2h) (Corona and Tamkun, 2004). Furthermore, the ISWI 
family is characterized by an ATPase domain and two additional domains termed 
SANT and SLIDE that may be important for nucleosome and DNA binding, 
respectively (Corona and Tamkun, 2004 and Saha et al., 2006). Interestingly, SWI2 and 
ISWI-containing complexes appear to regulate transcription in different ways. The 
SWI2–supported chromatin remodeling complexes generally disorder and reorganize 
nucleosomes to generate a transcriptionally accessible and competent DNA template. In 
contrast, ISWI–based complexes typically organize nucleosomes into precisely spaced, 
ordered arrays to promote transcriptional repression (Johnson et al., 2005 and Saha et 
al., 2006).  
The mechanisms responsible for ATP-dependent chromatin remodeling factors 
disrupting and re-establishing the interactions between the core histone and DNA 
backbone to facilitate nucleosome rearrangement or nucleosome ‘sliding’ are not well 
understood. However, numerous theories have been proposed including those of the 
‘twist diffusion’ and ‘bulge diffusion’ models (Flaus and Owen-Hughes, 2004 and 
Langst and Becker, 2004). The ‘twist diffusion’ model hypothesizes that DNA twisted 
at the edge nucleosome is transmitted around the histone octamer, ultimately creating 
new histone - DNA contacts and changing the position of the nucleosome (Langst and 
Becker, 2004).  The ‘bulge diffusion’ model proposes that DNA - histone contacts are 
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broken at the edge of the nucleosome and new contacts are made with outlying DNA 
sequences, creating a DNA bulge that is propagated around the nucleosome, thus 
causing nucleosome movement (Flaus and Owen-Hughes, 2004). Of further interest, in 
Saccharomyces cerevisiae, chromatin remodeling complexes have also been 
documented to catalyze histone H2A-H2B dimer removal or the exchange of H2A-H2B 
canonical histone dimers for histone H2A.Z-H2B variants, in an ATP-dependent 
manner (Bruno et al., 2003; Flaus and Owen-Hughes, 2004; Kobor et al., 2004; 
Mizuguchi et al., 2004 and Varga-Weisz and Becker, 2006). Therefore, ATP-dependent 
chromatin remodeling complexes may not only moderate chromatin structure by 
causing the effect of nucleosome relocation, but may also influence the composition of 
nucleosome histones during gene regulation (Jin et al., 2005).   
 
1.2.3. Histone Modifying Enzymes 
Histone modifications, in addition to DNA methylation contributes to 
“epigenetic regulation”. This refers to a heritable range of gene regulation controlled by 
modifications not inherently encoded in the genetic information derived from DNA 
(Santos-Rosa and Caldas, 2005; Lin et al., 2006 and Shilatifard, 2006). Histone 
modifiers encompass a broad category of enzymes responsible for introducing post-
translational covalent modifications onto histone proteins. Currently, about 150 
different modifications have been identified on specific histone residues with the 
majority of modifications instituted on the amino terminal tails, while fewer are located 
on the histone globular domains (Cosgrove and Wolberger, 2005). Histone 
modifications include: acetylation of lysine residues, methylation of lysines and 
arginines (R), phosphorylation of serine (S) and threonine (T) residues, ubiquitylation 
as well as sumoylation of lysines (Zhang and Dent, 2005 and Luger, 2006). Histone 
modifying enzymes that catalyze the accumulation of chromatin post-translational 
modifications on the amino-terminal tails of histones have been theorized to lay down a 
code, referred to as the “histone code”, which may be deciphered by chromatin-
associated proteins that recognize the pattern of modifications, and ultimately carry out 
changes in chromatin organization and gene regulation (Jenuwein and Allis, 2001 and 
Kouzarides, 2002). Therefore, histone modifications modulate chromatin organization 
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and regulate many nuclear processes, including transcription (Zhang and Dent, 2005 
and Santos-Rosa and Caldas, 2005). In the following section different histone modifiers 
will be discussed, with particular emphasis on this histone acetyltransferase (HAT) and 
histone deacetylase (HDAC) enzymes.  
1.2.3.1. Histone Acetyltransferases 
Histone acetyltransferase (HAT) enzyme activity has long been hypothesized to 
disrupt the electrostatic interactions between the negatively charged phosphodiester 
DNA backbone and the positively charged amino-terminal histone tails; when an acetyl 
group from acetyl coenzyme A is transferred to the epsilon nitrogen atom of the lysine 
residues the positive charge is neutralized (Allfrey et al., 1964). The theory follows that 
consequent weakening of histone - DNA electrostatic interactions leads to a more 
relaxed chromatin structure that is open to transcription factor target site binding. In 
addition, as observed upon histone H4 K16 acetylation, histone acetylation inhibits 
nucleosome – nucleosome interactions, thereby strengthening the role of HATs as 
transcriptional activators (Shogen-Knaak et al., 2006). HATs also have a supplementary 
function in transcription, as acetylated histone lysine residues may be involved in the 
recruitment of bromodomain-containing co-activator proteins (Zeng and Zhou, 2002). 
Furthermore, several HATs have been identified as components of large functional 
multi-protein complexes that can associate with combinations of transcriptional adaptor 
proteins, TATA binding protein (TBP)-associated factors (TAFs) and other HATs. Such 
associations further illuminate the role of HATs as transcriptional co-activators (Berger, 
1999). 
HATs can be divided into two separate classes that differ in origin and function. 
While A-type HATs are nuclear in origin and are involved in generating chromatin-
based histone modifications, the B-type HATs are cytoplasmic and responsible for 
chromatin assembly (Roth et al., 2001). To date several A-type HATs have been well 
characterized, including those from the Gcn5-related N-acetyltransferase (GNAT) and 
MYST families. p55 was the first A-type HAT discovered in Tetrahymena thermophila 
(Brownell et al., 1996). Due to high sequence similarity, this led to the identification of 
a previously classified yeast transcriptional co-activator, general control 
nonderepressible-5 (Gcn5), as a HAT (Brownell et al., 1996 and Kuo and Allis, 1998). 
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Gcn5 serves as the archetype for the GNAT family, which has been expanded to include 
two human HATs: hGCN5 and p300 CREB-binding protein-associated factor (PCAF). 
These proteins are categorized by a carboxy terminal bromodomain, a HAT domain, 
and an N-terminal region responsible for nucleosome recognition (Sterner and Berger, 
2000). Another family of HATs, known as the MYST family, is named after its 
members: MOZ (monocytic leukemia zinc finger protein), Ybf2/Sas3 (something about 
silencing 3, also named Ybf2), Sas2 (something about silencing 2) and Tip60 (Tat-
interactive protein 60kDa). Tip60, MOZ, MOZ-related factor (MORF) and histone 
acetyltransferase bound to origin recognition complex (HBO1) are four members of the 
MYST family that display HAT activity in humans (Sterner and Berger, 2000, 
Champagne et al., 2001 and Roth et al., 2001). In addition to the GNAT and MYST 
family members, other proteins have also been found to possess HAT activity in 
humans, including p300, its highly related homologue CREB binding protein (CBP), 
basal transcription factor TAF1, and several nuclear receptor co-activators (Kuo and 
Allis, 1998 and Sterner and Berger, 2000). Of particular note among these nuclear co-
activators is steroid receptor co-activator-1, activator of retinoid receptors and 
transcriptional intermediary factor 2 (Kuo and Allis, 1998 and Sterner and Berger, 
2000).  
Interestingly, while histones were the first elucidated targets of HATs, a number 
of non-histone proteins have been uncovered as HAT substrates. Aptly, the term 
‘acetylome’ has recently been coined, cataloging all histone acetyltransferase targets 
(Minucci and Pelicci, 2006). The transcription factor p53 was the first non-histone 
protein to be identified as a HAT substrate (Gu and Roeder, 1997). Acetylation of the 
p53 carboxy (C)-terminal DNA binding domain by p300/CBP results in activation of 
p53 sequence specific DNA binding ability, thereby promoting transcription (Gu and 
Roeder, 1997). Acetylation also enhances p53 protein stability by competing with 
MDM2 (mouse double minutes 2) ubiquitylation of lysine residues and proteasomal 
degradation (Gu and Roeder, 1997; Bode and Dong, 2004 and Glozak et al., 2005). 
GATA-1, E2F and yin yang 1 are other examples of transcription factors whose DNA 
binding affinities are regulated by p300/CBP and/or PCAF acetylation (Boyes et al., 
1998; Kouzarides, 2000; Martinez-Balbas et al., 2000; Yao et al., 2001; Glozak et al., 
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2005 and Minucci and Pelicci, 2006). Beyond affecting DNA binding and protein 
stability, HAT facilitated acetylation of non-histone proteins has also been documented 
to influence protein-protein interactions, protein dimerization and protein localization 
(Minucci and Pelicci, 2006 and Lin et al., 2006). For example, PCAF and CBP 
acetylation of Ku70 disrupts the interaction with Ku70 and the pro-apoptotic protein 
Bcl2-associated X protein (Bax), allowing Bax translocation to the mitochondria for 
cytochrome c release and apoptosis (Cohen et al., 2004). Also, p300 mediated 
acetylation of signal transducer and activator of transcription 3 (STAT3) prompts 
STAT3 dimerization and subsequent nuclear translocation for DNA binding (Yuan et 
al., 2005 and Minucci and Pelicci, 2006). Cumulatively, these findings indicate that 
HATs acetylate many targets beyond exclusively histones and therefore also regulate 
many processes beyond that of chromatin organization.   
1.2.3.2. Histone Deacetylases 
In opposition to HAT activity, histone deacetylase (HDAC) enzymes are also 
involved in gene regulation by catalyzing the removal of acetyl moieties on histone 
residues and other non-histone proteins (Glozak et al., 2005). By definition HDACs 
have been largely characterized as transcriptional co-repressors implicated in 
maintaining a compact chromatin environment inaccessible to DNA binding factors 
(Bolden et al., 2006). Therefore, it is assumed that the balance between HAT and 
HDAC activity dictates the overall histone acetylation status and, accordingly, the level 
of transcriptional competence (de Ruijter et al., 2003). Three diverse classes of HDACs, 
numbered I through III, have been defined based on homology to the yeast HDACs: 
reduced potassium dependency 3 (Rpd3), histone deacetylase 1 (Hda1) and silent 
information regulator 2 (Sir2), in that order (Sengupta and Seto, 2004). Class I and class 
II HDACs are Zn2+-dependent enzymes, which diverge significantly from the Class III 
Sir2-like HDACs that require nicotinamide adenine dinucleotide (NAD+) for their 
catalytic activity and are not inhibited by classical histone deacetylase inhibitors (HDIs) 
(Yang and Seto, 2003). Thus, only the Class I and class II HDACs will serve as the 
topic of further discussion.  
Class I HDACs include the proteins HDAC1, HDAC2, HDAC3 and HDAC8 
(Gregoretti et al., 2004). Each of these HDACs are ubiquitously expressed and are 
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characterized by an N-terminal catalytic domain and nuclear localization signal (NLS), 
which restricts them primarily to the nucleus (Bolden et al., 2006). Class I HDACs, 
analogous to class II HDACs, utilize their catalytic domain for acetyl removal through 
two histidine-asparagine charge-relay systems coordinated by a Zn2+ ion (de Ruijter et 
al., 2003; Holbert and Marmorstein, 2005 and Lin et al., 2006). However, 
unaccompanied HDAC1 and HDAC2 are rather inactive deacetylases which require the 
collaboration of a multi-protein complex to facilitate their deacetylase activity, 
recruitment and DNA binding ability (de Ruijter et al., 2003). Sin3 (switch independent 
3), NuRD (nucleosome remodeling histone deacetylase) and Co-REST (co-repressor to 
RE1 silencing transcription factor) are three such multi-subunit complexes in which 
HDAC1 interaction with HDAC2 constitutes the catalytic core (Yang and Seto, 2003). 
HDAC3 differs somewhat from the other class I HDACs in that it contains both a NLS 
and a nuclear export signal (NES), and is therefore capable of shuttling between the 
nucleus and cytoplasm (de Ruijter et al., 2003). Furthermore, HDAC3 has been 
implicated in other multi-protein complexes with the co-repressors N-CoR (nuclear 
receptor co-repressor) and SMRT (silencing mediator for retinoic acid and thyroid 
hormone receptor), as well as in combination with the class II HDACs, 4, 5 and 7 
(Gregoretti et al., 2004 and Sengupta and Seto, 2004). HDAC8 is the newest class I 
member and has yet to be isolated as part of a multi-subunit HDAC complex (Yang and 
Seto, 2003).  
Class II HDACs can be divided into two subclasses; Class IIa, which contains 
HDAC4, HDAC5, HDAC7 and HDAC9, and Class IIb, formed by HDAC6 and 
HDAC10 (Verdin et al., 2003; Gregoretti et al., 2004 and Bolden et al., 2006). Class II 
HDACs are characterized by a tissue specific expression pattern, with HDAC4, HDAC5 
and HDAC9 observed in heart, skeletal muscle and brain tissues, HDAC7 in primarily 
the heart and lung, HDAC6 in testis, and HDAC10 in the liver, spleen and kidney 
(Verdin et al., 2003). The members of the HDAC IIa class are distinguished by a single 
C-terminal catalytic domain, an NES, an NLS, and an N-terminal region comprised of 
numerous protein interaction domains (Verdin et al., 2003). Thus, these HDACs are 
capable of nucleo-cytoplasmic shuttling, and their subcellular localization is largely a 
determinant of their N-terminal mediated protein interactions (de Ruijter et al., 2003). 
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Class IIa HDACs have been discovered to interact directly with the transcription factors 
MEF2 (myocyte enhancer factor 2), BCL6 (B-cell lymphoma 6), and PLZF 
(promyelocytic leukemia zinc finger), and have been found together in complex with 
HDAC3 and the nuclear co-repressors N-CoR and SMRT (Yang and Seto, 2003). Class 
IIb HDACs are classified by the presence of two HDAC domains, and while HDAC6 
contains two functional catalytic HDAC domains, HDAC10 has only one functional 
domain but also contains a vestigial domain (Gregoretti et al., 2004). Interestingly, 
HDAC6 differs significantly from the other class I and class II HDACs since it is 
primarily localized in the cytoplasm with the microtubule network and deacetylates α-
tubulin (Verdin et al., 2003 and Bolden et al., 2006). HDAC6 has also recently been 
shown to deacetylate the molecular chaperone heat shock protein 90 (Hsp90) (Kovacs et 
al., 2005). HDAC10, on the other hand, resides mainly in the nucleus and has been 
reported to interact with HDAC3 and SMRT (Gregoretti et al., 2004). An additional 
protein, HDAC11, has also been identified (Gao et al., 2002). While HDAC11 remained 
unclassified for some time, it has now been suggested to be the founding member of a 
new class of HDACs, class IV (Bolden et al., 2006).  
While HDACs have been extensively implicated as transcriptional repressors, a 
number of recent reports suggest that HDAC activity may be required for gene 
activation in some cases. The first indication that HDACs may be involved in 
mechanisms beyond gene repression came from gene expression analysis of HDI treated 
cells, which drew attention to the fact that HDIs not only altered the expression of a 
small percentage of genes (2-22%), but both upregulated and downregulated similar 
proportions of genes. Second, HDAC activity of Hos2, a member of the yeast Rpd3 
class I HDACs, was determined to be a requirement for gene activation and an 
additional report identified that the yeast Rpd3 HDAC was associated with activating 
osmoresponsive genes (Wang et al., 2002 and De Nadal et al., 2004). Furthermore, 
STAT5 mediated transcriptional activation was found to require HDAC activity for the 
recruitment of TBP and RNA polymerase II (Rascle et al., 2003). HDAC activity has 
also been shown to be necessary for the transcription of many interferon stimulated 
response genes (Nusinzon and Horvath, 2003; Klampfer et al., 2004; Sakamoto et al., 
2004 and Nusinzon and Horvath, 2005). Therefore, in addition to acting as 
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transcriptional co-repressors, HDACs appear to play a role in the transcriptional 
activation of particular genes.  
1.2.3.3. Other Covalent Histone Modifying Enzymes 
Histone methyl transferases (HMTs) are another important group of histone 
modifying enzymes, responsible for transferring the methyl group from the donor, S-
adenosylmethionine (SAM), to the side chain amino group of lysine and arginine 
residues on histone H3 and H4 subunits (Santos-Rosa and Caldas, 2005 and Zhang and 
Dent, 2005). HMTs are capable of mono-, di, or tri- methylation on the epsilon amino 
group of lysine residues, while the guanidino nitrogens of arginines may only be 
monomethylated, as well as symmetrically or asymmetrically dimethylated (Shilatifard, 
2006). There are three prominent classifications of HMTs: the SET and non-SET 
domain-containing lysine methyl transferases (KMTs), and the protein arginines methyl 
transferases (PRMTs) (Shilatifard, 2006). Within the SET domain-containing KMT 
class, four KMT families are the SUV39 (suppression of position-effect variegation 39), 
SET1, SET2 and RIZ (retinoblastoma-interacting zinc finger) families, which are 
characterized by an evolutionarily conserved 130 amino acid catalytic SET (SUV39, 
Enhancer of zeste and trithorax) domain (Kouzarides, 2002 and Zhang and Dent, 2005). 
The SET-containing KMTs have been collectively reported to specifically methylate H3 
K4, 9, 27, 36 and H4 K20 (Shilatifard, 2006). Presently, Dot1 (disruptor of telomeric 
silencing 1), which methylates the H3 core at K79, is the only one non-SET domain-
containing KMT that has been identified (Shilatifard, 2006).  
There are two classes of PRMTs. Class I PRMTs are accountable for catalyzing 
the asymmetric dimethylation of histone arginine residues, and class II PRMTs catalyze 
symmetric arginine dimethylation (Kouzarides, 2002). CARM1 (co-activator-associated 
R-methyltransferase 1) belongs to the class I PRMTs and methylates H3 arginine 2, 17, 
and 26 (Santos-Rosa and Caldas, 2005). Interestingly, unlike acetylation, site specific 
histone methylation of lysine and arginine residues dictates different gene regulatory 
events. For example, methylation of H3 K4 is associated with transcriptionally active 
genes, while H3 K9 methylated residues recruit HP1 to bring about and sustain a 
heterochromatin state (Santos-Rosa and Caldas, 2005). CARM1 mediated methylation 
of H3 R2, 17, and 26 has also been linked with transcriptional activation of nuclear 
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receptors (Kouzarides, 2002; Santos-Rosa and Caldas, 2005 and Shilatifard, 2006). 
Therefore, HMTs generate specific histone methylation modifications and regulate an 
array of processes from gene activation to silencing (Shilatifard, 2006). 
Until recently, histone methylation was believed to be a permanent and 
irreversible histone modification. However, this phenomena appears to be reversible, as 
a newly discovered enzyme, LSD1 (lysine specific demethylase 1), has been reported to 
demethylate the mono- or dimethylated forms of H3 K4, but not the trimethylated 
conformation (Shi et al., 2004 and Bannister and Kouzarides, 2005). Furthermore, 
within the past year two new demethylases have been characterized, GASC1 (gene 
amplified in squamous cell carcinoma 1) and JHDM3A (jumonji C-domain-containing 
histone demethylase 3A), that demethylate di- and trimethylated H3 K9, and 
trimethylated H3 K9 and K36, respectively (Cloos, et al., 2006 and Klose et al., 2006). 
As well, a mechanism for the removal of H3 arginine 2, 8, 17 and 26 methylation by 
deimination has been described, where methylated arginine is converted to citrulline by 
the enzyme PADI4 (peptidyl arginine deiminase 4) (Bannister and Kouzarides, 2005 
and Cuthbert et al., 2004).  
Phosphorylation is another important covalent post-translational histone 
modification that targets histone H1, H2B, H3 and the histone variant H2A.X (Zhang 
and Dent, 2005). Two such examples of histone phosphorylation include aurora kinase 
family phosphorylation of H3 S10, which is associated with mitotic chromosome 
condensation, and phosphatidylinositol 3-kinase-like kinase catalyzed H2A.X S139 
phosphorylation, which facilitates DNA repair processes (Santos-Rosa and Caldas, 
2005). In addition to acetylation, methylation and phosphorylation, histones may also be 
modified by ubiquitin and the small ubiquitin-related modifier protein, SUMO (Santos-
Rosa and Caldas, 2005). Therefore, histones are substrates for numerous histone 
modifying enzymes that dictate gene regulatory events.   
 
1.2.4. Histone Deacetylase Inhibitors 
A delicate balance between histone acetylation and histone deacetylation is 
essential to carry out accurate gene regulatory events within the cell, therefore, it is not 
surprising that alterations in the balance of HAT and HDAC activity or expression have 
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been associated with a neoplastic phenotype. For example, HDAC1, HDAC2 and 
HDAC3 have been reported to be overexpressed in colon cancer, HDAC1 and HDAC2 
are upregulated in gastric tumors, and HDAC1 has increased expression levels in 
hormone refractory prostate carcinoma (Choi et al., 2001; Halkidou et al., 2004; Song et 
al., 2005; Bolden et al., 2006 and Wilson et al., 2006). In acute promyelocytic leukemia 
(APL), which is characterized by chromosomal translocations, cells produce fusion 
proteins of the transcription factor retinoic acid receptor-α (RARα) and promyelocytic 
leukemia (PML) or PLZF protein that facilitate abnormal HDAC recruitment to RAR 
target promoters and in turn prevent transcription (Minicci and Pelicci, 2006). A 
fraction of diffuse large-B cell lymphomas display high expression levels of the 
transcription factor, BCL6. Upon hypoacetylation of BCL6 by HDAC2, the 
transcription of BCL6-responsive genes is suppressed, including that of cyclin 
dependent kinase inhibitor p21WAF1 (Bolden et al., 2006). Additionally, CBP 
mutations that result in a loss of HAT activity have been observed in patients with 
Rubinstein-Taybi syndrome, who are particularly susceptible to cancer development 
(Kelly and Marks, 2005). As well, missense mutations of p300 have been reported in 
colorectal and gastric carcinomas (Muraoka et al., 1996 and Dokmanovic and Marks, 
2005). The overall deficit of H4 K16 monoacetylation and H4 K20 trimethylation has 
also recently been identified as a hallmark of cancer cells (Fraga et al., 2005). 
Therefore, observations like these have rationalized and intensified the study of histone 
deacetylase inhibitors (HDIs) as a therapeutic means of restoring the balance between 
HATs and HDACs in tumor cells.  
HDIs have been well documented as promising anti-cancer agents given their 
ability to selectively induce cell cycle arrest, differentiation and/or apoptosis of cancer 
cells without affecting normal cells (Marks et al., 2001; Burgess et al., 2004 and Carey 
and La Thangue, 2006). It is not yet precisely clear how HDIs exert these effects, 
however, at the structural level, HDIs have been proposed to prevent histone 
deacetylation activity by binding in the active site pocket and chelating the Zn2+ ion of 
class I and class II Zn2+-dependent HDACs (Finnin et al., 1999; Somoza et al., 2004 
and Vannini et al., 2004). At the molecular level, HDIs were initially predicted to carry 
out their effects on gene regulation by disrupting the overall balance between histone 
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deacetylation and acetylation levels within the cell. Therefore, HDIs were hypothesized 
to bring about a hyperacetylated histone state that enhanced activator and basal 
transcription factor promoter accessibility, ultimately leading to gene de-repression 
(Strahl and Allis, 2000). Suitably, this theory was greatly supported for a number of 
years by the observation that HDIs transcriptionally activated the p21WAF1 promoter, 
independent of p53 (Nakano et al., 1997). Furthermore, p21WAF1 upregulation was 
linked to HDI mediated cell cycle arrest, and only strengthened the model that HDIs 
achieved their anti-tumor effects as a result of histone hyperacetylation and consequent 
gene activation (Archer et al., 1998). At the present time, HDIs do not appear to act as 
simplistically as once believed. For instance, early gene profiling experiments indicated 
that HDIs do not globally activate genes, as predicted, but only specifically alter the 
expression levels of approximately 2% of genes (Van Lint et al., 1996). In addition, a 
significant amount of gene profiling work, using DNA microarrays, identified that 
between 10-22% of genes may be regulated by HDIs (Mariadason et al., 2000 and Peart 
et al., 2005). It was found that HDIs not only increase gene expression levels but 
repress a surprisingly equivalent number of gene expression profiles, including those of 
c-myc cyclin D1 and cyclin A (Lallemand et al., 1996; Nair et al., 2001 and Sasakawa 
et al., 2003). It was these initial results which provided the basis for the argument that 
HDIs may elicit their chemo-therapeutic effects by a much broader range of gene 
regulatory mechanisms than simply histone acetylation.  
Over the past few years, evidence has accumulated suggesting that HDIs are 
capable of altering multiple levels of gene regulation, including stimulating and 
repressing gene transcription, as well as influencing mRNA stability. Numerous verified 
examples now exist of genes that are downregulated by HDIs. Recently, it has also been 
reported that HDIs compromise DNA methyltransferase-3B (DMT3B) and DNA 
methyltransferase 1 (DMT1) mRNA stability, further suggesting that HDIs may also 
alter the methylation status of DNA (Xiong et al., 2005 and Januchowski et al., 2007). 
Still, the mechanisms are unclear as to how HDIs elicit changes in gene expression to 
ultimately promote cell cycle arrest, apoptosis and/or differentiation of tumor cells. 
Primarily, the mechanism of non-histone protein acetylation has been examined. HDIs 
have been proposed to trigger acetylation of non-histone proteins resulting in changes in 
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the binding affinity of transcription factors, as well as alterations in protein stability, 
protein dimerization and protein localization (Drummond et al., 2005; Lin et al., 2006 
and Minucci and Pelicci, 2006). Accordingly, HDI mediated acetylation of p53 has 
recently been reported to stabilize p53 protein levels, which in turn stimulates p53-
dependent activation of the p21WAF1 and Bax gene promoters (Bolden et al., 2006, 
Zhao et al., 2006). This ultimately causes an induction of cell cycle arrest and apoptosis, 
respectively (Bolden et al., 2006 and Lin et al., 2006). Furthermore, the modification of 
Ku70 acetylation by HDIs initiates Bax release from the Ku70/Bax complex, allowing 
Bax translocation to the mitochondria for subsequent cytochrome c release and 
apoptosis (Subramanian et al., 2005 and Lin et al., 2006). Histone and non-histone 
acetylation are, however, likely not the only means of HDI action. Recently, another 
potential mechanism has been proposed, based on observations that protein phosphatase 
1 (PP1) forms complexes with HDAC1, HDAC6 and HDAC10 and that HDIs are 
capable of disrupting HDAC-PP1 complexes (Brush et al., 2004). HDAC-PP1 
complexes have been implicated in preventing the transcription of CREB responsive 
genes by dephosphorylating the transcription factor CREB, thereby inhibiting 
subsequent HAT recruitment, histone acetylation and gene activation (Canettieri et al., 
2003). HDI mediated disruption of the HDAC-PP1 complexes also leads to CREB 
phosphorylation and the likely transcriptional activation of target genes, as well as an 
enhanced association of PP1 with the Akt protein kinase, which mediates Akt 
dephosphorylation and inactivation (Canettieri et al., 2003 and Chen et al., 2005). 
Therefore, these findings suggest that HDIs have the potential to alter the 
phosphorylation pattern of yet unidentified proteins, including histones and 
transcriptional co-activators, as well as other transcription factors and signaling 
molecules to selectively regulate gene expression levels and signaling pathways (Alao 
et al., 2006). Finally, HDIs may mechanistically decrease transcription levels by simply 
preventing histone deacetylation, such as in the cases of STAT5 and many interferon 
responsive genes that require HDACs for gene activation (Rascle et al., 2003 and 
Nusinzon et al., 2005). Taken together, HDIs elicit their anti-tumor activity through a 
much broader range of regulatory actions than previously anticipated and highlight the 
great diversity and complexity by which these drugs function. 
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1.2.4.1. Histone Deacetylase Inhibitor Classes and Clinical Trials 
  HDIs can be categorized into four predominant different structural classes: 
aliphatic acids, hydroxamic acids, benzamides and cyclic peptides (Garcia-Manero and 
Issa, 2005; Bolden et al., 2006 and Minucci and Pelicci, 2006) (Table 1.1.). 
Interestingly, a number of these compounds have been reported to exhibit both chemo-
preventive and chemotherapeutic activity in a range of human cancer cell lines in vitro 
and tumor bearing models in vivo (Marks et al., 2001; Vigushin and Coombes, 2002 
and Arts et al., 2003). Butyrate was the first discovered HDI and belongs to the 
aliphatic acid class of HDIs. This compound has been found to reside naturally in the 
colonic lumen as a product of anaerobic bacterial fermentation of dietary fibers 
(Roediger, 1980). Along with butyrate, acetate and propionate are also generated from 
the microbial fermentation process, but only propionate has weak HDI activity 
(Cousens et al., 1979). Butyrate is a non-competitive inhibitor of HDACs and requires 
millimolar concentrations to effectively inhibit histone deacetylation, which are 
physiologically realistic in the colon, as butyrate concentrations in the range of 
approximatley 12 - 24 mM have been detected in the human adult feces (Topping and 
Clifton, 2001 and Davie, 2003). Besides acting as a HDI, butyrate also exhibits 
pleiotropic effects on the cytoskeleton and alters protein phosphorylation and DNA 
methylation levels within the cell (Kruh, 1982; Sowa et al., 2000; Vigushin and 
Coombes, 2002 and Arts et al., 2003). Importantly, butyrate serves as the primary 
energy source of colonocytes and plays an essential role in maintaining the homeostatic 
balance and growth of normal colonic epithelial cells (Roediger, 1980). However, 
butyrate also displays anti-proliferative effects and has been documented to stimulate 
cell cycle arrest, differentiation and apoptosis in tumor cells, while normal cells show 
little sensitivity (Carey and La Thangue, 2006). Therefore, butyrate has been implicated 
as a chemo-preventive agent against the progression of colorectal tumorigenesis, further 
strengthening the argument that high fiber diets may decrease colorectal cancer 
incidence (Burkitt, 1971 and Sowa and Sakai, 2000).  
Sodium phenylbutyrate has been clinically approved for use in the management 
of urea cycle disorders since 1996 and was the first HDI to be investigated as a chemo-
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Table 1.1. Histone deacetylase inhibitors, classes, structures, status of clinical trials.
(Minucci 2006, Inche 2006, Dokmanovic 2005, Garcia-Manero
2005)




limited clinical utility owing to its rapid clearance rate, low potency and lack of 
specificity (Vigushin and Coombes, 2002 and Rosato and Grant, 2004). Despite this, 
there were a couple of notable observations derived from butyrate studies, such as a 
partial remission of a child with acute myelogenous leukemia (AML) treated with 
sodium butyrate, and complete clinical remission of a young patient with relapsed APL 
for a seven month period when treated in combination with all-trans-retinoic acid 
(ATRA) and sodium phenylbutyrate (Novogrodsky et al., 1983 and Warrell et al., 
1998). These observations suggested that a more potent and specific HDI may be of 
clinical value. Currently, pivaloyloxymethyl butyrate (AN-9) and valproic acid are two 
different HDIs that belong to the aliphatic acid class that are going through clinical 
trials (Table 1.1). AN-9 is a butyrate prodrug, which is hydrolyzed to form pivalic acid, 
formaldehyde and butyrate once it has been transported into the cell (Patnaik et al., 
2002). When compared to butyrate, AN-9 has 10-fold greater potency and reduces 
tumor growth in human breast, ovarian, colorectal and non-small cell lung carcinomas 
to a much greater degree (Patnaik et al., 2002). Phase II clinical trials of AN-9 
administered in forty seven advanced non-small cell lung cancer patients have provided 
promising results, with three patients going into partial remission and fourteen other 
patients encountering cancer stabilization for 12 weeks or more (Reid et al., 2004). 
Valproic acid is an anticonvulsant drug that has been clinically used for over a decade, 
but has only recently been identified as a HDI (Rosato and Grant, 2004). Interestingly, 
valproic acid has a much longer half-life than butyrate, appears to function as a 
competitive inhibitor of HDACs, and has been documented to induce growth inhibition, 
differentiation and apoptosis of leukemia cells in vitro (Garcia-Manero and Issa, 2005). 
Furthermore, valproic acid has a well documented history of potential side effects, 
making it an appealing drug to study as a potential anti-cancer agent (Rosato and Grant, 
2004).  Phase I clinical trials have generated compelling results, as 30% of older patients 
with AML or myelodysplastic syndrome displayed clinical improvement upon 
treatment with valproic acid (Pilatrino et al., 2005 and Minucci and Pelicci, 2006). 
Currently, a new formulation of valproic acid, named Savicol, is in phase II trials for the 
treatment of Familial Adenomatous Polyposis, an inherited colorectal cancer disorder 
(Garber, 2007).   
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 Trichostatin A (TSA) is the original member of the hydroxamic acid class of 
HDIs and was initially isolated from the antifungal antibiotic Streptomyces 
hygroscopicus (Yoshida et al., 1990) (Table 1.1). This compound is a reversible and 
specific inhibitor of class I and class II HDACs, directly interacting with the Zn2+ ion at 
the bottom of the HDAC catalytic pocket (Somoza et al., 2004 and Vannini et al., 
2004). Furthermore, TSA is significantly more potent that butyrate, inducing cell cycle 
arrest, differentiation and apoptosis in tumor cells at micromolar and nanomolar 
concentrations rather than the millimolar concentrations of butyrate (Rosato and Grant, 
2004). However, due to high cellular toxicity, TSA has not entered clinical trials (Lin et 
al., 2006). Suberoylanilide hydroxamic acid (SAHA) is a synthetic inhibitor from the 
hydroxamic acid class that has faired notably well in clinical trials featuring patients 
with solid and hematological tumors (Table 1.1). Decreases in tumor size have been 
experienced in patients with non-Hodgkin’s lymphoma, Hodgkin’s disease, 
mesothelioma, bladder, thyroid, renal and laryngeal cancers. Partial remissions have 
also been accrued in five patients with relapsed T-cell lymphoma and one complete 
clinical response has been reported in a patient with AML (Garcia-Manero and Issa, 
2005 and Minucci and Pelicci, 2006). Among concerns with SAHA administration is 
the relatively short half-life and list of side effects, including dehydration, fatigue, 
diarrhea, nausea, anorexia, thrombocytopenia and anemia, which are all completely 
reversed upon SAHA removal (Garcia-Manero and Issa, 2005; Monneret, 2005 and 
Minucci and Pelicci, 2006). Excitingly, in October of 2006 SAHA was approved by the 
Food and Drug Administration (FDA) as the first HDI anti-cancer drug for the treatment 
of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin’s disease (Garber, 
2007 and Marks and Breslow, 2007). In addition to SAHA, other next generation 
hydroxamic acids have since been designed in an attempt to enhance retention times and 
minimize side effects. One of these, PXD101, is currently being evaluated in phase II 
clinical trials as a treatment for multiple myeloma and T- cell lymphomas, as well as 
ovarian and colorectal cancer (Monneret, 2005) (Table 1.1).  
The benzamide and cyclic peptide classes also have HDI compounds in clinical 
trials. MS-275 is a synthetic benzamide derivative that has a particularly long retention 
time and requires micromolar concentrations to stimulate cell cycle arrest, 
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differentiation and apoptosis in tumor cells (Minucci and Pelicci, 2006 and Garber, 
2007) (Table 1.1). Currently, MS-275 is undergoing phase II clinical trials for AML. 
Depsipeptide (FK228) is a natural polypeptide that was initially isolated from 
Chromobacterium violaceum (Monneret, 2005) (Table 1.1). FK-228, like AN-9,  
functions as a HDI prodrug, and contains an intramolecular disulfide bond that is 
reduced by glutathione to produce its active form, redFK, upon entering the cell 
(Garcia-Manero and Issa, 2005; Monneret, 2005 and Lin et al., 2006). FK-228 is a 
potent HDI prodrug and requires only nanomolar concentrations to inhibit HDACs and 
cause anti-tumor effects in neoplastic cells (Rosato and Grant, 2004 and Garber, 2007). 
In phase II clinical trials, FK-228 has demonstrated partial and complete clinical 
responses in as many as 57% of patients with T-cell lymphomas, warranting possible 
clinical approval (Minucci and Pelicci, 2006). An application for FDA authorization is 
expected to be filed in 2007 for FK-228 treatment of CTCL and peripheral T-cell 
lymphoma (PTCL), although some clinical skepticism exists over the use of this drug 
given its past association with cardiac side effects (Minucci and Pelicci, 2006 and 
Garber, 2007).  
  While HDIs have primarily been discussed as monotherapies in clinical trials, it 
is important to note that a number of clinical trials are ongoing to investigate the role of 
HDIs in combination with many other compounds including differentiation agents 
(ATRA, phorbol myristate acetate), DNA demethylating agents (5-aza-2’-
deoxycytidine, 5-azacytidine), cyclin dependent kinase inhibitors (Flavopiridol), Hsp90 
antagonists (17-AAG), proteasome inhibitors (Borezomib), angiogenesis inhibitors 
(Avastin), and other approved chemotherapeutic drugs (Taxol, Herceptin, doxorubicin, 
cisplatin, fludarabine, fluorouracil) (Rosato and Grant, 2004; Lin et al., 2006; Minucci 
and Pelicci, 2006 and Garber, 2007). In addition, a great deal of work is currently 
focused on the identification of HDAC isozyme specific inhibitors, given that SAHA 
and other HDIs in clinical trials are broad range inhibitors of both class I and class II 
HDACs (butyrate, valproic acid, TSA, SAHA, PXD101), or purely the class I HDACs 
(MS-275, FK-228) (Bolden et al., 2006 and Garber, 2007). One such example of an 
isoform specific HDI exists for HDAC6, named tubacin, which exclusively prevents α-
tubulin deacetylation (Haggarty et al., 2003). Taken together, a number of HDIs have 
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presented encouraging clinical trial results for treatment of hematological and solid 
malignancies, both alone and in combination with other chemotherapeutic agents, 
meriting further study of the mechanisms associated with HDI mediated induction of 
cell cycle arrest, differentiation and apoptosis. Furthermore, it is likely that the recent 
FDA approval of SAHA as an anti-cancer drug will only serve to further intensify the 
study of this rapidly developing field. 
 
 
1.3. Eukaryotic Transcriptional Regulation 
The expression of genes is a tightly regulated process, centrally controlled by 
transcription, which facilitates normal cellular growth, development and survival 
(Saunders et al., 2006) Gene transcription is characterized by six cyclic stages: pre-
initiation complex assembly, open complex arrangement, transcriptional initiation, 
promoter clearance, transcript elongation and termination (Sims et al., 2004 and 
Svejstrup, 2004). However, chromatin structure regulates transcription even before pre-
initiation complex (PIC) assembly. This is best exemplified by the repressive state that 
associated nucleosomes impose on promoter DNA, largely as a consequence of 
promoter site inaccessibility for the transcriptional machinery and RNA polymerase II 
(Pol II), which transcribes all protein encoding genes in eukaryotes (Boeger et al., 
2005). 
1.3.1. Promoter Architecture  
 There are numerous cis-regulatory DNA elements present in eukaryotic 
promoters which recruit trans-acting factors to cooperate in the direction of Pol II 
mediated transcription (Lemon and Tjian, 2000). Generally, cis-acting elements that 
control Pol II transcription include core promoter, proximal promoter, enhancer, 
silencer and boundary/insulator elements (Butler and Kadonaga, 2002; Kadonaga, 2002 
and Szutorisz et al., 2005) (Figure 1.1.). The core promoter resides within 40 bp 
upstream and downstream of the transcription start site, may contain a core promoter 
element and represents the minimal DNA sequence necessary for the correct assembly 
and orientation of the PIC for Pol II driven transcription (Butler and Kadonaga, 2002; 
Szutorisz et al., 2005; Thomas and Chiang, 2006 and Yang et al., 2007). The proximal  
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Figure 1.1. Eukaryotic promoter architecture and components of the RNA
Polymerase II transcriptional machinery. The regions of the distal, proximal
and core promoters are outlined. Silencer and Enhancer elements reside in
the distal promoter. Transcription factor binding sites are present in the proximal
promoter, the TATA box, Inr and DPE are shown in the core promoter. The
factors necessary to activate transcription are displayed, including activator and
co-activator complexes, transcription factors, GTFs - TFIID, TFIIA (A), TFIIB (B),
TFIIF (F), TFIIE (E), TFIIH (H), RNA Pol II and Mediator. Potential post-
translational histone modifications are denoted as Ac (acetylation), Me
(methylation), P (phosphorylation). (Boeger 2005, Thomas and Chiang,
2006)
et al.,
Ac, Me, P TBP/TAFs
CTD
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promoter is located between 40 and 200 bp upstream of the transcription start site and 
houses proximal promoter elements or transcription factor binding sites that associate 
with trans-activating factors and serve to boost promoter activity (Kadonaga, 2002 and 
Szutorisz et al., 2005). Distal enhancer elements stimulate transcription of associated 
promoters via the recruitment of specific activators to DNA recognition sites, regardless 
of distance or location (either upstream or downstream) from the transcription start site 
(Blackwood and Kadonaga, 1998). Silencer elements recruit repressor proteins to 
inhibit transcription over long distances and boundary or insulator elements block the 
effects of enhancers and silencers (Butler and Kadonaga, 2002). 
1.3.1.1. The Core Promoter Element 
Currently, seven core promoter elements have been elucidated, termed the 
TATA box, initiator (Inr) element, downstream promoter element (DPE), motif ten 
element, downstream core element, upstream TFIIB-recognition element (uBRE), 
downstream TFIIB-recognition element (dBRE) and X core promoter element 1 
(Thomas and Chiang, 2006 and Tokusumi et al., 2007). Of these, the most widely 
studied are the TATA box and Inr elements. The TATA box element is 
characteristically located 25 – 30 bp upstream of the transcription start site, is 
recognized by the consensus sequence TATA(A/T)A(A/T)(A/G) and bound by the 
TATA-binding protein (TBP) subunit of TFIID (transcription factor for RNA 
polymerase II), the core component of PIC assembly (Thomas and Chiang, 2006). 
Conversely, the Inr element covers the transcriptional start site, has the consensus 
sequence PyPyA+1N(T/A)PyPy, is found in both TATA-containing and TATA-less 
promoters and is recognized by the TBP-associated factor (TAF) subunits of the TFIID, 
TAF1 and TAF2 (Chalkley and Verrijzer, 1999 and Thomas and Chiang, 2006). 
Interestingly, 24% of human genes hold a TATA box-like element but only 10% have a 
consensus TATA box (Yang et al., 2007). Moreover, 16% of human promoters contain 
an Inr element in combination with a TATA-box element and 30% possess only an Inr 
element (Yang et al., 2007). In addition to TATA-box and Inr elements, the DPE, 
located between 28 to 34 bp downstream of the start site, associates with TAF6 and 
TAF9 of the TFIID complex (Burke and Kadonaga, 1997 and Shao et al., 2005). The 
BREs, residing at -38 to -32 bp (uBRE) and -23 to -27 bp (dBRE) upstream of the start 
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site in some promoters bind the general transcription factor (GTF), TFIIB (Lagrange et 
al., 1998 and Thomas and Chiang, 2006). Thus, a number of diverse core promoter 
elements provide a platform for the recognition and collection of the RNA Pol II multi-
protein PIC. 
1.3.1.2. Proximal Promoter and Enhancer Elements 
  Often preliminary to PIC formation, activator binding occurs at either 
exposed, nucleosome free, distal enhancer elements or proximal promoter elements 
(Szutorisz et al., 2005). Examples of two common proximal promoter elements include 
GC boxes that associate with the specificity protein (Sp) family of transcription factors 
and CCAAT boxes bound by the CCAAT/enhancer binding protein (C/EBP) family, 
which are present in 97% and 64% of potential human proximal promoter regions, 
respectively (Suzuki et al., 2001). Activators bound to enhancer and proximal promoter 
elements regularly recruit co-activator complexes, including ATP-dependent chromatin 
remodeling complexes that mediate nucleosome movement and /or histone removal, and 
histone modifying enzyme complexes that introduce covalent post-translational 
modifications on the N-terminal tails of histones (Li et al., 2004b). Such modifications 
may locally decondense chromatin associated with promoter DNA, or establish docking 
sites for further co-activator or transcription factor recruitment. Taken together, co-
activators enhance promoter DNA availability by uncovering cis-regulatory elements, 
including core promoter elements, and thereby facilitate TFIID binding and PIC 
complex assembly (Szutorisz et al., 2005). A “facilitated tracking mechanism” has been 
proposed to describe enhancer involvement in transcriptional activation (Blackwood 
and Kadonaga, 1998 and Hatzis and Talianidis, 2002). In this model, enhancer bound 
activator and co-activator complexes track along the DNA progressively remodeling 
nucleosomes and chromatin. Once the complex reaches the core promoter it is proposed 
that a stable looped structure is formed at the promoter that aids in transcriptional 
activation. Furthermore, activators also recruit the multi-protein co-activator complex 
Mediator, which communicates regulatory signals to the PIC (Jones and Kadonaga, 
2000). Therefore, transcriptional regulation is fundamentally dependent on cis-acting 
promoter elements, and their interaction with trans-acting factors collaborates to define 
the net activation potential of a given promoter.   
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1.3.2. Pre-initiation and the RNA Polymerase II Transcriptional Machinery 
Following nucleosome remodeling or accessibility of core promoter element, the 
first phase of transcription is characterized by formation of the PIC. The PIC is 
composed of six GTFs (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH), and RNA 
polymerase II (Boeger et al., 2005 and Klug, 2005) (Figure 1.1.). In addition to the PIC, 
a multi-subunit co-activator complex Mediator is necessary for activator mediated Pol II 
transcription (Szutorisz et al., 2005).   
1.3.2.1. Pre-initiation Complex Assembly and Open Complex Arrangement 
 Intensive efforts have gone into understanding the assembly pattern of the PIC 
in Pol II directed transcription, given that accurate formation of the PIC culminates in 
RNA synthesis. Two models describing PIC assembly have been proposed: a sequential 
assembly model and a preassembly or holoenzyme model. In the sequential assembly 
model, GTFs gather at the core promoter in a structured manner, such that TFIID binds 
the TATA box or core promoter, followed by the stepwise recruitment of TFIIA, TFIIB, 
Pol II/TFIIF, TFIIE and TFIIH to activate transcription (Lemon and Tjian, 2000 and 
Thomas and Chiang, 2006). Conversely, in the holoenzyme model, TFIID and TFIIA 
associate with the core promoter prior to the recruitment of a large preassembled 
complex containing Pol II, TFIIB, TFIIE, TFIIF, TFIIH, and possibly other chromatin 
remodeling factors, to stimulate promoter activation (Lemon and Tjian, 2000 and 
Thomas and Chiang, 2006). While neither model has yet to be definitively confirmed, 
the sequential model appears to be favored at this time (Lemon and Tjian, 2000 and 
Thomas and Chiang, 2006). 
Regardless of the pattern of PIC assembly, TFIID is the GTF that facilitates 
interaction with the core promoter (Figure 1.1.). TFIID is a large, multi-subunit 
complex composed of TBP and approximately 13 TAFs (Thomas and Chiang, 2006). 
The TBP subunit of TFIID promotes the recognition of TATA box promoters, directly 
interacting with the TATA box and stimulating DNA bending around the core promoter 
element (Burley and Roeder, 1996 and Woychik and Hampsey, 2002). Furthermore, a 
group of TFIID TAF subunits also play a role in promoter recognition, as identification 
of Inr elements arises from TAF1-TAF2 complexes and TAF6-TAF9 recognizes DPEs 
(Chalkley Verrijzer, 1999 and Lagrange et al., 1998). TFIID is, therefore, central to 
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promoter site detection. However, TFIID also has co-activator capability, largely due to 
the presence of TAF1 (Thomas and Chiang, 2006).  
TAF1 is an essential protein in yeast, fruit flies, and hamster cell lines and is 
responsible for the regulation of approximately 30% and 18% of genes in yeast and 
hamster cells, respectively (Holstege et al., 1998 and O’Brien and Tjian, 2000). 
Furthermore, TAF1 is a multidimensional protein capable of interacting with a number 
of activator proteins including jun, RB, MDM2 and cyclin D, and other GTFs such as 
TFIIA, TFIIE and TFIIF (Wassarman and Sauer, 2001). As well, TAF1 binds acetylated 
histone H3 K14 and histone H4 K5, K8, K12, K16 residues via its two bromodomains 
and also yields acetyltransferase (AT) and kinase activities (Wassarman and Sauer, 
2001 and Thomas and Chiang, 2006) (Figure1.2.). Hence TAF1 endows TFIID with co-
activator function by linking activators to the PIC, as well as the ability to modify 
histones, GTFs and other components of the Pol II transcription complex. Taken 
together, TFIID functions both in core promoter element recognition by serving as the 
platform for PIC assembly, and as a transcriptional co-activator. 
Following TFIID recruitment to the core promoter, TFIIA may associate with 
the promoter to stabilize the interaction between TBP and the TATA box by binding 
both TBP and the DNA upstream of the TATA box (Thomas and Chiang, 2006). 
However, TFIIA does not appear to be required for the transcription of all genes 
(Thomas and Chiang, 2006). TFIIB, on the other hand, is an indispensable component 
of the PIC. As an individual polypeptide, the C-terminal or core domain of TFIIB 
interacts with sequences both upstream and downstream of the TATA box, as well as 
with BREs (Woychik and Hampsey, 2002 and Bushnell et al., 2004). Association of 
TFIIB with the TATA-TFIID complex further stabilizes the formation of the bent DNA, 
thereby inhibiting TBP loss, and provides a docking site within the N-terminal zinc 
binding domain of TFIIB for Pol II entry into the PIC (Bushnell et al., 2004). The 
twelve subunit Pol II catalytic enzyme contacts TFIIB near the RNA exit channel of the 
polymerase, via its Rpb1 and Rpb2 subunits, and concurrently draws TFIIF into the PIC 
(Thomas and Chiang, 2006). TFIIB promotes RNA Pol II recognition of the 
transcription start site, facilitating the entry of downstream DNA into the polymerase 
active center (Boeger et al., 2005 and Thomas and Chiang, 2006). TFIIF is a  
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Figure 1.2. The protein structure of TAF1. The enzymatic domains of TAF1
include N-terminal and C-terminal kinase domains and an acetyl-transferase
(AT) domain. The two tandem bromodomains of TAF1 are also outlined.
(Wassarman 2001)et al.,
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heterotetramer that associates with Pol II, and is composed of two subunits of serine-
threonine kinase RNA polymerase II-associated protein 74 (RAP74) and two subunits 
of RNA polymerase II-associated protein 30 (RAP30) (Woychik and Hampsey, 2002). 
TFIIF encourages RNA Pol II recruitment to TFIIB associated PICs, interacts with 
DNA sequences on both sides of the TATA box, assists in selection of the transcription 
start site, stabilizes the TATA-TFIID-TFIIB complex, and drafts both TFIIE and TFIIH 
to the PIC (Woychik and Hampsey, 2002 and Thomas and Chiang, 2006). Accordingly,  
the heterotetramer TFIIE, made up of two TFIIEα and two TFIIEβ subunits, interacts 
with the promoter DNA, TFIIB, Pol II and TFIIF to recruit TFIIH to the PIC (Boeger et 
al., 2005 and Thomas and Chiang, 2006). TFIIH is the biggest and sole GTF with 
enzymatic activities (Woychik and Hampsey, 2002). The ten subunits that comprise 
TFIIH include: two ATPase DNA helicases, gene defective in xeroderma pigmentosum 
patients complementation group B (p89/XPB) and gene defective in xeroderma 
pigmentosum patients complementation group D (p80/XPD), p62, p52, p44, p40/CDK7, 
p38/Cyclin H, p34, p32/MAT1 and TFB5 (Thomas and Chiang, 2006). The 
ATPase/helicase activity of TFIIH triggers DNA unwinding of approximately 11-15 bp 
around the transcription start site, forming an open complex (Saunders et al., 2006). A 
single stranded DNA template then enters the active center of Pol II while the non-
template strand is confined by TFIIF (Bushnell et al., 2004 and Boeger et al., 2005). 
Accurate assembly of GTFs and Pol II into a PIC is proficient for the initiation of in 
vitro basal transcription, however, the presence of the Mediator co-activator complex, 
enhances basal transcription levels and is necessary to activate transcription in response 
to activators (Kornberg, 2005 and Malik and Roeder, 2005). 
1.3.2.2. Mediator 
 Mediator is a multi-protein co-activator complex which communicates 
regulatory signals from enhancer and proximal promoter elements to the PIC to either 
activate or repress transcription. As such, it is considered an essential constituent of the 
Pol II transcriptional machinery (Kornberg, 2005) (Figure 1.1). Mediator was initially 
isolated from Saccharomyces cerevisiae as a 20 subunit complex and has since been 
found to interact with the activation domains of transcription factors as well as with Pol 
II (Conaway et al., 2005). Exploitation of activator – Mediator associations has led to 
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the identification of various mammalian Mediator counterparts, such as thyroid 
hormone receptor-associated proteins/SRB (suppressors of RNA pol B) - Med 
containing cofactor (TRAP/SMCC), vitamin D receptor-interacting protein (DRIP), and 
cofactor required for Sp1 activation (CRSP) (Conaway et al., 2005). However, a 
unifying mechanism of Mediator recruitment to the region of the promoter, as well as 
the process by which Mediator is able to connect activators to the PIC remains to be 
elucidated (Conaway et al., 2005; Kornberg, 2005; Malik and Roeder, 2005 and Roeder, 
2005).    
 
1.3.3. Transcription Initiation and Promoter Clearance 
Assembly of the transcriptional machinery (PIC and Mediator) poises RNA 
polymerase II for initiation, while the ATPase / helicase activity of the p89/XBP subunit 
of TFIIH initiates ribonucleotide synthesis by melting the double stranded DNA and 
promoting entry of the template strand into the active center of Pol II (Sims et al., 2004 
and Saunders et al., 2006). This generates an initially transcribing complex, however, 
Pol II must break away from the core promoter and some of the general transcriptional 
machinery before promoter clearance occurs and transcript elongation ensues (Saunders 
et al., 2006). Promoter clearance, or the transition from an initially transcribing complex 
into an early elongation complex, is characterized by the rivalry between TFIIB and the 
synthesizing RNA transcript for the Pol II active center and exit channel. Early in 
transcription, synthesis of the first 5 bp of RNA is stabilized by the interaction of the 
TFIIB N terminus with the Pol II active site that occurs through the RNA exit channel 
(Bushnell et al., 2004 and Boeger et al., 2005). Continued ribonucleotide synthesis, 
therefore, eventually forces a competition between TFIIB and a 9 bp RNA transcript for 
the Pol II active center and departure from the Pol II exit channel (Bushnell et al., 2004 
and Boeger et al., 2005). If the transcript is unable to overtake TFIIB, abortive 
transcription occurs, and a new round of transcription must be initiated. However, if the 
RNA prevails, the initially transcribing complex clears the promoter and transitions into 
an early elongating complex (Bushnell et al., 2004; Boeger et al., 2005 and Saunders et 
al., 2006). Furthermore, a subsequent round of transcription can be initiated at the core 
promoter, following promoter clearance (Sims et al., 2004). 
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 Pol II also plays a fundamental role in the maturation of the initiating complex 
into an early elongating complex. The largest subunit of Pol II, Rpb1, has a large 
unstructured carboxy-terminal domain (CTD), consisting of 52 tandem consensus 
heptapeptide repeats of Y1S2P3T4S5P6S7, which may be phosphorylated, glycosylated, 
ubiquitylated, or undergo cis/trans proline isomerization (Meinhart et al., 2005; 
Phatnani and Greenleaf, 2006; Saunders et al., 2006 and Thomas and Chiang, 2006). 
Interestingly, the phosphorylation status of Ser 2 and Ser 5 residues within the CTD 
heptapeptide repeats is representative of the transcriptional stage: the CTD of Pol II 
assembled into the PIC is hypophosphorylated (Pol IIA), while the elongating Pol II is 
hyperphosphorylated (Pol IIO) (Sims et al., 2004 and Saunders et al., 2006). In 
particular, Ser 5 phosphorylation elevates in association with promoter clearance but 
decreases in the 3’ region of the gene, while Ser 2 phosphorylation predominates during 
productive elongation toward the 3’ of the gene (Svejstrup, 2004 and Phatnani and 
Greenleaf, 2006). Ser 5 phosphorylation within the CTD is carried out by the TFIIH 
subcomplex of CDK7/Cyclin H and MAT1, the kinase activity of which is significantly 
enhanced by Mediator association (Svejstrup, 2004 and Meinhart et al., 2005). The 
mechanism by which Ser 5 phosphorylation facilitates promoter clearance and 
conversion into an early elongating complex is unclear, however, it has been 
hypothesized that phosphorylation of the CTD may result in the disruption of Pol II 
contacts with the PIC and, possibly, Mediator (Svejstrup, 2004). In addition, 
phosphorylated Ser 5 also behaves as a platform for the recruitment of mRNA capping 
enzymes (Phatnani and Greenleaf, 2006).   
 
1.3.4. Transcript Elongation  
1.3.4.1. From the Early Elongation Complex to Productive Elongation 
The early elongating complex is still a slightly unstable complex that may 
undergo transcript slippage, backtracking, and arrest within the first 30 nucleotides of 
RNA synthesis (Saunders et al., 2006). It is therefore the penultimate complex en route 
to the development of a mature elongating complex. During or following transcript 
initiation, DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) sensitivity inducing 
factor (DSIF), composed of a suppressor of Ty 4 (SPT4) and 5 (SPT5) subunit, interacts 
 31
with Pol II (Orphanides and Reinberg, 2002 and Sims et al., 2004). The negative 
elongation factor (NELF), which is subsequently recruited to the early elongating 
complex, cooperates with DSIF to stimulate an early Pol II pause between +20 to +40. 
This has been hypothesized to coincide with the capping of the emerging nascent RNA, 
and may serve as a fundamental checkpoint for an adequately equipped Pol II complex 
or a properly capped RNA prior to productive elongation (Orphanides and Reinberg, 
2002; Shilatifard, 2004; Sims et al., 2004; Svejstrup, 2004 and Saunders et al., 2006). A 
commitment to productive elongation is facilitated by the kinase activity of positive 
transcription elongation factor b (P-TEFb), which is comprised of Cdk9 and one of 
cyclin T1, cyclin T2a, cyclin T2b or cyclin K (Shilatifard, 2004 and Sims et al., 2004). 
P-TEFb phosphorylates the SPT5 subunit of DSIF and Ser 2 of the Pol II CTD, leading 
to NELF dissociation and relief of the Pol II pause (Shilatifard, 2004 and Sims et al., 
2004). In addition, the TFIIS elongation factor alleviates the elongation pause by 
realigning the Pol II active center with the correct 3’-OH of the RNA transcript upon 
backtracking (Sims et al., 2004). TFIIF also re-associates with the paused Pol II 
complex to reactivate elongation (Saunders et al., 2006). 
 Throughout productive elongation, the Pol II CTD remains phosphorylated at 
Ser 2. The rate of elongation is stimulated by TFIIS and TFIIF, as well as members of 
the eleven-nineteen lysine-rich in leukemia (ELL) and Elongin families (Shilatifard et 
al., 2003). Similar to TFIIF, the ELL and Elongin family members bear a repressive 
effect on transient Pol II transcriptional pausing and are, therefore, important enhancers 
of elongation (Shilatifard, 2004 and Sims et al., 2004). In addition, accessory elongation 
factors allow Pol II to transverse chromatin during transcript elongation. One such 
factor, known as facilitates chromatin transcription (FACT), interacts with H2A-HAB 
dimers to promote nucleosome destabilization by loss of a single H2A-H2B dimer, and 
subsequent nucleosome reassembly following Pol II passage (Reinberg and Sims, 2006 
and Workman, 2006). 
 
1.3.5. Termination 
Transcript termination occurs when Pol II is released from the DNA template. 
Accurate termination of transcription is imperative for the induction of gene expression 
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levels. Distinct from transcription initiation, however, termination is not defined by 
consensus terminator sequences (Svejstrup, 2004). But is tightly linked to mRNA 
polyadenylation, and will be discussed in further detail within the following section.  
Cumulatively, this section highlights the multiple levels in the transcriptional 
process at which gene expression is regulated; from the chromatin template, to the 
assembly of the PIC, transcriptional initiation, promoter clearance, the transition from 
early elongation to productive elongation and precise termination.  
 
 
1.4. mRNA  
1.4.1. Co-transcriptional mRNA Processing Events 
 A newly synthesized RNA transcript is not readily amenable for nuclear export 
and translation into a protein. Rather, a series of processing events are required to 
generate a mature mRNA, including the addition of a 5’ cap structure, intron excision of 
the precursor-mRNA (pre-mRNA), and the acquisition of a 3’-polyadenylated (poly(A)) 
tail (Orphanides and Reinberg, 2002 and Proudfoot et al., 2002). A considerable amount 
of evidence suggests that most nascent RNA transcript processing occurs as Pol II 
traverses the gene, in a co-transcriptional or coupled manner. The CTD of Pol II is 
imperative to pre-mRNA processing, as deletion of the CTD has been shown to obstruct 
capping, splicing and polyadenylation site cleavage events (McCracken et al., 1997a; 
McCracken et al., 1997b; Fong and Bentley, 2001 and Zoria and Bentley, 2004). 
Fundamentally, the CTD acts as a platform for the recruitment of various pre-mRNA 
processing factors throughout the transcription cycle and, in return, the execution of 
processing events may influence Pol II directed transcription (Neugebauer, 2002).  
1.4.1.1. Addition of the 5’ Cap Structure at the Early Elongation Pause 
 The addition of a 5’ 7-methyl-guanosine cap is the first processing reaction 
carried out on a Pol II synthesized pre-mRNA. The reaction proceeds following the 
synthesis of approximately 20 to 40 nucleotides and nascent RNA departure from the 
exit channel of the Pol II enzyme. Three enzymes are responsible for the formation of 
the cap (Shatkin and Manley, 2000; Proudfoot et al., 2002; Shilatifard et al., 2003 and 
Gu and Lima, 2005). First, a RNA 5’-triphosphatase (RT) enzyme removes the γ-
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phosphate from the first nucleotide of the pre-mRNA transcript to generate a 
diphosphate. This reaction is followed by the action of RNA guanylyltransferase (GT), 
which transfers a GMP cap to the diphosphate nucleotide at the beginning of the chain 
in a 5’-5’ triphosphate linkage. Finally, RNA N7 guanine methyltransferase (MT) shifts 
a methyl group from SAM to the N7 position on the GMP moiety to ultimately form a 
methyl-7-guanosine(5’)ppp(5’)N cap on the pre-mRNA. In mammalian cells, the RT 
and GT capping enzymes reside in a single bifunctional polypeptide (Zorio and Bentley, 
2004 and Sims et al., 2004).  
The phosphorylated form of the Pol II CTD interacts directly with the GT and 
MT capping enzymes. Importantly, TFIIH mediated phosphorylation of Ser 5 residues 
within the CTD stimulates GT activity (Cho et al., 1997 and McCracken et al., 1997). 
In addition, GT is also recruited to the CTD by SPT5, a component of the early 
elongation complex, which positively affects capping activity (Wen and Shatkin, 1999). 
Therefore, capping enzymes are recruited to the transcription complex following 
promoter clearance by the Ser 5 phosphorylated form of the CTD and the DSIF subunit 
SPT5 (Shilatifard et al., 2003; Sims et al., 2004 and Zorio and Bentley, 2004). As such, 
the capping process coincides with the early pause in Pol II elongation. Following 
completion of the 5’cap on the nascent RNA chain, the elongation repressor NELF is 
released from the paused transcriptional complex (Bentley, 2005). Furthermore, a 
phosphatase, possibly Fcp1, is responsible for the removal of Ser 5 phosphates from the 
CTD, which correlates with dissociation of the capping enzymes from the CTD 
(Bentley, 2002).  
Addition of a 5’cap to the pre-mRNA transcripts may be an important 
checkpoint prior to productive elongation, as an intact 5’cap is necessary to protect the 
pre-mRNA from 5’ to 3’ exonucleases, as well as for slicing and polyadenylation events 
to be carried out (Neugebauer, 2002; Orphanides and Reinberg, 2002 and Proudfoot et 
al., 2002). Cap binding complex (CBC), composed of cap binding protein 20 (CBP20) 
and 80 (CBP80), interacts co-transcriptionally with the cap structure in the nucleus 
(Proudfoot et al., 2002). CBC is utilized in removal of the earliest pre-mRNA intron, 
stimulates cleavage of the 3’-end of the nascent RNA transcript, functions in mRNA 
export and continues to interact with the 5’cap of mature mRNAs until it is replaced by 
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the translation initiation factor eIF-4E in the cytoplasm (Neugebauer, 2002; Orphanides 
and Reinberg, 2002; Proudfoot et al., 2002; Bentley, 2005 and Cheng et al., 2006). 
Therefore, the co-transcriptional 5’ cap processing reactions, mediated by the Pol II 
CTD, are critical for mRNA stability, additional processing events, mRNA export and 
prospective translation.  
1.4.1.2. Intron Splicing During Productive Elongation 
 The production of functional and mature mammalian mRNAs requires that large 
noncoding intronic sequences, surrounding small coding exons, are excised from pre-
mRNAs and that exons are joined together. However, intron removal, or splicing is not 
necessarily straight forward, as alternative splicing incorporates or omits different exons 
into mature mRNA products in as many as 75% of human genes to facilitate differential 
protein expression (Lynch, 2006). Splicing is carried out by a multi-protein complex 
called the spliceosome (Neugebauer, 2002; Proudfoot et al., 2002 and Zorio and 
Bentley, 2004). The spliceosome harbors five small nuclear ribonucleoproteins 
(snRNPs): U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP and U6 snRNP, as well as 
numerous associated proteins (Neugebauer, 2002; Proudfoot et al. 2002 and Zorio and 
Bentley, 2004). Various components of the spliceosome recognize consensus sequences 
at the 5’ splice site, the branchpoint located 100 bp upstream of the 3’ intron-exon 
border, and the 3’ intron-exon boundary of pre-mRNAs (Proudfoot et al., 2002). 
Following identification of the 5’ splice site by U1 snRNP, the 3’ intron-exon boundary 
by the U2 snRNP auxiliary factor (U2AF), the branchpoint by U2 snRNP, and 
subsequent spliceosome assembly, intron splicing proceeds by two trans-esterification 
reactions (Neugebauer, 2002). First, a nucleophilic attack is carried out by the hydroxyl 
group from a conserved branchpoint adenosine nucleotide on the 5’ exon-intron 
junction, leaving an open 5’ boundary with a 3’OH group (Proudfoot et al., 2002). 
Consequently, the free 3’OH of the 5’splice site behaves as a nucleophile by attacking 
the 3’ intron-exon junction to release the intron (Proudfoot et al., 2002). CBC may 
facilitate splicing of the first intron by stimulating interactions between the 5’ 
recognition splice site and various components of the spliceosome (Proudfoot et al., 
2002).  
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 It has been recognized for some time that the CTD of Pol II enhances intron 
splicing of the nascent RNA transcripts and slicing proceeds co-transcriptionally. 
However, the identification of slicing factors associated with the Pol II CTD or the 
transcriptional machinery in mammals has lagged considerably (McCracken et al., 
1997b and Fong and Bentley, 2001). Recently, four pre-mRNA splicing factors have 
been reported to associate with the transcriptional unit of the intron-containing human 
FOS gene (Listerman et al., 2006). The U2AF 65kDa subunit (U2AF65), U1 snRNP, 
U5 snRNP and heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) accumulate 
on the gene following upregulation of transcription, and correlate with co-
transcriptional splicing of the pre-mRNA (Listerman et al., 2006). Furthermore, 
U2AF65 interacts with the phosphorylated form of the Pol II CTD in a manner 
dependent on nascent RNA transcript association (Listerman et al., 2006). Therefore, at 
least a percentage of intron splicing occurs during Pol II driven productive elongation. 
Interestingly, effective co-transcriptional splicing of the final intron and the presence of 
U2AF65 is strongly interconnected with 3’ polyadenylation processing (Zhao et al., 
1999). In addition, pre-mRNA splicing enhances mRNA export to the cytoplasm 
(Orphanides and Reinberg, 2002). 
1.4.1.3. 3’ Polyadenylation of Precursor-mRNA and Transcript Termination 
 Polyadenylation of the pre-mRNA is carried out by the endonucleolytic cleavage 
of the nascent RNA chain and the addition of approximately 200 adenylate nucleotides 
to the cleaved 3’end of the transcript (Shilatifard, 2003). Cleavage and polyadenylation 
reactions are largely defined by poly(A) signal sequences within the 3’-region of the 
nascent RNA transcript (Zhao et al., 1999). In mammals, the poly(A) signal is 
characterized by three RNA sequences: an upstream AAUAAA motif, a poly(A) site or 
cleavage site, and a downstream element (DSE) (Zhao et al., 1999 and Zarudnaya et al., 
2003) (Figure 1.3.). The highly conserved AAUAAA, or alternatively AUUAAA, 
hexamer motif is located within 11 to 23 nucleotides upstream of the cleavage / poly(A) 
site and is necessary for pre-mRNA cleavage and polyadenylation (Chen et al., 1995). 
The DSE is comprised of less well conserved stretches of U- or GU-rich nucleotide 
tracts and typically resides 10 to 30 nucleotides downstream of the poly(A) site (Chen et 
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Figure 1.3. Polyadenylation of the pre-mRNA. Polyadenylation requires two
distinct reactions. The endonucleolytic cleavage reaction is stimulated by
CPSF, CstF, PAP, CFI and CFII. The polyadenyation reaction of the pre-mRNA
3'-end is mediated by CPSF, PAP and PABP II. The poly(A) signal sequences
are denoted by the AAUAAA motif, CA cleavage site, and DSE. (Zhao ,











DSE are thought to define the poly(A) / cleavage site, which is most often denoted by 
an adenosine nucleotide, and a penultimate cytosine (CA) (Chen et al., 1995; Wahle and 
Ruegsegger, 1999 and Zhao et al., 1999). Five multisubunit proteins are required for 
pre-mRNA endonucleolytic cleavage: cleavage and polyadenylation specificity factor 
(CPSF), cleavage stimulatory factor (CstF), cleavage factor I (CFI), cleavage factor II 
(CFII) and poly(A) polymerase (PAP) (Wahle and Ruegsegger, 1999; Zhao et al., 1999 
and Proudfoot et al., 2002). Following cleavage, polyadenylation is carried out by 
CPSF, PAP and poly(A) binding protein II (PABP II) (Wahle and Ruegsegger, 1999; 
Zhao et al., 1999 and Proudfoot et al., 2002).  
Cleavage of the pre-mRNA is initiated by CPSF and CstF which recognize and 
interact with the AAUAAA motif and DSE, respectively (Wahle and Ruegsegger, 1999 
and Proudfoot et al., 2002). Furthermore, interactions between CPSF and CstF  
stabilize the core of the cleavage complex (Zhao et al. 1999). Subsequent recruitment of 
PAP to CPSF, in addition to the association of CFI and CFII, completes the active 
complex and dictates cleavage of the nascent transcript (Figure 1.3.) (Proudfoot et al., 
2002). In addition, the CBC at the 5’ end of the pre-mRNA stimulates the cleavage 
reaction. Polyadenylation proceeds immediately following cleavage by the concerted 
action of CPSF-bound PAP, and PABP II further stabilizes the complex after the 
addition of ten nucleotides to the mRNA tail (Figure 1.3.) (Wahle and Ruegsegger, 
1999). Polyadenylation of the mRNA transcript is important for excision of the very last 
pre-mRNA intron, as U2AF65 interacts with PAP (Neugebauer, 2002). Furthermore, 
the poly(A) tail protects the 3’-end of the mRNA from rapid 3’ to 5’ exoribonuclease 
degradation. 
 In a comparable fashion to capping enzymes and splicing factors, proteins 
involved in 3’-end formation of the pre-mRNA also interact with the Pol II CTD. Both 
CPSF and CstF bind to the hypophosphorylated and hyperphosphorylated forms of the 
CTD in vitro (McCracken et al., 1997b). Additionally, 3’-end processing factors have 
also been reported to associate with components of the transcriptional apparatus, such as 
TFIID, which directly interacts with CPSF, and the transcriptional coactivator positive 
cofactor 4, which binds CstF (Dantonel et al., 1997 and Calvo and Manely, 2001). 
Interestingly, CPSF appears to interact with TFIID during formation of the PIC, but 
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later associates with the CTD during transcript elongation and, subsequently, the 
poly(A) signal of the pre-mRNA during 3’-end processing. (Dantonel et al., 1997). 
Therefore, CPSF, and possibly CstF, are likely recruited to the PIC and transferred to 
the Pol II CTD upon TFIIH mediated phosphorylation of Ser 5 and promoter clearance 
(Calvo and Manley, 2003). Furthermore, CPSF and CstF are carried by the CTD 
throughout elongation, but dissociate from the Pol II CTD to interact with the nascent 
RNA hexamer AAUAAA motif and DSE, respectively, to initiate co-transcriptional 
endonucleolytic cleavage and polyadenylation of the 3’ pre-mRNA (Calvo and Manely, 
2003).  
   Polyadenylation is also intimately linked to Pol II transcript termination. 
Although precise consensus terminator sequences have yet to be identified, the poly(A) 
signal is necessary to halt RNA synthesis and stimulate Pol II release from the DNA 
template to allow recycling back to the PIC (Proudfoot, 2004; Zorio and Bentley, 2004; 
Buratowski, 2005 and Gromak et al., 2006). Termination of transcription often occurs 
many bp downstream of the poly(A) addition site; pause sequences downstream of the 
poly(A) signal also play a role in termination (Yonaha and Proudfoot, 1999 and Gromak 
et al., 2006). There are currently two models that explain the connection between 
polyadenylation and termination of transcription: the ‘anti-terminator’ model and the 
‘torpedo’ model (Proudfoot et al., 2002 and Buratowski, 2005). In the ‘anti-terminator’ 
model, synthesis of the pre-mRNA poly(A) signal leads to a change in Pol II-associated 
factors, such as the dissociation of positive elongation factors or the recruitment of 
negative elongation factors, which ultimately suppress the processivity of Pol II and 
consequently lead to Pol II release (Proudfoot et al., 2002 and Buratowski, 2005). 
Conversely, the ‘torpedo’ model stipulates that upon pre-mRNA cleavage a new 
uncapped 5’-RNA end is generated from the surplus transcript length that is gradually 
degraded by the 5’ to 3’ exoribonuclease Xrn2, and eventually promotes dissociation of 
paused Pol II (Proudfoot et al., 2002 and Buratowski, 2005). Therefore, 3’-end 
formation represents another example of the interrelated nature of transcription and pre-




1.4.2. cis-Acting mRNA Stability Determinants 
 The regulation of mRNA stability is another important area of gene expression 
control. Numerous factors influence mRNA rates of decay, including cis-acting stability 
determinants, secondary structure, the cellular setting of the mRNA, and the rate of 
translation (Ross, 1995). The following section will focus on examples of cis-acting 
mRNA stability determinants and the trans-acting mRNA binding factors that associate 
with mRNAs to regulate stability.  
1.4.2.1. The mRNA Cap and 5’ Untranslated Region 
 At the very 5’-end of the mRNA moiety, the 7-methyl-guanosine cap is an 
important stability determinant which enhances mRNA stability a minimum of fourfold 
in vitro (Ross, 1995). The cap structure fundamentally protects mRNAs from 5’ to 3’ 
exoribonuclease activity, as well as interacts with the translation initiation factor eIF-4E 
to promote further stabilization of the mRNA and attachment to the 43S ribosome for 
translation (Wilusz et al., 2001 and Newbury, 2006). The 5’ untranslated region (UTR) 
may influence mRNA half-life by the presence of hairpin loop structures, alteration of 
5’ UTR length or by the presence of stability determinants (Table 1.2.) (Guhaniyogi and 
Brewer, 2001). For example, the iron responsive element (IRE) stem-loop structure, 
present in the 5’ UTR of human ferritin mRNA, may be bound by iron regulatory 
proteins (IRPs) during conditions of low iron (Ross, 1995 and Theil, 2000). Binding of 
the IRPs to the stem-loop within the 5’ UTR sterically hinders the ferritin mRNA 5’cap 
from interacting with the 43S ribosome and thus has an inhibitory effect on translation, 
which ultimately precludes ferritin sequestration of iron (Ross, 1995 and Theil, 2000). 
A further example specifies how lengthening the 5’ UTR can enhance mRNA stability, 
as the introduction of immunoglobulin 5’ UTR sequence into c-myc, by reciprocal 
translocation, produces a significantly more stable mRNA product than wild-type c-myc 
mRNA (Ross, 1995). In addition, the 5’ UTR may also contain sequence determinants 
that influence mRNA stability. The human interleukin-2 mRNA is stabilized during T-
cell activation by the interaction of the RNA binding proteins nucleolin and Y-box 1 
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Table 1.2. mRNA -acting stability determinants of the 5' UTR and coding
region. Examples of -stability determinants and their -binding proteins
are highlighted for different mRNAs. The Cap structure represents the 5'-end
of the mRNA, followed by the 5' UTR (straight line), coding region (solid black
box), the 3' UTR and 3'-end poly(A) tail. Sequence determinants are denoted by










1.4.2.2. Coding region 
 The coding regions of c-fos, c-myc and β-tubulin have been identified to carry 
sequence instability determinants (Ross, 1995 and Guhaniyogi and Brewer, 2001). c-fos 
mRNA contains a major coding region determinant (mCRD), which is 320 nucleotides 
in length, centrally located in the coding region of the mRNA and responsible for 
encoding the essential basic leucine zipper domain of c-fos (Table 1.2.) (Ross, 1995 and 
Guhaniyogi and Brewer, 2001). The mCRD associates with five proteins including the 
RNA binding protein, upstream of N-Ras (UNR), the cytoplasmic PABP, PABP-
interacting protein, hnRNP D and hnRNP Q (Chang et al., 2004). mCRD bound by 
UNR mediates rapid destabilization of c-fos mRNA upon recruitment of a multiprotein 
deadenylation / decay complex to the instability determinant, in a translation dependent 
manner (Chang et al., 2004). The instability or coding region determinant (CRD) of c-  
myc resides in the most C-terminal 249 coding nucleotides of the mRNA, and interacts 
with a CRD-binding protein which plays a protective role against endoribonucleolytic 
cleavage during translational pauses (Herrick and Ross, 1994 and Lemm and Ross, 
2002). However, dissociation of CRD-BP from the CRD at the ribosome appears to  
open up the c-myc mRNA for endonucleolytic attack, by RNase1- like 
endoribonuclease, during pauses in translation (Lemm and Ross, 2002 and Tafech et al., 
2007). Microtubules are comprised of heterodimer α-tubulin and β-tubulin subunits. β-
tubulin mRNA stability, which is autoregulated by the intracellular concentration of the 
unassembled tubulin subunit pool, is mediated by the first four N-terminal amino acids 
of β-tubulin, M-R-E-I (Yen, et al., 1988 and Bachurski et al., 1994). These amino acids 
likely interact with a peptide binding factor, and trigger degradation of the remaining 
mRNA sequence as translation proceeds (Yen, et al., 1988 and Bachurski et al., 1994).  
1.4.2.3. The Poly(A) Tail and 3’Untranslated Region 
The 3’ poly(A) tail of the mRNA functions in a manner similar to the 5’cap, 
given that progressive shortening of the poly(A) tail to approximately 30 to 65 
nucleotides stimulates rapid and irreversible mRNA decay (Ford et al., 1999). 
Fundamentally, the poly (A) tail is protected, by bound cytoplasmic poly(A) binding 
proteins (PABPs), from the action of 3’ to 5’ exonucleases (Ford et al., 1999). In 
addition to the poly(A) tail, the mRNA 3’ UTR has been documented to possess a 
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wealth of cis-acting stability elements. Examples of 3’ UTR determinants that influence 
mRNA stability include the α-globin C-rich element, transferrin receptor IREs, insulin-
like growth factor II (IGF II) long range stem loop, histone stem loop and AU-rich 
elements (Table 1.3.). The C-rich element associated with the 3’ UTR of α-globin 
facilitates formation of an α-globin stabilizing α-complex (Waggoner and Liebhaber, 
2003). The α-complex is composed of α-globin poly(C) binding protein 1 (αCP1) and 2 
(αCP2). This complex shields the α-globin mRNA from endoribonucleolytic cleavage 
and prevents deadenylation by interacting with PABPs bound to the poly (A) tail 
(Waggoner and Liebhaber, 2003). The 3’ UTR of the transferrin receptor contains five 
stem-loop IREs that interact with IRPs when intracellular iron levels are low (Theil, 
2000). However, in contrast to ferritin mRNA, IRP binding to transferrin receptor IREs 
obstructs endonuclease access to the mRNA and, therefore, enhances transferrin 
receptor mRNA stability and stimulates iron uptake (Guahaniyogi and Brewer, 2001 
and Theil, 2001). The mRNA stability of IGF-II is regulated by a long-range stem-loop 
determinant in the 3’ UTR that is susceptible to endoribonucleolytic cleavage (Ross, 
1995). Furthermore, replication dependent histone mRNAs lack a poly(A) tail, but 
possess a 3’ terminal stem loop structure that mediates their mRNA decay upon 
interaction with a stem-loop binding protein (Guhaniyogi and Brewer, 2001).  
Undoubtedly, the preeminent example of a 3’ UTR determinant is a sequence 
element high in adenosine and uridine nucleotides, known as an AU-rich element 
(ARE). AREs have been estimated to reside in 5-8% of human mRNAs, including those 
of cytokines, transcription factors, proto-oncogenes, and growth regulatory proteins 
(Wilusz et al., 2001; Barreau et al., 2005 and Bakheet et al., 2006). Interestingly, AREs 
are powerful instability elements that vary from 50-150 nucleotides and are, therefore, 
usually found in the 3’ UTRs of short lived mRNAs (Chen and Shyu, 1995). AREs can 
be divided into three classes (Chen and Shyu, 1995 and Barreau et al., 2005). Class I 
AREs have 1-5 copies of the AUUUA pentamer motif within a U-rich environment and 
are present in the c-fos, c-myc and p21WAF1 mRNAs (el-Deiry et al., 1993; Chen and 
Shyu, 1995 and Barreau et al., 2005). Granulocyte macrophage-colony stimulating 
factor (GM-CSF) and tumor necrosis factor alpha (TNF-α) mRNAs contain Class II 
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Table 1.3. -acting stability determinants of the mRNA 3' UTR. Examples of -
stability determinants and their -binding proteins are highlighted for different
mRNAs. The 3' UTR is represented by the solid line preceding the poly(A) tail.





























U-rich context (Chen and Shyu, 1995 and Barreau et al., 2005). Lastly, the Class III 
AREs are U-rich but do not have an AUUUA motif and are found in mRNAs including 
the c-jun mRNA (Chen and Shyu, 1995 and Barreau et al., 2005). The potent 
destabilizing nature of AREs was initially observed upon insertion of an ARE from 
GM-CSF into the 3’UTR of a previously stable β-globin gene (Chen and Shyu, 1995 
and Ross, 1995). This destabilizing phenomenon can be explained by the ability of 
AREs to mediate rapid deadenylation, and the subsequent 3’ to 5’ or 5’ to 3’ 
exonuclease degradation of mRNAs (Chen and Shyu, 1995 and Stoecklin et al., 2006).  
A number of trans-associated factors have been identified to interact with AREs, 
however, only AU-rich binding factor 1 (AUF1), members of the embryonic lethal 
abnormal visual (ELAV) family and the tristetraprolin (TTP) family impart either 
positive or negative effects on mRNA stability in response to cellular stimuli. The first 
ARE binding protein to be characterized was the nucleo-cytoplasmic shuttling protein 
hnRNP D, otherwise known as AUF1 (Barreau et al., 2005). In vitro RNA binding 
studies have identified that AUF1 interacts with AREs from multiple mRNAs, including 
c-fos, c-myc, p21WAF1, GM-CSF and TNF-α mRNAs (Barreau et al., 2005). 
However, the effect that AUF1 elicits on mRNA stabilization remains controversial, as 
AUF1 has been reported to increase the decay rate of c-fos, c-myc, p21WAF1 and GM-
CSF ARE-containing mRNAs, but has also been proven to enhance stabilization of c-
fos, c-myc, GM-CSF and TNF-α ARE-associated mRNAs in different cell lines (Loflin 
et al., 1999; Xu et al., 2001 and Barreau et al., 2005).  
Members of the ELAV family represent a group of evolutionary conserved ARE 
binding proteins, and are represented by the ubiquitously expressed HuR and neuronal 
HuC, HuD and Hel-N1 members (Antic and Keene, 1997). HuR is the most thoroughly 
characterized of the human ELAV proteins. It is primarily situated in the nucleus, 
although it may shuttle between the nucleus and the cytoplasm, and has been reported to 
target a number of ARE-containing mRNAs, such as c-fos, c-myc, p21WAF1, GM-CSF 
and TNF-α (Brennan and Steitz, 2001 and Barreau et al., 2005). HuD association with 
the 3’ UTRs of these mRNAs occurs through a 17 to 20 nucleotide U-rich motif 
predicted to display a hairpin secondary structure (Silanes et al., 2004). Unlike AUF1, a 
more clearly defined role exists for HuR, which has extensively been reported to 
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stabilize levels of mRNAs containing Class I, Class II and Class III AREs (Peng et al., 
1998 and Barreau et al., 2005). Importantly, HuR does not appear to inhibit mRNA 
decay by preventing mRNA deadenylation, but may retard mRNA decay by stabilizing 
deadenylated intermediates and inhibiting exonuclease access (Peng et al., 1998 and 
Ford et al., 1999). In addition, HuD, HuC and Hel-N1 have also been linked to 
enhanced stabilization of ARE-containing mRNAs (Barreau et al., 2005).  
TTP is the newest ARE binding protein to be investigated. TTP is a CCCH 
tandem zinc finger protein that interacts with the consensus nonamer UUAUUUAUU of 
ARE associated mRNAs, and has notably been documented to trigger the decay of 
mRNAs possessing Class II AREs, such as GM-CSF and TNF-α (Lai et al., 2006). The 
mechanism by which TTP triggers destabilization of mRNA is unclear, however 5’ to 3’ 
and 3’ to 5’ exonuclease components have been localized to TTP bound ARE 
sequences, suggesting that TTP may stimulate decay through the recruitment of 
exonuclease factors to the mRNA (Hau et al., 2006). Thus, given the sheer number of 
identified mRNA cis-acting stability and instability determinants, as well as the broad 
array of trans-acting factors, it is easy to conclude that mRNA stabilization is an 
important juncture in the regulation of gene expression.  
 
 
1.5. c-Src and the c-Src Family Kinase Members 
1.5.1. Overview of the Rous Sarcoma Virus, v-Src and the c-Src Proto-oncogene  
In 1911, Peyton Rous made a revolutionary contribution to the field of tumor 
biology when he observed that a cell-free filterable agent derived from a chicken 
sarcoma could induce the formation of a solid tumor in a new host (Rous, 1911). 
However, his work met with a considerable level of skepticism, due to the belief that an 
infectious agent could not be the cause of a malignancy; it was not until years later that 
the Rous Sarcoma Virus (RSV) was finally accepted as the agent responsible for this 
tumor production. Subsequent work demonstrated that RSV not only induced 
transformation, but that the resulting tumor cells had an enhanced survival rate and both 
produced and released the virus, thereby suggesting that RSV played a fundamental role 
in tumor propagation (Rubin, 1955).  Furthermore, RSV was also shown to induce 
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morphological changes in tumor cells (Temin and Rubin, 1958). Over a decade later, 
the theory that a gene encoded in the RNA genome of RSV may be responsible for its 
transformation potential was spurred by the observations that mutant strains of RSV 
displayed transformation defects but were still competent for replication (Golde, 1970 
and Martin, 1970). In addition, the genomes of replication and transformation proficient 
RSV strains were reported to be larger in size than the genomes of mutant RSV strains 
defective in transformation (Duesberg and Vogt, 1970 and Martin, 2001). This 
suggested that the ribonucleotide sequence missing from the non-transformed RSV 
strains likely harbored the transforming gene. The retroviral oncogene accountable for 
the transforming potential of RSV, viral-Src (v-Src), was later sequenced (Czernilofsky, 
et al., 1980 and Czernilofsky, et al., 1983). Interestingly, a normal cellular counterpart 
of v-Src, named cellular-Src (c-Src), was detected upon hybridization of a 
complementary DNA v-Src probe to normal vertebrate DNA (Stehelin et al., 1976). c-
Src was denoted the first proto-oncogene, given its nature as a cellular precursor to the 
retroviral transforming gene, although it displayed inferior transforming activity toward 
chicken embryo fibroblast compared to its viral homologue (Iba et al., 1984 and Martin, 
2001). However, a role for c-Src in cancer has been extensively documented, as 
aberrant regulation leading to overexpression and/or activation of c-Src have been 
linked to events such as cellular transformation, tumorigenesis and metastasis (Summy 
and Gallick, 2003). 
 
1.5.2. c-Src Family Kinase Protein Structure and Regulation  
The gene products of the v-Src and c-Src genes encode highly similar 60 kDa 
non-receptor tyrosine kinases. v-Src, however, possesses 18 point mutations and is 
truncated by the replacement of 19 amino acids with 12 different amino acids at the C-
terminal end of the protein (Takeya and Hanafusa, 1983). c-Src is the archetype for a 
group of related c-Src family non-receptor tyrosine kinase (SFK) family members 
including: c-Yes, Fyn, Lyn, Lck, Hck, Fgr and Blk (Thomas and Brugge, 1997). The 
protein structures of c-Src and the SFK members range in size from 52-62 kDa and are 
similarly comprised of six functional domains, the N-terminal Src homology 4 (SH4) 
domain, the unique domain, the SH3 domain, the SH2 domain, the kinase or SH1 
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domain, and the C-terminal regulatory domain (Figure 1.4.) (Thomas and Brugge, 1997 
and Boggon and Eck, 2004). The SH4 domain is 14 amino acids in length and fosters 
the co-translational covalent linkage of myristic acid and, occasionally, palmitic acid at 
the very N-terminal of the SFK proteins (Biscardi et al., 1999 and Dehm and Bonham, 
2004a). These linkages tether the SFKs to the plasma membrane and facilitate 
interactions between signaling molecules, such as membrane bound receptor tyrosine 
kinases and integrin associated focal adhesions. The unique domain, of 40-70 amino 
acids, is weakly conserved among the SFKs and may be involved in mediating specific 
protein-protein interactions with individual family members, although the function of 
this domain is poorly understood (Brown and Cooper, 1996; Biscardi et al., 1999 and 
Boggon and Eck, 2004). Further, protein interactions with SFKs occur through the 
approximately 50 amino acid SH3 domain and the roughly 100 amino acid SH2 
domain, which bind to proline-rich consenus sequences (P-X-X-P) and phospotyrosine 
(pY) residues, respectively (Thomas and Brugge, 1997 and Alvarez et al., 2006). The 
SH2 domain has two binding pockets that prefer to interact with the pY-E-E-I amino 
acid sequence of proteins, where one pocket interacts with the phosphotyrosine (pY) 
residue and the other with the third amino acid residue downstream of the 
phosphotyrosine residue (Roskoski, 2004 and Thomas and Brugge, 1999). The SH1 
domain is a highly conserved, 250 amino acid tyrosine kinase catalytic domain that 
harbors a tyrosine residue within the activation loop that is critical for complete kinase 
activation of the SFK members (Brown and Cooper, 1996 and Boggon and Eck, 2004). 
The activating residue in the SH1 domain of c-Src resides at Y416 in chickens and 
Y419 in humans (Bjorge et al., 2000a). Finally, a 15-17 amino acid C-terminal 
regulatory domain holds an essential autoinhibitory phosphorylation site, which 
negatively regulates SFKs (Boggon and Eck, 2004). The c-Src autoinhibitory residue is 
Y527 in chickens and Y530 in humans (Brown and Cooper, 1996). v-Src lacks this 
autoinhibitory tyrosine residue (Takeya and Hanafusa, 1983). 
Regulation of SFK activity is maintained by a dynamic interplay of 
phosphorylation and dephosporylation events in coordination with intramolecular 
protein interactions (Frame, 2002). Inactivation of c-Src occurs following carboxy-
terminal Src kinase (Csk) phosphorylation of the autoinhibitory Y527 residue,  









Figure 1.4. The protein structure of chicken c-Src. The SH4 myristolation domain,
Unique domain, SH3 domain, SH2 domain, Linker, SH1 catalytic kinase domain
and regulatory domain are shown from the N- to C-terminal of the protein. The




prompting c-Src to bind its own SH2 domain, resulting in a “closed” conformation 
(Okada and Nakagawa, 1989). In addition, the SH3 domain contributes to the inactive 
kinase state by interacting with a linker region between the SH2 and the kinase domain 
(Xu et al., 1997). An open and active c-Src kinase configuration, on the other hand, can 
be stimulated by dephosphorylation of the Y527 by phosphatases, such as protein 
tyrosine phosphatase 1B (Bjorge et al., 2000b). A decrease in Csk activity also 
stimulates c-Src activation while direct phosphorylation of Y416 positively activates the 
c-Src kinase domain and encourages substrate interactions (Bjorge et al., 2000a and 
Cam et al., 2001). Also, higher affinity binding proteins, such as platelet-derived 
growth factor receptor (PDGFR) and focal adhesion kinase (FAK), may compete for c-
Src SH2 and SH3 domains to disrupt intramolecular interactions and activate c-Src 
(Bjorge et al., 2000a; Frame, 2002 and Yeatman, 2004). Moreover, mutation of Y527 or 
deletion of the c-Src C-terminal domain, as observed in v-Src, leads to constitutive 
activation of c-Src and the enhancement of cellular transformation (Cartwright et al., 
1987).  
 
1.5.3. Signaling Events Mediated by the c-Src Family Kinase Members 
Members of the family of c-Src kinases are differentially expressed across 
tissues. c-Src, Yes, and Fyn are expressed ubiquitously, while expression of the 
remaining SFKs Lck, Lyn, Hck, Blk are Fgr is primarily localized to hematopoietic 
cells (Thomas and Brugge, 1997). SFK members contribute to various signaling 
pathways, in different cellular contexts, through cell surface receptors including 
receptor protein tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs), 
integrin receptors, cadherin cell to cell adhesion molecules, and antigen receptors 
(Thomas and Brugge, 1997 and Parsons and Parsons, 2004). For example, c-Src, Yes 
and Fyn are activated upon stimulation of many RTKs and have been shown to mediate 
signaling of PDGFR, EGFR, FGFR, insulin growth factor receptor 1 receptor (IGF1R) 
and colony stimulating growth factor 1 receptor (CSF1R), in addition to a number of 
other RTKs, to positively regulate mitogenic events (Frame, 2002 and Bromann et al., 
2004). While in exchange, SFKs have been reported to reciprocally transactivate RTKs, 
and regulate RTK turnover (Bromann et al., 2004). Hormone stimulated GCPRs 
 50
enhance c-Src, Yes and Fyn recruitment and kinase activity, either by direct interaction 
with components of the GPCR or via crosstalk with the RTKs and focal adhesion 
complexes, to respectively control GPCR-containing vesicular trafficking, cellular 
proliferation and cytoskeleton rearrangements (Luttrell and Luttrell, 2004). Integrin 
receptors, bound by extracellular matrix proteins, facilitate the assembly of multi-
protein focal adhesion complexes, which encompass numerous proteins including FAK, 
p130CAS, talin, paxillin, vinculin, and c-Src (Playford and Schaller, 2004). Activated c-
Src, Yes and Fyn appear to stimulate focal adhesion disassembly, disrupt cell contact 
with the extracellular matrix and consequently enhance cellular motility (Playford and 
Schaller, 2004 and Yeatman, 2004). Furthermore, activated c-Src, in collaboration with 
FAK, has been implicated in the negation of cellular apoptosis resulting from cellular 
detachment from the extracellular matrix (Playford and Schaller, 2004). E-cadherin 
molecules from neighboring cells interact to form adherens junctions which activated c-
Src has been documented to upset by inhibiting E-cadherin localization to the cell 
surface and promoting E-cadherin endocytosis (Yeatman, 2004). A deficit in E-cadherin 
levels has been shown to increase cell invasion, therefore, c-Src prevents cell adhesion 
and promotes both cellular motility and invasion (Yeatman, 2004). In a more tissue 
specific manner, Lck and Fyn are activated during thymocyte development and 
maintenance of peripheral T-cells by the T-cell antigen receptor (Palacios and Weiss, 
2004). Similarly, Lyn, Fyn and Blk are activated by the B-cell antigen receptor to both 
positively and negatively regulate B-cell signaling events (Gauld and Cambier, 2004 
and Geahlen et al., 2004). Taken together, SFK members engage in a number of cellular 
signaling pathways associated with proliferation, differentiation, adhesion, migration, 
invasion, survival and development.  
 
1.5.4. c-Src Family Kinase Knockout Mice  
 Given that the SFK members have been implicated in such a diverse array of 
signaling processes, individual SFK knockout mice were predicted to display major 
phenotypic abnormalities. However, it was surprising to observe that src-/- mice were 
viable and only developed a bone remodeling defect that resulted in bone buildup, 
called osteopetrosis (Soriano et al., 1991). Hck and Fgr are two other SFKs, besides c-
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Src, which are expressed at high levels in mouse osteoclasts (Lowell and Soriano, 
1996). Interestingly, upon examination of src-/- mice, Hck protein levels were elevated 
in osteoclasts (Lowell and Soriano, 1996). Furthermore, the generation of double src-/- 
and hck-/- knockout mice produced a more severe osteopetrosis phenotype, suggesting 
that SFK members may compensate for one another in the absence of a family member 
(Lowell et al., 1996). Of the remaining ubiquitously expressed SFK members, Yes and 
Fyn, yes-/- knockout mice have no visible defects, while fyn-/- mice exhibited 
deficiencies in hippocampal development, long term potentiation, memory and 
thymocyte signaling (Stein et al., 1992 and Stein et al., 1994). Double knockout mice of 
src-/- yes-/- and src-/- fyn-/-, however, died perinatally, whereas a portion of yes-/- fyn-/- 
mutant mice survived with renal disease (Stein et al., 1994). In addition, other SFK 
knockout mice have been generated for SFK members expressed in a tissue specific 
manner. T-cells express high levels of Lck and Fyn. Mice possessing kinase dead Lck 
developed impairments in T-cell development and T-cell antigen receptor signaling, 
however, fyn-/- lck-/- double knockout mice were reported to display a significant 100-
fold reduction in T-cells (Levin et al., 1993 and Lowell and Soriano, 1996). 
Furthermore, high expression levels of Lyn, Fyn and Blk are present in B-cells. In 
accordance, lyn-/- knockout mice produced 50-65% less peripheral B-cells than wild 
type mice, while blk-/- mice have no abnormalities (Lowell and Soriano, 1996). 
Cumulatively, these observations suggest that there is significant functional redundancy 
between the SFK members. 
 
1.5.5. Role of the c-Src Family Kinase Members in Cancer  
Numerous groups have reported that aberrant regulation of SFK members is 
linked to cancer (Summy and Gallick, 2003). Of the SFK members, c-Src protein 
overexpression and/or enhanced kinase activity has been most thoroughly implicated in 
cellular transformation, tumor progression and metastasis (Biscardi et al., 1999; Frame, 
2002; Russello and Shore, 2003 and Summy and Gallick, 2003). Deregulation of c-Src, 
leading to high c-Src protein levels or elevated kinase levels, has been recurrently 
observed in colon and breast carcinomas, and less commonly detected in pancreatic, 
lung, brain, ovarian, bladder, gastric, head, neck and esophageal tumors (Summy and 
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Gallick, 2003). The relationship between c-Src and colorectal malignancies remains the 
most clearly defined example of c-Src involvement of tumorigenesis. Colon carcinoma 
cells and tissues prominently display up to a 40 fold increase in c-Src kinase activity 
when compared to normal adjacent colonic mucosa (Rosen et al., 1986; Bolen et al., 
1987 and Cartwright et al., 1989). Furthermore, enhanced c-Src kinase activity has been 
documented in early pre-malignant ulcerative colitis and colonic polyps (Cartwright et 
al., 1990 and Cartwright et al., 1994). As well, highly metastatic cells display 
constitutively elevated c-Src kinase activity above that in poorly metastatic cells in 
colon neoplasias (Han et al.1996, and Mao et al., 1997). In accordance, c-Src tyrosine 
kinase activity has been shown to increase with tumor progression, as pre-malignant 
polyps exhibit high c-Src kinase activity, which is elevated in primary colonic tumors, 
and greatest in hepatic metastases derived from colon carcinoma (Talamonti et al., 1993 
and Summy and Gallick, 2003). Recently, Gallick’s group has reported that elevated c-
Src kinase activity may serve as an independent indicator of poor clinical prognosis in 
colorectal carcinoma (Aligayer et al., 2002). In addition, antisense studies targeting c-
Src reduced tumor cell growth rate and tumorigenicity, indicating that c-Src may be an 
important therapeutic target in the treatment of carcinomas expressing high levels of c-
Src (Staley et al., 1997).  In tumor cells, the rise in c-Src protein levels and kinase 
activity may be mediated by multiple mechanisms, such as the overexpression of RTKs, 
high FAK protein levels, or a decrease in Csk expression levels (Summy and Gallick, 
2003). Moreover, activating c-Src mutations have been identified in a small percentage 
of highly advanced colon cancers, however, these results remain controversial (Irby et 
al., 1999). Elevated c-Src expression and enhanced kinase activity have also, more 
recently, been attributed to increased transcriptional activation in a subset of colon 
cancer cell lines (Dehm et al., 2001).  
In addition to c-Src overexpression in cancer, deregulation of Yes, Lck, Lyn 
expression and kinase activity have also been implicated in tumor development, 
proliferation, motility, invasiveness and progression (Summy and Gallick, 2003). The 
kinase activity of Yes is commonly enhanced in premalignant colonic adenomas and is 
high in both primary colon carcinomas and liver metastatic lesions, compared to normal 
colonic mucosa (Park et al., 1993; Pena et al., 1995 and Han et al., 1996). Furthermore, 
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augmented Yes protein kinase activity has been documented in breast, melanoma and 
small cell lung cancer cells (Loganzo et al., 1993 and Krystal et al., 1998). Lyn has 
been shown to be activated in T cell leukemia and lymphomas derived from B-cells, 
glioblastomas, and has also been reported to display significant levels of expression in 
colon and prostate cancer (Uchiumi et al., 1992; Chen et al., 1999; Bates et al., 2001; 
Goldenberg-Furmanov et al., 2004 and Stettner et al., 2005). Lck overexpression and 
/or kinase activation have been observed in colon cancer, small cell lung cancer and 
lymphocytic leukemia cells (Veillette et al., 1987; Abts et al., 1991; Nakamura et al., 
1996 and Krystal et al., 1998). 
 
1.5.6. SRC Gene Transcription 
 The human SRC gene resides on chromosome 20q12.3 and is comprised of 15 
exons (Figure 1.5.) (Anderson et al., 1985; Tanaka et al., 1985; Bonham and Fujita, 
1993 and Bonham et al., 2000). The first two exons, 1α and 1A, are separated by 
approximately 1 kb and are associated with their own individual promoter, SRC1α and 
SRC1A, respectively (Bonhman and Fujita, 1993 and Bonham et al., 2000). Exons 1B 
and 1C encode for the 5’ UTR of the c-Src mRNA while exons 2 through 12 code for 
the c-Src protein and the 3’ noncoding region. Alternative usage of the SRC1A and 
SRC1α promoters linked to their respective exons produce transcripts that commonly 
splice to exon 1B and, therefore, differ only in their extreme 5’ UTR and so code for 
identical c-Src proteins (Figure 1.5.).  
 The SRC1A promoter exhibits characteristics consistent with a housekeeping 
gene promoter, such as the presence of a high GC content and multiple transcription 
start sites (Bonham and Fujita, 1993). Regulation of this promoter is mediated by the Sp 
family of zinc finger transcription factors and hnRNP K (Ritchie et al., 2000 and 
Ritchie et al., 2003). Two proximal promoter binding elements, GC1 and GA2, interact 
with the Sp1 and Sp3 members of the Sp family, while hnRNP K associates with three 
polypurine:polypyrimidine tracts, TC1, TC2 and TC3 (Figure 1.5.) (Ritchie et al., 2000 
and Ritchie et al., 2003). Sp1 and Sp3 are ubiquitously expressed proteins that encode 
highly analogous structures and bind GC boxes with equivalent affinity, however, Sp1 
and Sp3 differ in their DNA binding characteristics and regulatory abilities (Li et al.,  
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Figure 1.5. The human SRC gene. The organization of the SRC intron and exon
(colored boxes) boundaries are denoted. The 5' non-coding SRC exons are 1 (green), 1
A (blue), 1B, (red), and 1C (red). The SRC coding region and 3' UTR are encoded by
exons 2 through 12 (black = coding region, orange = 3' UTR). The SR1 and SRC1A
promoters with their associated exons shown. The SRC1 promoter contains a -
acting HNF-1 proximal promoter element.The SRC1A promoter is regulated by the
GC1, GA2, TC1, TC2 and TC3 proximal promoter elements. The SRC promoters
transcribe products that vary only in their extreme 5' end and commonly splice to Exon
1B. The arrows indicate the approximate transcription start sites. (Bonham and Fujita,
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2004a). While Sp1 binds GC boxes as multimers and synergistically trans-activates 
promoters that possess multiple Sp binding sites, Sp3 binds DNA binding elements as a 
monomer and may act as either a transcriptional activator or repressor, based on the 
promoter context (Mastrangelo et al., 1991; Su et al., 1991; Yu et al., 2003 and Li et al., 
2004a). In the case of the SRC1A promoter, both Sp1 and Sp3 activate SRC1A 
transcription through the GC1 and GA2 sites, although the sumoylated form of Sp3 may 
negatively regulate SRC1A transcription (Ritchie et al., 2000 and Ellis et al., 2006). 
Polypurine:polypyrimidine tracts have been reported to assume non-B-DNA structures 
and develop H-DNA conformations of triple- and single-stranded DNA (Mirkin and 
Frank-Kamenetskii, 1994). Interestingly, hNRNP K binds the TC1 and TC2 tracts in 
both double and single-stranded forms, and has single-stranded DNA binding ability 
toward the TC3 tract (Ritchie et al., 2000). Cumulatively, Sp1/Sp3 interaction with the 
GC1 and GA2 sites and hnRNP K binding of TC1 and TC2 tracts cooperate to activate 
transcription and ensure ubiquitous expression of the SRC1A promoter (Ritchie et al., 
2000).  
 In contrast to the SRC1A promoter, the SRC1α promoter is much more tissue 
specific; it is expressed primarily in stomach, pancreas, liver, kidney, prostate and gut 
tissues (Figure 1.5) (Bonham et al., 2000). This promoter is controlled by a single 
hepatocyte nuclear factor-1 (HNF-1) proximal promoter DNA binding element and is 
regulated by the liver enriched transcription factor, HNF-1α (Bonham et al., 2000).   
Although the SRC1A and SRC1α promoters differ vastly, both promoters lack a 
TATA-box proximal promoter element and have recently been documented to harbor 
potential Inr elements (Dehm et al., 2004). Furthermore, these SRC1A and SRC1α Inr 
elements directly interact with TAF1-TAF2 in vitro and have been demonstrated to 
possess TAF1 dependency in temperature sensitive (ts) tsBN462 cells (Dehm et al., 
2004). tsBN462 cells are derived from a baby hamster kidney cell line (BHK-21) that 
harbors a TAF1 mutation in the AT domain (G690A), which results in TAF1 AT 
inactivation, G1 cell cycle arrest and cell death at the nonpermissive temperature 




1.5.7. The c-Src Family Kinase YES, LYN and LCK Gene Promoters 
 Relatively little is known about the YES and LYN promoters, aside from initial 
observations (Matsuzawa et al., 1991 and Uchiumi et al., 1992). The YES promoter, 
similar to the SRC1A promoter, is a ubiquitously expressed housekeeping-like 
promoter, lacking a TATA-box, possessing multiple transcription sites and a GC-rich 
sequence (Figure 1.6.) (Matsuzawa et al., 1991). Moreover, five GC boxes have been 
identified in the YES promoter, four of which are immediately upstream of the major 
transcription start site, referred to as the GC-cluster (GC1-GC4), while the additional 
GC-box further upstream is called GC5 (Matsuzawa et al., 1991). All five GC-boxes 
were shown to be important cis-acting regulatory sequences within the YES promoter, 
and Sp1 was documented to interact with GC5 as well as the four GC boxes in the 
cluster (Matsuzawa et al., 1991). The LYN promoter is primarily expressed in B 
lymphocytes, and to a lesser degree in T cells (Uchiumi et al., 1992). Interestingly, the 
LYN promoter also does not contain a TATA box, and harbors multiple transcription 
start sites as well as three GC box sequence motifs (Figure 1.6.) (Uchiumi et al., 1992). 
In addition, an octamer transcription factor (OTF) consensus site in the LYN proximal 
promoter interacts with OTF-1 and likely facilitates LYN transcription (Uchiumi et al., 
1992). Surprisingly, the LCK gene has been quite well characterized and contains two 
distinct promoters spaced approximately 35 kb apart, LCK type I and LCK type II,  
which produce transcripts that diverge only in their 5’ UTR and encode the same 
protein (Adler et al., 1988 and Takadera et al., 1989). Lck expression is largely 
restricted to T cells and B cells, but has also been reported in colorectal carcinoma cells 
and small cell lung carcinomas (Veillette et al., 1987; Adler et al., 1988; Abts et al., 
1991; Nakamura et al., 1996 and Krystal et al., 1998). The proximal LCK type I 
promoter is activated in immature thymocytes and colon cancer cells, while the distal 
LCK type II promoter is predominantly expressed T and B cells (Sartor et al., 1989; 
Leung et al., 1993 and Nakamura et al., 1996). Furthermore, malignant lymphocytes 
have been reported to use both the proximal and distal LCK promoters (Sartor et al., 
1989 and Leung et al., 1993). Similar to the other SFK promoters, the LCK type I 
promoter is TATA-less and has more than one transcription start site (Leung et al., 


















GC1 GC2 GC3 OTF
Figure 1.6. Gene promoters of human c-Src family kinase members. The proximal
promoter -acting DNA binding elements are shown for the YES, LYN and LCK
type I promoters. The YES promoter is regulated by five GC boxes, GC5 through
GC1. LYN transcription is controlled by GC1, GC2, GC3, and an OTF motif. Activity
of the LCK type I promoter is regulated by a repressive element, EBE and HMG
consensus site in colorectal carcinoma cells. The EBE and Myb sites control LCK
type I transcription in T cells. The arrows indicate the approximate transcription start
sites. (
cis
Matsuzawa , 1991, Uchiumi , 1992, Leung , 1993, McCraken
, 1994, Muise-Helmericks and Rosen, 1995 and McCraken , 1997)
et al. et al. et al.
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LCK type I promoter, an ETS binding element (EBE) and a Myb binding site, which 
interact with Ets1 or Ets2 and Myb transcription factors, respectively (Leung et al., 
1993 and McCraken et al., 1994). Transactivation of the LCK type I promoter in 
colorectal carcinoma cells requires the EBE and a high mobility group (HMG) 
consensus binding site in the proximal promoter (McCraken et al., 1997).  The 
transcription factors Ets1 and Sox-4 have been reported to associate with these elements 
in colon cancer cells and cooperatively activate the LCK type I promoter (McCraken et 
al., 1997). Furthermore, a cis-acting repressive element has also been identified in the 
LCK type I promoter that may control LCK transcription in colorectal cancer cells 




In 1993, back to back reports were published in ‘Cell’ describing a novel protein 
that interacted with and inhibited cyclin dependent kinase (Cdk) activity, termed Cdk-
interacting protein 1 (CIP1), as well as a gene product whose promoter was directly 
transactivated by the transcription factor p53, and so named wild-type p53-activated 
factor (WAF1) (Harper et al., 1993 and el-Deiry et al., 1993). Four months later, a third 
laboratory reported their discovery of a protein derived from senescent cells that 
inhibited DNA synthesis, labeled senescent cell-derived inhibitor 1 (sdi1) (Noda et al., 
1994). Interestingly, CIP1, WAF1 and sdi1 shared identical sequences and encoded the 
same 21 kDa protein, here on referred to as p21WAF1. 
1.6.1. p21WAF1 Protein Function 
 The cell cycle is regulated by the ordered activation and inactivation of cyclin-
Cdk complexes. p21WAF1 is a cyclin dependent kinase inhibitor (CKI) that belongs to 
the Cip/Kip family and plays an important role in the regulation of cyclin-Cdk kinase 
activity. Through interactions with the catalytic subunits Cdk2, Cdk4 and Cdk6, 
p21WAF1 is involved in regulating the transition from G1 (Gap1) to S (synthesis) 
phase of the cell cycle (Harper et al., 1995). At the start of the G1 phase, mitogenic 
signals stimulate transcription and translation of D-type cyclins (D1, D2, and D3), and 
promote their assembly into cyclin D-Cdk complexes with either the Cdk4 or Cdk6 
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catalytic subunit (Sherr and Roberts, 2004). Upon assembly, cyclin D-Cdk complexes 
are imported to the nucleus and activated by Cdk-activating kinases (CAK) (Sherr and 
Roberts, 1999). At the G1 midpoint, activated cyclin D-Cdk complexes, in succession 
with activated cyclin E-Cdk2 complexes, phosphorylate Rb family members (Coqeret, 
2002). These phosphorylation events disrupt the interaction of Rb with E2F 
transcription factors and, therefore, relieve the inhibitory effect of Rb on E2F family 
members, enabling E2F activation of target genes in late G1 phase (Sherr and Roberts, 
1999). Genes trans-activated by E2F include a cluster involved in DNA synthesis, as 
well as cyclin E and cyclin A2 (Sherr and Roberts, 2004). Newly assembled cyclin E-
Cdk2 complexes prolong Rb phosphorylation, further enhancing the expression of E2F 
responsive genes (Sherr and Roberts, 2004). In addition, activated Cyclin D-Cdk4 and 
Cyclin E-Cdk2 complexes inhibit transforming growth factor beta (TGF-β) anti-
proliferative signals by phosphorylating the Smad3 transcription factor, which prevents 
Smad3 transactivation of CKI genes, including p15 and p21WAF1 (Sherr and Roberts, 
2004 and Liu and Matsuura, 2005). Cyclin E-Cdk2 and cyclin A2-Cdk2 complexes also 
facilitate entry into S-phase of the cell cycle by inducing phosphorylation of the CKI 
p27, marking it for proteasomal degradation (Sherr and Roberts, 2004).  
p21WAF1 arrests the cell cycle in the G1 phase by inhibiting Cdk kinase 
activity of cyclinE-Cdk2 and cyclin A-Cdk2 complexes and averting Rb and Smad3 
hyperphosphorylation (Sherr and Roberts, 2004 and Liu and Matsuura, 2005). In this 
manner, p21WAF1 is involved in both maintaining the repression of E2F-responsive 
genes and activating the transcription of Smad3 target CKIs. Additionally, p21WAF1 
inactivates Cdk2 complexes, abolishing p27 phosphorylation and subsequent 
degradation, providing a tertiary means of inhibiting cell cycle progression beyond G1 
(Sherr and Roberts, 1999 and Sherr and Roberts,. 2004). However, in proliferating cells, 
p21WAF1 appears to be sequestered by cyclin D-Cdk complexes. While Cdk activity is 
not inhibited by this association, cyclin D-Cdk assembly, nuclear translocation and 
activation are promoted (Sherr and Roberts 1999 and Coqeret, 2002). At the same time, 
the pool of p21WAF1 available for cyclin E-Cdk2 and cyclin A2-Cdk2 binding is 
decreased (Sherr and Roberts 1999 and Coqeret, 2002). Therefore, p21WAF1 may be 
titrated by cyclin D-Cdk complexes, allowing the activation of Cdk2 complexes in the 
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late phase of G1 (Coqeret, 2002). Upon inhibition of cyclin D-Cdk by either CKI p16 or 
inactivation of mitogenic signals, cyclin D-Cdk complexes are disrupted and 
sequestered p21WAF1 is consequently released, promoting p21WAF1 association with 
cyclin E-Cdk2 and cyclin A2-Cdk2 and inhibition of the cell cycle (Sherr and Roberts, 
1999). In addition to inducing G1 arrest, elevated p21WAF1 levels have been 
implicated as a contributing factor in S and G2/M phase arrest (Ogryzko et al., 1997 and 
Niculescu et al., 1998). Furthermore, p21WAF1 suppresses DNA synthesis and induces 
growth arrest by a supplementary mechanism, in which the activity of proliferating cell 
nuclear antigen (PCNA), a DNA polymerase delta processivity factor, is directly 
inhibited (Kelman, 1997). An additional role for p21WAF1 as a transcriptional cofactor 
has also been proposed, given that mutant p21WAF1 lacking the ability to bind either 
Cdks or PCNA is still able to suppress the expression of E2F-responsive genes (Perkins, 
2002). p21WAF1 has been shown to transcriptionally upregulate the insulin-like growth 
factor I (IGF-I) gene and behaves as a function repressor of c-myc and cdc25 
transcription upon association with these promoters (Devgan et al., 2006 and Vigneron 
et al., 2006). Taken together, p21WAF1 is an essential component of cell cycle, and an 
important regulator of cellular proliferation.  
 
1.6.2. Regulation of p21WAF1  
The mechanisms facilitating p21WAF1 regulation have been intensively studied, 
along with their possible connections to cellular transformation, given that p21WAF1 is 
a critical modulator of the cell cycle arrest and an essential factor in the maintenance of 
normal cell growth. p21WAF1, itself, has rarely been found to harbor mutations in 
tumor cells, however, a key regulator of p21WAF1 expression has been explicitly 
implicated in human malignancies (Shiohara et al., 1994 and Shiohara et al., 1997). The 
tumor suppressor protein p53 is an important trans-activator of p21WAF1 transcription, 
mediating induction of the CKI and cell cycle arrest when met with cellular stress (el-
Deiry et al., 1993). In excess of 21,000 mutations have been reported in the p53 gene, 
with a large percentage of these residing in the DNA-binding domain, which prevents 
p53 mediated trans-activation of target genes (Liu and Chen, 2006 and Toledo and 
Wahl, 2006). Therefore, it has been suggested that tumors lacking wild-type p53 may 
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have compromised p21WAF1 expression levels. However, p21WAF1 may also be 
activated by p53 independent transcriptional mechanisms, including HDI stimulated 
transcription upon introduction of these anti-tumor agents (el Deiry et al., 1994 and 
Nakano et al., 1997). While p21WAF1 expression levels are relatively low in normal 
dividing cells, the regulation of p21WAF1 is primarily controlled at the transcriptional 
level by p53 dependent and p53 independent regulatory mechanisms (el Deiry et al., 
1994 and Gartel and Tyner, 1999). In addition, post-transcriptional mechanisms have 
also been reported to play a supporting role in the regulation of p21WAF1 levels 
(Gorospe et al., 1998).  
1.6.2.1. p53 Dependent Regulation of p21WAF1 Transcription 
Loss of p53 function is evident in the majority of human neoplasms. While 50% 
of human cancers display mutations in the p53 gene itself, many other tumors exhibit 
alterations in p53 regulatory proteins, such as amplification or overexpression of the 
p53 regulatory factor, MDM2 (Baker et al., 1989 and Toledo and Wahl, 2006). p53 is a 
well characterized tumor suppressor protein involved in stimulating cell cycle arrest, 
apoptosis, senescence and DNA repair upon cellular stresses, such as genotoxic stress 
(UV irradiation, carcinogens, cytotoxic drugs) induced DNA damage, non-genotoxic 
stress (physical strain, ribonucleotide depletion, hypoxia) and oncogenic stress (high 
growth signaling and oncogene expression) (Guimaraes and Hainaut, 2002; Bode and 
Dong, 2004 and Toledo and Wahl, 2006). Protein stabilization is the major regulatory 
mechanism of p53 expression, allowing rapid accumulation of p53 in response to 
cellular stress and the inhibition of damaged cell growth. Under normal or unstressed 
cellular conditions, p53 is a relatively unstable and inactive protein regulated by the E3 
ubiquitin ligase activity of MDM2 and consequential 26S proteasome degradation. 
(Bode and Dong, 2004). However, upon cellular stress, p53 is stabilized and amasses in 
the nucleus, where it forms active homotetrameric transcription factor complexes that 
interact with and activate genes carrying p53 responsive elements, such as p21WAF1 
(Bode and Dong, 2004). Post-translational modifications of the N-terminal 
transactivation domain, proline-rich domain and C-terminal regulatory domain of p53 
have been proposed to regulate p53 stabilization and activity (Brooks and Gu, 2003 and 
Bode and Dong, 2004). In this model, unstressed cells maintain p53 in an inactive state 
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through MDM2 interaction with the N-terminal transactivation domain, while MDM2 
ubiquitylation of the p53 C-terminal regulatory domain marks p53 for proteasome 
degradation (Brooks and Gu, 2003; Bode and Dong, 2004 and Toledo and Wahl, 2006). 
Conversely, post-translational modifications activate and stabilize p53 upon genotoxic 
cellular stress by inducing phosphorylation events within the N-terminal transactivation 
and proline-rich domains of p53 that disrupt MDM2 binding and enhance histone 
acetyltransferase association (Brooks and Gu, 2003; Bode and Dong, 2004 and Toledo 
and Wahl, 2006).  p300 and CBP co-activator recruitment to the transactivation domain 
of p53 has been proposed to promote the acetylation of lysine residues in the C-terminal 
regulatory domain of p53, which consequently blocks ubiquitylation of these residues 
and possibly assists in histone acetylation of target genes (Brooks and Gu, 2003; Bode 
and Dong, 2004 and Toledo and Wahl, 2006). Furthermore, Set9 methylation of the p53 
C-terminal domain has also been suggested to contribute to p53 stabilization by 
blocking MDM2 ubiquitylation (Liu and Chen, 2006). However, the role that MDM2 
and post-translational mechanisms play in stabilizing p53 protein levels and activating 
p53 responsive genes may not be as simplistic nor as prominent as discussed 
(Guimaraes and Hainaut, 2002 and Toledo and Wahl, 2006). Nonetheless, p53 is an 
important regulator of p21WAF1 transcription and downstream p21WAF1 mediated 
growth arrest. 
The p21WAF1 promoter contains two p53 responsive elements (RE), positioned 
at -2301 and -1384 bp relative to the transcription start site (Figure 1.7) (el Deiry et al., 
1993). Each of these REs contain two 10 bp sequences of 5’ PuPuPuC(A/T)(T/A)Gpy 
PyPy-3’, separated by a maximum of 13 bp (el Deiry et al., 1993 and Gartel and 
Tyner,1999). The p21WAF1 promoter is activated by p53 in response to genotoxic 
stress, such as caused by γ-ionizing radiation and doxorubicin, which induces DNA 
damage (el Deiry et al., 1994). Resultant p21WAF1 induction has been suggested to be 
a definitive requirement for p53 facilitated G1 cell cycle arrest in tumor cells (Waldman 
et al., 1995). In addition to DNA damaging events, upregulation of p53 and the 
consequent enhancement of p21WAF1 transcription also occur upon ribonucleotide 
depletion and enhanced Ras oncogene signaling (Gartel and Tyner, 1999). Therefore, 
part of the tumor suppressor function of p53 is mediated by p21WAF1 upregulation 
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when the cell is under various forms of stress. Hence, the absence of wild-type p53 in 
many human cancers may prevent cell cycle arrest in response to cellular stress.  
1.6.2.2. p53 Independent Regulation of p21WAF1 Transcription 
The p21WAF1 promoter is also activated in a p53 independent manner by a 
wide array of signaling events and downstream transcription factors (el Deiry et al., 
1994). The p21WAF1 proximal promoter contains a consensus TATA box and 
negotiates many p53 independent actions through six proximal Sp1 binding sites 
between -119 and -50 bp (Sp1-1: -119 to -114 bp, Sp1-2: -109 to -104 bp, Sp1-3: -82 to 
-76 bp, Sp1-4: -70 to -64 bp, Sp1-5: -60 to -53 bp, Sp1-6: -56 to -50 bp) (Figure 1.7.) (el 
Deiry et al., 1993 and Gartel and Tyner, 1999). For example, in the absence of p53, the 
tumor suppressor protein breast cancer gene 1 (BRCA1) induces p21WAF1 expression 
through p53 independent transcription by mediating transactivation through a BRCA1  
responsive element (BRE) located between -143 and -93 bp of the proximal promoter 
(Gartel and Tyner, 1999 and Somasundaram, 2003). In contrast, the differentiating 
agents phorbol myristate acid (PMA) and okadaic acid (OA) mediate p21WAF1 
transcription through Sp1 association with the Sp1-1 and Sp1-2 binding elements 
(Gartel and Tyner, 1999). HDIs have been reported to upregulate p21WAF1 
transcription via the Sp1-3 and Sp1-4 sites of the promoter (Nakano et al., 1997). 
Androgen stimulation of p21WAF1 requires androgen receptor interaction with both the 
androgen response element and Sp1 at the Sp1-3 site in the p21WAF1 proximal 
promoter (Lu et al., 1999 and Lu et al., 2000). Furthermore, progesterone controls 
activation of the p21WAF1 promoter by progesterone receptor binding of Sp1 linked to 
the Sp1-3 and Sp1-4 binding elements, in cooperation with CBP/p300 (Owen et al., 
1998 and Gartel and Tyner, 1999). The p21WAF1 promoter is also activated in 
response to TGF-β signaling, via binding of Smad3 and Smad4 proteins to Sp1, which 
enhances the affinity of Sp1 for the Sp1-3 site of the p21WAF1 proximal promoter 
(Pardali et al., 2000). TGF-β also stimulates p21WAF1 transcription by inducing the 
expression of c-jun, a known Sp1 superactivator (Kardassis et al., 1999). As well, four 
E2F transcription factor binding elements and an activator protein 2 (AP2) binding 
motif also exist in the p21WAF1 proximal promoter that regulate transcription (Gartel 
and Tyner, 1999).  
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Figure 1.7. Regulation of the p21WAF1 promoter. Various -acting responsive
elements and proximal promoter elements mediate transactivation of the p21WAF1
promoter in response to cellular stress (DNA damage, ribonucleotide depletion,
oncogenic signaling), tumor suppressor genes (p53, breast cancer gene 1 - BRCA1),
growth factor signaling (epidermal growth factor - EGF, fibroblast growth factor -
FGF, transforming growth factor beta -TGF- ), hormones (dexamethasone, retinoic
acid - RA, vitamin D , androgen, progesterone), differentiation factors (phorbol
myristate acetate - PMA, okadaic acid - OA), and histone deacetylase inhibitors -
HDIs. The Sp1 binding sites are numbered 1-6. (Gartel 1999 and Gartel
2005)
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In addition, the p21WAF1 promoter contains cis-regulatory elements beyond the 
proximal promoter region responsible for activating transcription (Figure 1.7) (Gartel 
and Tyner, 1999). To name a few, Vitamin D3 stimulates the p21WAF1 promoter 
through a vitamin D responsive element at -771 bp, and a retinoic acid responsive 
element has been characterized at -1203 bp that facilitates RA activation of p21WAF1 
(Liu et al., 1996a and Liu et al., 1996b). A DNA binding element for CCAAT/enhancer 
binding protein-α (C/EBPα), which resides at -1270 bp, is required for dexamethasone 
activation of the p21WAF1 promoter (Cha et al., 1998 and Gartel and Tyner, 1999). 
Furthermore, three STAT binding sites are present at -690, -2590, and -4233 bp, which 
mediate epidermal growth factor (EGF), fibroblast growth factor (FGF), and IFN-γ 
activation of the p21WAF1 promoter by STAT1 (Chin et al., 1996 and Gartel and 
Tyner, 1999). Thus, the p21WAF1 promoter is activated through various cis-acting 
elements by an array of factors, including cellular stress, tumor suppressor genes, 
differentiation agents, hormones and growth factors (Kardassis et al., 1999). 
1.6.2.3. Histone Deacetylase Inhibitor Regulation of p21WAF1/Cip1 Transcription 
As HDIs are such promising chemotherapeutic agents, and p21WAF1 has been 
thoroughly implicated as an inducer of cell cycle arrest, the role that p21WAF1 may 
play in mediating the anti-tumor effects of HDIs has been extensively investigated. 
Early studies into the involvement of p21WAF1 in HDI facilitated cell cycle arrest, 
differentiation and apoptosis identified that p21WAF1 was an absolute requirement for 
G1 growth arrest in response to butyrate in colon cancer cells (Archer et al., 1998). 
Furthermore, parallel observations have since been documented upon butyrate and MS-
275 treatment in myelomonocytic leukemia cells (Rosato et al., 2001 and Rosato et al., 
2003). Hence, as a consequence of this information, the cyclin dependent kinase 
inhibitor p21WAF1 has easily become the most extensively studied HDI responsive 
gene.  
Reports by Toshiyuki Sakai’s group have provided the foundation of HDI 
mediated p21WAF1 regulation, outlining that the HDIs butyrate, TSA and SAHA 
induced p21WAF1 transcription independent of p53 and free of new protein synthesis 
(Nakano et al., 1997; Sowa et al., 1997 and Huang et al., 2000). HDI transcriptional 
activation of the p21WAF1 promoter was reported to chiefly require the third Sp1 
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binding element upstream of the TATA box, Sp1-3, while the Sp1-4 site also appeared 
to display involvement (Figure 1.7.) (Nakano et al., 1997 and Sowa et al., 1997). 
Furthermore, both Sp1 and Sp3 were identified to interact with these Sp1 sites, and 
while the binding affinity of neither transcription factor changed upon TSA or SAHA 
treatment, the transactivation domain of Sp3, but not Sp1 was found to mediate TSA 
upregulation of p21WAF1 transcription (Sowa et al. 1999 and Huang et al. 2000). Sp1 
and Sp3 were, however, reported to facilitate SAHA induced transcription of the 
p21WAF1 promoter (Huang et al., 2000). In addition to these observations, Sakai also 
noted prominent increases in global H4 acetylation levels and growth arrest at the G1 
and G2/M phases of the cell cycle in association with TSA treatment (Sowa et al., 
1997). Similarly, other groups reported that HDIs, including MS-275 and apicidin, 
increased p21WAF1 transcription independent of p53 and de novo protein synthesis, as 
well as enhanced global histone H3 and/or H4 acetylation and the percentage of cells in 
G1 cell cycle arrest (Saito et al., 1999; Han et al., 2000 and Han et al., 2001). 
Furthermore, the advent of the chromatin immunoprecipitation (ChIP) assay revealed 
that overall H3 and H4 acetylation levels were selectively induced in the chromatin 
associated with the p21WAF1 promoter and downstream gene, upon treatment with 
SAHA and apicidin (Richon et al., 2000 and Kim et al., 2001). This suggested that local 
histone acetylation may regulate HDI activation of selective genes, such as p21WAF1. 
Fueling greater support of this theory, p300 was implicated in TSA stimulation of the 
p21WAF1 promoter via the Sp1-4 element, while HDAC1, HDAC2 and HDAC3, 
which are capable of attenuating butyrate induced p21WAF1 transactivation, were 
conversely identified as repressors of p21WAF1 transcription (Xiao et al., 2000; Lagger 
et al., 2003; Gui et al., 2004; Huang et al., 2005 and Wilson et al., 2006). Taken 
together, HDIs have been proposed to induce cell cycle inhibition via p21WAF1 
transcriptional activation as a consequence of gene hyperacetylation, subsequent 
chromatin remodeling and transcription factor recruitment.  
However, histone hyperacetylation of the p21WAF1 gene may not fully justify 
transcriptional activation. A report has identified protein kinase C (PKC) as an essential 
signaling molecule associated with butyrate, TSA and apicidin driven p21WAF1 
upregulation (Han et al., 2001). More specifically, a signaling pathway that proposes 
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phosphatidylinositol 3-kinase (PI 3-kinase) as the upstream effector of the PCK 
epsilon isoform has been elucidated. The PCKε isoform then, via the Sp1-3 site of the 
p21WAF1 promoter facilitates apicidin induced p21WAF1 expression, (Han et al., 
2001 and Kim et al., 2003). Apicidin treatment has also been shown to enhance histone 
H3 acetylation levels in the p21WAF1 promoter (Han et al., 2000 and Han et al., 2001). 
Treatment with either a PI 3-kinase or PKC inhibitor in addition to apicidin, however, 
reduced p21WAF1 promoter expression without decreasing apicidin induced H3 
acetylation, thereby suggesting that histone hyperacetylation and chromatin remodeling 
are inadequate for p21WAF1 activation (Kim et al., 2003). PI 3-kinase activity has also 
been independently identified as a prerequisite for HDI transactivation of p21WAF1 in 
the study of Ataxia telangiectasia disorder (Ju and Muller, 2003). Furthermore, another 
report suggests that HDI mediated downregulation and release of c-myc from the 
p21WAF1 proximal promoter may play a contributing role in p21WAF1 gene 
induction, as c-myc is a known repressor of p21WAF1 (Gui et al., 2004 and Li and Wu, 
2004). In addition, the HDI depsipeptide has been documented to enhance p21WAF1 
promoter activity by p53 independent and p53 dependent mechanisms, where p53 
acetylation at K373/K382 promoted a p53 protein longer half-life and enhanced DNA 
binding affinity of p53 to the p21WAF1 promoter (Zhao et al., 2006). Therefore, the 
mechanism of HDI mediated growth arrest via p21WAF1 upregulation likely requires 
extra events beyond enhancing histone acetylation levels. 
1.6.2.4. p21WAF1 mRNA stability 
  While regulation of p21WAF1 expression levels has been prominently 
documented to arise from transcriptional mechanisms, control of p21WAF1 mRNA 
stability should not be disregarded as an additional p53 independent regulatory means. 
To date, many cellular agents have been reported to induce p21WAF1 mRNA stability. 
For example, PMA and Vitamin D3 mediate differentiation of human promyelocytic 
cells into monocytes by enhancing p21WAF1 mRNA stability, without affecting the 
rate of p21WAF1 transcription (Schwaller et al., 1995). Furthermore, p21WAF1 mRNA 
stability is also upregulated by: novel retinoid CD437 prolonged stimulation of the 
p42/44 mitogen-activated protein kinase pathway, amino acid depletion, ultraviolet light 
(UVC) irradiation, prostaglandin A2, the α1-adrenergic receptor agonist phenylephrine, 
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and EGF (Li et al., 1996; Gorospe et al., 1998; Johannessen et al., 1999; Liu et al., 
2000; Park et al., 2000; Giles et al., 2003; Leung-Pineda et al., 2004 and Yang et al., 
2004).  
Investigation into the mechanism underlying p21WAF1 post-transcriptional 
regulation has focused on cis-acting stability determinants within the 3’ UTR of the 
p21WAF1 mRNA and the identification of trans-associated RNA binding proteins 
(Figure 1.8.). Importantly, the p21WAF1 3’UTR (corresponding to nucleotides 571 
through 2102 of the mRNA) contains three highly destabilizing AREs, termed A (742 to 
759 ntd), B (798 to 810 ntd) and C (812 to 825 ntd), as well as a 42 nucleotide HuD 
binding element (658 to 700 ntd) located within a U-rich tract (el-Deiry et al., 1993 and 
Joseph et al., 1998). UVC mediated stabilization of p21WAF1 mRNA levels provided  
the first direct evidence for the involvement of the p21WAF1 3’ UTR in mRNA 
stabilization, as UVC was shown to trigger an interaction between cytoplasmic HuR and 
a fragment of the 3’ UTR, which mapped to the proximal 3’ UTR nucleotide sequence 
571 to 851 (Wang et al., 2000). An additional report specified that UVC caused a 
decrease in the association of AUF1 with the 3’ UTR and enhanced the interaction of 
HuR with the p21WAF1 mRNA, which ultimately led to an overall increase in the 
abundance of HuR-bound p21WAF1 mRNA in the polysomal fraction (Lal et al., 
2004). As well, Poly(C) binding protein, CP1, has also been documented to interact 
with the ribonucleotide sequence between 571 to 829 and may potentially play a role in 
p21WAF1 mRNA stabilization upon UVC exposure (Giles et al., 2003). Similar to 
what happens following UVC exposure, HuR interacts with nucleotides 570 to 830 of 
the p21WAF1 3’ UTR and stabilizes p21WAF1 mRNA levels following prostaglandin 
A2 treatment (Yang et al., 2004). Furthermore, nucleotides 630-707 of the p21WAF1 3’ 
UTR have also been implicated in mRNA stabilization and interact with an unidentified 
trans-RNA binding protein in the presence of phenylephrine (Liu et al., 2000). 
Therefore, the first 300 bases of the p21WAF1 3’ UTR appear to contain important 
determinants of p21WAF1 mRNA stability. However, evidence also exists for yet 
uncharacterized p21WAF1 3’ UTR stability determinants downstream of the HuD and 
ARE elements, as removal of the proximal region of the 3’ UTR still results in rapid 
mRNA destabilization (Li et al., 1996 and Giles et al., 2003). Furthermore, EGF has  
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Figure 1.8. The p21WAF1 mRNA and the -acting RNA binding proteins that
regulate p21WAF1 mRNA stability in response to various agents. Nucleotides 1-75
encompass the 5' UTR, 76-570 the coding region and 571-2102 the 3' UTR. The HuD
and ARE (A, B, and C) -acting determinants are shown in the 3' UTR. Regions of
the 3' UTR and the -acting factors important for mRNA stabilization of p21WAF1
upon exposure of UVC, prostaglandin A2, phenylephrine and EGF are denoted above







recently been reported to regulate p21WAF1 mRNA stability through multiple cis-
acting determinants associated with the mRNA sequence between nucleotides 879 and 
2102 of the 3’ UTR (Giles et al., 2003). Therefore the 3’ UTR of the p21WAF1 mRNA 



































2. SPECIFIC AIMS AND HYPOTHESIS 
Histone deacetylase inhibitors (HDIs) are impressive anti-tumor agents that 
elicit a wide range of regulatory actions in malignant cells. The HDI butyrate is a 
naturally manufactured product of dietary fiber in the colon responsible for the 
maintenance of normal colonic mucosa growth. Conversely, butyrate invokes cell cycle 
arrest, differentiation, and/or apoptosis in tumor cells, suggesting that high fiber diets 
may have a chemo-preventive effect against colonic malignancies. Interestingly, 
elevated expression levels and/or kinase activity of the proto-oncogene c-Src and the c-
Src family kinase (SFK) members have been extensively reported in human neoplasms, 
in particular those of the colon. Furthermore, downregulation of c-Src decreases tumor 
cell growth and tumorgenicity, suggesting that c-Src may be an important therapeutic 
target in the treatment of carcinomas expressing high levels of c-Src.  
The mechanisms of HDI action are not well understood. HDIs have 
characteristically been associated with histone acetylation coupled to transcriptional 
activation. The cyclin dependent kinase inhibitor p21WAF1 has served as the model 
gene for HDI mediated regulation, although transcriptional repression of a number of 
genes has also been observed following treatment with these drugs. Furthermore, HDIs 
have been implicated in non-histone acetylation and the alteration of phosphorylation 
status. We, therefore, sought to investigate HDI mediated gene regulation in tumor 
cells. 
 
HYPOTHESIS: Histone deacetylase inhibitors regulate the expression levels of the c-




SPECIFIC AIMS:   
1) To examine the effects of butyrate on the expression levels of c-Src and the c-Src 
family kinase members in colon cancer cells. 
2) To identify the mechanism of histone deacetylase inhibitor stimulated p21WAF1 








3. MATERIALS AND METHODS 
3.1. Reagents, Equipment, Software and Distributors 
 The distributors of the reagents and commercially available kits used throughout 
these studies are detailed in Table 3.1. and 3.2., respectively. Table 3.3. outlines the 
equipment utilized and product distributor. The distributor names and addresses are 
presented in Table 3.4. All primers and oligonucleotides presented in this thesis are 
documented in Table 3.5. The underlined nucleotides represent the sequence to be 
mutated and the nucleotides shown in bold constitute the poly(A) signal. The primers 
and the oligonucleotides under 100 nucleotides were purchased from Invitrogen. Those 
oligonucleotides greater than 100 nucleotides were obtained from Integrated DNA 
Technologies (IDT). 
 ____________________________________________________________________ 
Table 3.1. The List of Reagents and Distributors 
Reagents and Materials Distributor Name 
4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid Sigma-Aldrich Co. 
[α-32P] dCTP PerkinElmer Life Sciences Inc. 
[α-32P] rUTP PerkinElmer Life Sciences Inc. 
Acetic acid (glacial) BDH  
Acrylamide Sigma-Aldrich Co. 
Actinomycin D Sigma-Aldrich Co. 
Agarose EMD Chemicals Inc. 
Ammonium persulfate EMD Chemicals Inc. 
Ampicillin EMD Chemicals Inc. 
Anti-v-Src (Ab-1) mouse monoclonal 
antibody  Calbiochem 
Bis-Acrylamide Sigma-Aldrich Co. 
β-Mercaptoethanol EMD Chemicals Inc. 
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Bacto Agar BD Biosciences 
BioMax XAR film Kodak 
Boric acid EMD Chemicals Inc. 
Bromophenol blue BDH  
Calcium chloride dihydrate BDH  
Calf Intestinal Alkaline Phosphatase New England Biolabs Ltd.  
Chloroform EMD Chemicals Inc. 
CMV c-jun ATCC 
Cycloheximide Sigma-Aldrich Co. 
Diethyl pyrocarbonate  Sigma-Aldrich Co. 
Disodium hydrogen phosphate  EMD Chemicals Inc. 
Dithiothrietol Fermentas Canada Inc.  
DMEM Invitrogen – Gibco Cell Culture Systems 
DMEM-F12 Invitrogen – Gibco Cell Culture Systems 
DMSO Sigma-Aldrich Co. 
dNTPs New England Biolabs Ltd.  
Dodecyl sodium sulfate EMD Chemicals Inc. 
EDTA EMD Chemicals Inc. 
Ethidium bromide BDH  
Fat-free skim milk powder  Carnation 
Fetal Bovine Serum HyClone  
Formaldehyde EMD Chemicals Inc. 
Formamide BDH  
Fyn EST (7997662) ATCC 
GeneScreen Plus Hybridization 
Transfer Membrane  PerkinElmer Life Sciences, Inc.  
Glycerol EMD Chemicals Inc. 
Glycine EMD Chemicals Inc. 
goat anti-mouse IgG-HRP SC-2005 Santa Cruz Biotechnology 
Guanidinium thiocyanate BDH  
Humulin Eli Lilly Canada Inc. 
Hydrochloric acid EMD Chemicals Inc. 
Isoamyl alcohol BDH  
Isopropanol EMD Chemicals Inc. 
Kanamycin EMD Chemicals Inc. 
Klenow Fragment  Fermentas Canada Inc.  
Lambda DNA GE Healthcare Bio-Sciences Inc.  
Lck EST (6883710) ATCC 
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Lyn EST (5509761) ATCC 
Manganese chloride tetrahydrate  BDH  
Magnesium chloride BDH  
Molecular Iamger FX Imaging Screen 
K Bio-Rad Laboratories Ltd. 
Morpholinopropanesulfonic acid  Sigma-Aldrich Co. 
N-Lauroyl sarcosine Sigma-Aldrich Co. 
N,N,N',N'-
Tetramethylethylenediamine  EMD Chemicals Inc. 
Nonidet-P-40  Sigma-Aldrich Co. 
O’GeneRuler 50 bp DNA Ladder  Fermentas Canada Inc.  
O’GeneRuler 1 kb DNA Ladder  Fermentas Canada Inc.  
o-nitrophenyl-β-D-galactopyranoside Sigma-Aldrich Co. 
Optitran Supported Nitrocellulose  Schleicher & Schuell 
p21 (187) sc-817 mouse monoclonal 
antibody Santa Cruz Biotechnology 
pBluescript KS + Stratagene 
pCAT3-Basic Promega 
penicillin-streptomycin  Invitrogen – Gibco Cell Culture Systems 
Pfu DNA Polymerase Fermentas Canada Inc.  
Phenol (water saturated) EMD Chemicals Inc. 
Phenylmethylsulphonyl flouride GE Healthcare Bio-Sciences Inc.  
Potassium Acetate BDH  
Potassium Chloride EMD Chemicals Inc. 
Potassium dihydrogen phosphate EMD Chemicals Inc. 
Potassium hydroxide BDH 
Protease Inhibitor Mix Sigma-Aldrich Co. 
Protein Assay Dye Reagent 
Concentrate Bio-Rad Laboratories Ltd. 
Rubidium Chloride EMD Chemicals Inc. 
Restriction endonucleases New England Biolabs Ltd.  
RPMI–1640 Invitrogen – Gibco Cell Culture Systems 
Shrimp Alkaline Phosphatase Fermentas Canada Inc.  
Sodium acetate  BDH  
Sodium butytrate Sigma-Aldrich Co. 
Sodium bicarbonate EMD Chemicals Inc. 
Sodium carbonate EMD Chemicals Inc. 
Sodium chloride EMD Chemicals Inc. 
Sodium citrate BDH  
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Sodium dihydrogen phosphate  BDH  
Sodium dodecyl sulfate EMD Chemicals Inc. 
Sodium hydroxide BDH  
Sodium phosphate (monobasic) EMD Chemicals Inc. 
Sodium phosphate (dibasic) EMD Chemicals Inc. 
SuperFect Transfection Reagent Qiagen Inc.  
T4 DNA Polymerase GE Healthcare Bio-Sciences Inc.  
Taq DNA Polymerase Qiagen Inc.  
Trichostatin A  Sigma-Aldrich Co. 
Tris EMD Chemicals Inc. 
Trypan blue stain Invitrogen – Gibco Cell Culture Systems 
Trypsin-EDTA 1X Invitrogen – Gibco Cell Culture Systems 
TWEEN-20 Sigma-Aldrich Co. 
Western Lightening 
Chemiluminescence Reagent Plus  PerkinElmer Life Sciences, Inc.  
X-OMAT Blue XB-1 film  Kodak 
Xylene Cyanol FF BDH 
Yes EST A50(7497767) ATCC 
 
_____________________________________________________________________ 
Table 3.2. Commercial Kits and Distributors  
Commercial Kit Distributor Name 
CAT ELISA Kit Roche Diagnostics 
EndoFree Plasmid Maxi Kit Qiagen Inc.  
FastPlasmid Mini Kit Eppendorf AG 
QIAfilter Plasmid Midi Kit  Qiagen Inc.  
QIAprep Miniprep Kit Qiagen Inc.  
QIAquick Gel Extraction Kit Qiagen Inc.  
Quick Ligation Kit  New England Biolabs, Ltd.  
Riboprobe in vitro Transcription 
System Promega 
RNeasy Mini Kit Qiagen Inc. 
Total Protein Kit, Micro Lowry  Sigma-Aldrich Co. 






Table 3.3. Equipment & Software and Distributors 
Equiptment and Software Distributor Name 
Biofuge 13 microcentrifuge Thermo Electron Corporation - Heraeus  
CO2 Incubator 3326 Forma Scientific, Inc.  
Coulter Counter ZM  Coulter Electronics, Ltd. 
Gel Doc 2000 Bio-Rad Laboratories Ltd. 
Gel Dryer Model 583 Bio-Rad Laboratories Ltd. 
Gene Amp PCR System 2700 Applied Biosystems Canada 
Horizontal Gel Electrophoresis 
System Owl Separation Systems 
Isotemp Incubator 230D Fisher Scientific Company 
JA-10 rotor Beckman Coulter Canada, Inc. 
J2-MI highspeed centrifuge Beckman Coulter Canada, Inc. 
MacVector 7.2.3 Accelrys Inc. 
Micro Hybridization Incubator Model 
2000 Robbins Scientific 
Microplate Reader Model 3550 Bio-Rad Laboratories Ltd. 
Mini-PROTEAN II Cell  Bio-Rad Laboratories Ltd. 
Molecular Imager FX Bio-Rad Laboratories Ltd. 
ORBIT Incubator Shaker  BarnsteadIThermolyne Corp. International  
PROTEAN II xi Cell Bio-Rad Laboratories Ltd. 
SmartSpec 3000 Spectrophotometer  Bio-Rad Laboratories Ltd. 
Sorvall RT6000D Du Pont Canada, Inc. 
Quantity One Software, Version 4 Bio-Rad Laboratories Ltd. 
UV Stratalinker 2400 Stratagene 
 
 _____________________________________________________________________ 
Table 3.4. Distributor Addresses 
Distributor Name Address 
Accerlrys Inc.  Accelrys Inc., San Diego, CA, USA 
Applied Biosystems Canada 
Applied Biosystems Canada, Streetsville, 
ON, Canada 
ATCC (American Type Culture 
Collection) 
American Type Culture Collection, 
Manassas, VA, USA 
BarnsteadIThermolyne Corp. 
International  
BarnsteadIThermolyne Corp., Dubuque, 
Iowa, USA 
BD Biosciences BD Biosciences, Mississauga, ON, Canada 
BDH Inc. BDH Inc., Toronto, ON, Canada 
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Beckman Coulter Canada, Inc.  
Beckman Coulter Canada, Inc., 
Mississauga, ON, Canada  
Bio-Rad Laboratories Ltd.  
Bio-Rad Laboratories Ltd., Mississauga, 
ON, Canada 
Calbiochem EMD Bioscinces Inc., La Jolla, CA, USA 
Coulter Electronics Ltd.  
Coulter Electronics Ltd. Luton, Beds., 
England 
Du Pont Canada, Inc. 
Du Pont Canada, Inc., Mississauga, ON, 
Canada 
Eli Lilly Canada Inc. 
Eli Lilly Canada Inc., Scarborough, ON, 
Canada 
EMD Chemicals Inc. EMD Chemicals Inc., Gibbstown, NJ, USA 
Eppendorf AG Eppendorf AG, Hamberg, Germany 
Fermentas Canada Inc.  
Fermentas Canada Inc., Burlington, ON, 
Canada 
Fisher Scientific Company 
Fisher Scientific Company, Nepean, ON, 
Canada 
Forma Scientific, Inc.  Forma Scientific, Inc., Marietta, OH, USA 
GE Healthcare Bio-Sciences Inc. 
GE Healthcare Bio-Sciences Inc., Baie 
d'Urfe, QC, Canada 
HyClone HyClone, Logan, UT, USA 
Integrated DNA Technologies, Inc. 
Integrated DNA Technologies, Inc., 
Coralville, IA, USA 
Invitrogen Canada Inc. 
Invitrogen Canada Inc., Burlington, ON, 
Canada 
Kodak 
Eastman Kodak Company, Rochester, NY, 
USA 
New England Biolabs, Ltd.  
New England Biolabs, Ltd., Pickering, ON, 
Canada 
Owl Separation Systems 
Owl Separation Systems, Portsmouth, NH, 
USA 
PerkinElmer Life Sciences, Inc.  
PerkinElmer Life Sciences, Inc., Boston, 
MA, USA 
Promega  Promega, Madison, WI, USA 
Qiagen Inc.  Qiagen Inc., Mississauga, ON, Canada 
Robbins Scientific Robbins Scientific, Sunnyvale, CA, USA 
Roche Diagnostics Roche Diagnostics, Laval, QC, Canada 
Santa Cruz Biotechnology Inc. 




Schleicher & Schuell Inc. 
Schleicher & Schuell Inc., Keene, New 
Hampshire, USA 
Sigma-Aldrich Co. Sigma-Aldrich Co., Oakville, ON, Canada 
Stratagene Stratagene, La Jolla, CA, USA 
Thermo Electron Corporation - 
Heraeus  
Thermo Electron Corporation, Waltham, 
MA, USA  
 
_____________________________________________________________________ 
Table 3.5. PCR Primers and Oligonucleotides  
Name  Sequence Description 
FWD LCK KpnI -634 
5’ CATGGTACCTTAAACTTTGAGG AC 
AGCGCTTTCC 3’  PCR primer 
REV LCK XhoI +145  
5’ CTCCCTCGAGATCTGCTCCCCCA   
ACATCAG 3’ PCR primer 
FWD LYN -593  5’ CCCGGTACCGAAAGGTACACG 3’ PCR primer 
REV LYN +14 5’ CGGCTCGAGAGGAACTGGCTG 3’  PCR primer 
FWD p21WAF1 3'UTR 591 5’ GGAAGTCTAGAGTCCTGGAAG 3’ PCR primer 
REV p21WAF1 3’UTR 
2079 5’ CGTTTCTAGAGCACCTGCTG 3’ PCR primer 
FWD p21WAF1 3’UTR 712  5’ CATACTCTAGACGCCCCCTGC 3’ PCR primer 
FWD p21WAF1 3’UTR 788 5’ GAGGTTTCTAGAAGTGCTGGGC 3’ PCR primer 
FWD p21WAF1 3’UTR 840 5’ CCTCATCTAGAGTTCTCCTTTTCC 3’ PCR primer 
REV p21WAF1 3’UTR 840  5’ GAGAACTCTAGATGAGGAGGC 3' PCR primer 
FWD p21WAF1 3’UTR 932 
5’ GTACCCTCTAGAGGGGTGTGGCT    C 
3’ PCR primer 
FWD p21WAF1 3’UTR 
1045 5’ GGCATCTAGAAGGGGCCTCAC 3’ PCR primer 
FWD p21WAF1 3’UTR 
1173 5’ GTACCCTCTAGACTCTTGATACC 3’ PCR primer 
FWD p21WAF1 3’UTR 
1272 5’ CCTGCTCTAGAGAGCCCGTCTC 3’ PCR primer 
REV p21WAF1 3’UTR 
1470 
5’ CCCCTTCTAGACCATTGAGCTGG   G 
3’ PCR primer 
REV p21WAF1 3’UTR 
2064 5’ CCTGCTCTAGATTCAGCATTG 3’ PCR primer 
REV p21WAF1 3’UTR 
2031 5’ GAAAGATCTAGAACAGTACAGG 3’ PCR primer 
REV p21WAF1 3’UTR 
2000 5’ GCCCTCTAGAGGTTTACAGTC 3’ PCR primer 
REV p21WAF1 3’UTR 
1979 
5’ CTAGGTCTAGAAACGGGAACCA GG 
3’ PCR primer 
FWD p21WAF1 3’UTR 
1467 5’ CCCCATCTAGATGGACTGGAAGG 3’ PCR primer 
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GCGAGG 3' PCR primer 




CCTCTC 3' PCR primer 




GGAAGGG 3' PCR primer 




Site - directed 
mutagenesis primer 
REV -210WAF1 XbaI 
destroy 
5’ CGCGCTTCCAGGACTGCAGATTA  
CGCCCCGC 3’ 
Site - directed 
mutagenesis primer 




Site - directed 
mutagenesis primer 




Site - directed 
mutagenesis primer 





cloning - mut #1 
complementary 
oligonucleotide 






cloning - mut #1 
complementary 
oligonucleotide 





cloning - mut #2 
complementary 
oligonucleotide 






cloning - mut #2 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #3 
5' ATCCTCTCGAGGGCAGGAGTTGC   
ACCCTGTACTGTTCTGTGTCTTTCA   
CAGCTCCTCCCACAATGCTGAATA   
TACAGCAGGTGCT 3' 
cloning - mut #3 
complementary 
oligonucleotide 






cloning - mut #3 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #4 
5' ATCCTCTCGAGGGCAGGGACCAT   
GTTTTGTACTGTTCTGTGTCTTTCA   
CAGCTCCTCCCACAATGCTGAATA   
TACAGCAGGTGCT 3' 












cloning - mut #4 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #5 
5' ATCCTCTCGAGGGCAGGGACCAC  
ACCCCACGTTGTTCTGTGTCTTTCA   
CAGCTCCTCCCACAATGCTGAATA   
TACAGCAGGTGCT 3' 
cloning - mut #5 
complementary 
oligonucleotide 






cloning - mut #5 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #6 




cloning - mut #6 
complementary 
oligonucleotide 






cloning - mut #6 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #7 
5' ATCCTCTCGAGGGCAGGGACCAC  
ACCCTGTACTGTTCCACACCTTTCA 
CAGCTCCTCCCACAATGCTGAATA   
TACAGCAGGTGCT 3' 
cloning - mut #7 
complementary 
oligonucleotide 
antisense WAF1 3'UTR mut 
#7 
5' CTAGAGCACCTGCTGTATATTCA 
GCATTGTGGGAGGAGCTGTGAAAG   
GTGTGGAACAGTACAGGGTGTGGT    
CCCTGCCCTCGAGAGGAT 3' 
cloning - mut #7 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut #8 
5' ATCCTCTCGAGGGCAGGGACCAC  
ACCCTGTACTGTTCTGTGTTCCCTA   
CAGCTCCTCCCACAATGCTGAATA   
TACAGCAGGTGCT 3' 
cloning - mut #8 
complementary 
oligonucleotide 






cloning - mut #8 
complementary 
oligonucleotide 





cloning - mut #9 
complementary 
oligonucleotide 
antisense WAF1 3'UTR mut 
#9 




cloning - mut #9 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut 
#10 















cloning - mut #10 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut 
#11 




cloning - mut #11 
complementary 
oligonucleotide 






cloning - mut #11 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut 
#12 




cloning - mut #12 
complementary 
oligonucleotide 
antisense WAF1 3'UTR mut 
#12 
5' CTAGAGCACCTGCTGTATATTCG  
ATGCTGTGGGAGGAGCTGTGAAAG   
ACACAGAACAGTACAGGGTGTGGT  
CCCTGCCCTCGAGAGGAT 3' 
cloning - mut #12 
complementary 
oligonucleotide 






cloning - mut #13 
complementary 
oligonucleotide 






cloning - mut #13 
complementary 
oligonucleotide 






cloning - mut #14 
complementary 
oligonucleotide 






cloning - mut #14 
complementary 
oligonucleotide 






cloning - mut #15 
complementary 
oligonucleotide 
antisense WAF1 3'UTR mut 
#15 




cloning - mut #15 
complementary 
oligonucleotide 
sense WAF1 3'UTR mut 
#16 









antisense WAF1 3'UTR mut 
#16 









5’ CCATTATAAGCTGCACTAGTCA   
AGTTAACAAC 3’ 




5’ GTTGTTAACTTGACTAGTGCAGC  
TTATAATGG 3’ 
Site - directed 
mutagenesis primer 
sense WAF1 3'UTR wt + 
poly(A) signal 
5' ATCCTCTCGAGGGCAGGGACCAC 








antisense WAF1 3'UTR wt 










sense WAF1 3'UTR mut#15 
+ poly(A) signal 
5' ATCCTCTCGAGGGCAGGGACCAC  
ACCCTGTACTGTTCTGTGTCTTTCA   
CAGCTCCTCCCACAATGCTGAATA   
TACAGTGAACGCTCAATAAATGAT  
TCTTAGTGACTTTT 3' 
cloning - mut#15 + 
poly (A) signal 
complementary 
oligonucleotide 
antisense WAF1 3'UTR 
mut#15 + poly(A) signal 
5' CTAGAAAAGTCACTAAGAATCA 
TTTATTGAGCGTTCACTGTATATTC 
AGCATTGTGGGAGGAGCTGTGAAA   G 
ACACAGAACAGTACAGGGTGTG GT C 
CCTGCCCTCGAGAGGAT 3' 
cloning - mut#15 + 
poly (A) signal 
complementary 
oligonucleotide 
sense WAF1 3'UTR 






cloning - mut#15/16 
+ poly (A) signal 
complementary 
oligonucleotide 
antisense WAF1 3'UTR 






cloning - mut#15/16 




3.2. Culture of Cell Lines 
3.2.1. Culture and Maintenance of Cell Lines  
The cell lines utilized in this study were obtained from the American Type 
Culture Collection (ATCC). The cell culture media used for cell maintenance was 
purchased by Invitrogen – Gibco Cell Culture Systems. HT29, WiDr, LS 174T, SW480 
colorectal adenocarcinoma cells and the SW620 lymph node metastasis derived 
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colorectal cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM). The 
COLO 201, COLO 205, COLO 320 and DLD-1 colon adenocarcinoma cells were 
maintained in RPMI–1640 medium. The T-47D breast ductal carcinoma cells were 
grown in RPM1-1640 media with 0.2 units / mL Humulin. The HepG2 hepatocellular 
carcinoma cells were grown in Dulbecco’s modified Eagle’s medium and Ham’s F-12 
medium. BHK-21 baby hamster kidney cells and the temperature sensitive tsBN462 
cells derived from them were obtained from Dr. T. Sekiguchi (Kyushu University, 
Fukuoka Japan) and maintained in DMEM. All cells described were grown in media 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and 
grown in a CO2 Incubator 3326 at 5% CO2 and 37oC, except tsBN462 cells which were 
sustained at 32.6oC and 5% CO2. Upon expansion and cell seeding, adherent cells were 
dislodged from their tissue culture plate using Trypsin-EDTA. 
 
3.2.2. Histone Deacetylase Inhibitor and Cycloheximide Treatments 
 Cells were trypsinized, seeded and grown to approximately 50% confluency. 
Five mM sodium butyrate (NaB), or 1.0 µM Trichostatin A (TSA) was added directly to 
the growth media and treated cells were harvested at subsequent time intervals. In dose 
response experiments, cells were treated with 0.5, 1.0, 2.0, 5.0 and 10.0 mM NaB and 
harvested 24 hours following exposure. In a similar manner, tumor cells were 
propagated to 50% confluency and treated with 50 µM cycloheximide (CHX) alone or 
in unison with 5.0 mM NaB or 1.0 µM TSA, added directly to the cell culture media. 
 
3.2.3. Actinomycin D Treatments 
Cells were grown to 50% confluency as described above and treated with 5.0 
µg/mL actinomycin D (Act.D), added directly to the growth media for mRNA half-life 
studies. Alternatively, cells were pre-treated 12 hours with 5.0 mM NaB or 1.0 µM TSA 
prior to the addition of 5.0 µg/mL Actinomycin D.    
 
3.3. Cellular Growth Curve Experiments 
 Confluent SW480, HT29, T-47D and HepG2 cells were trypsinized, seeded at 
1.0 x 105 cells / 35 mm well (9.6cm2), and  allowed to grow under normal conditions for 
 85
a period of 48 hours. At this time, fresh cell culture media was administered to the cells, 
which were treated with different doses of NaB (0.5, 1.0, 2.0, 5.0, 10.0 mM), TSA (0.5, 
1.0, 2.0, 5.0, 10.0 µM), or left untreated. Subsequently, these cells were trypsinized at 
24, 48, 72 and 96 hours following treatment and counted in phosphate-buffered saline 
(PBS, 8 g sodium chloride (NaCl), 0.2 g potassium chloride (KCl), 1.44 g disodium 
hydrogen phosphate (Na2HPO4), and 0.24 g Potassium dihydrogen phosphate (KH2PO4) 
/ L of water) with a Coulter Counter ZM .  
 
3.4. Bacterial Strains 
 The DH5α and TOP10 competent Escherichia coli strains were routinely used 
as host cells for ligation reactions, site directed mutagenesis, DNA plasmid 
amplification and glycerol stock plasmid storage in these studies. Individual DH5α or 
TOP10 transformed colonies were isolated from Luria-Bertani (LB) plates containing 
ampicillin, following overnight growth in a 37oC Isotemp Incubator 230D. LB plates 
were made by combining 2.5% (w/v) LB Broth, Miller with Bacto Agar and water prior 
to autoclaving. Ampicillin was added to the autoclaved LB agar mixture upon reaching 
65oC and LB ampicillin plates were poured and cooled to room temperature. DH5α and 
TOP10 transformed plasmids were amplified for plasmid preparations and glycerol 
stock generation by inoculating LB ampicillin media (lacking Bacto Agar) with the 
isolated colonies from LB ampicillin agar plates, and grown overnight at 37oC in an 
ORBIT Incubator Shaker. Plasmid glycerol stocks contained 850 µL of overnight cell 
culture and 150 µL 50% glycerol, which were stored at -80oC. 
 
3.5. General Molecular Biology Techniques 
The basis of numerous molecular biology techniques described in this thesis 
have been previously published in a Molecular Cloning Laboratory Manual (Sambrook 






3.5.1. Cloning Techniques 
3.5.1.1. Restriction Enzyme Digestion 
 Restriction enzyme digests were performed on double stranded DNA in the 
presence of the recommended buffer and 1 unit of restriction endonuclease / µg DNA. 
Reactions proceeded at 37oC for a minimum of 1 hour. 
3.5.1.2. Preparation of Blunt End DNA Fragments  
 5’-overhangs generated from restriction enzyme digests were filled in by 
extending 3’ recessed ends with DNA polymerase I Klenow Fragment. Twenty five µL 
of restriction digested DNA were incubated with 5 µL 10X reaction buffer, 0.5 µL 
5mM dNTP mixture and 5 units DNA polymerase I Klenow fragment. Reactions were 
incubated at 37oC for 10 minutes and stopped by heating to 70oC for 10 minutes. 3’-
overhangs were removed using T4 DNA polymerase. Twenty five µL of digested DNA 
was combined with 5 uL of 10X reaction buffer, 0.5 µL 5 mM dNTP mixture and 5 
units T4 DNA polymerase. Reactions occurred at 15oC for 15 minutes and were 
terminated by heating to 70oC for 10 minutes.  
3.5.1.3. Removal of the 5’ Phosphate Group of DNA 
 The phosphate group was removed from the DNA 5’ termini with either calf 
intestinal alkaline phosphatase, or shrimp alkaline phosphatase. Calf intestinal alkaline 
phosphatase was added directly to the DNA at 0.5 units / µg of DNA to be 
dephosphorylated. The reaction was carried out at room temperature for 1.5 hours. 
Conversely, 40 µL of DNA solution was combined with 10 X shrimp alkaline 
phosphatase reaction buffer and 1 unit of shrimp alkaline phosphatase. This reaction 
was incubated at 37oC for 30 minutes and stopped by heating at 65oC for 15 minutes.  
3.5.1.4. Polymerase Chain Reaction 
 Sequence specific, forward and reverse, primers were designed to amplify DNA 
fragments of interest. In some cases, restriction endonuclease sites were incorporated 
into the primers to aid in subsequent cloning procedures. DNA fragments were 
amplified from plasmid DNA vectors using Taq DNA polymerase. Alternatively, Pfu 
DNA polymerase was employed to amplify DNA fragments from genomic DNA. The 
DNA polymerase specific buffer, dNTPs, sequence specific primers, and template DNA 
were combined prior to DNA polymerase addition. The polymerase chain reaction 
 87
(PCR) was performed in a GeneAmp PCR System 2700. Initially, template DNA was 
denatured at 95oC for 5 minutes, followed by 25 – 35 cycles of: denaturation at 95oC, 
primer annealing, and primer extension at 72oC or 68oC for Taq and Pfu DNA 
polymerase, respectively. Following cycling, a final extension step was performed at the 
DNA polymerase specified temperature. The optimal primer annealing temperature for 
each reaction was determined by entering the template and primer sequences into 
MacVector 7.2.3 software. In addition, the extension time was determined based on the 
rate of Taq extension at 2 kb / minute, and Pfu at 0.5 kb / minute. 
3.5.1.5. Annealing of Complementary Oligonucleotides 
 1µg of each complementary oligonucleotide was combined in the presence of 
10X Annealing Buffer (100 mM Tris (hydroxymethyl) aminomethane hydrochloric acid 
(HCl) pH 8.0; 1 M NaCl; and 10 mM ethylenediaminetetraacetic acid (EDTA) and 
heated at 100oC for 5 minutes. The reactions were gradually cooled to room temperature 
to anneal the complementary oligonucleotides. 
3.5.1.6. Agarose Gel Electrophoresis 
 DNA gel loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene 
cyanol FF, and 30% (v/v) glycerol was added to DNA samples prior to separation on an 
agarose gel. Agarose gels of 1.0 to 1.5% (w/v) were prepared in TAE buffer (40 mM 
Tris-acetate, 1 mM EDTA, pH 8.0) or TBE buffer (45 mM Tris-borate, 1 mM EDTA, 
pH 8.0), and gel electrophoresis was performed in a Horizontal Gel Electrophoresis 
System with the corresponding buffer at 100V. Upon completion of electrophoresis, 
double stranded DNA was stained with 0.5 µg/mL ethidium bromide and DNA 
fragments were visualized using a Gel Doc 2000 Gel Documentation System. 
3.5.1.7. Gel Extraction of Linear DNA Fragments 
 Ethidium bromide stained DNA fragments were excised from agarose gels with 
a scalpel and stored at -20oC. A QIAquick Gel Extraction Kit was used to extract and 
purify the fragment of DNA as per the manufacture’s protocol, with the exception that 
the samples were not incubated at 50oC, but remained at room temperature and were 




3.5.1.8. DNA Ligation Reaction 
A Quick Ligation Kit was employed for DNA ligation reactions. Purified DNA 
insert and 50 ng of restriction digested, dephosphorylated, purified DNA vector were 
combined with 10 µL of 2 X Quick Ligation Reaction Buffer and 1 µL Quick T4 DNA 
ligase. The reactions were allowed to proceed at room temperature for 10 minutes, 
placed on ice and stored at -20oC. For vector re-circularization ligations, 100 ng of 
DNA was used in the ligation reaction.  
 
3.5.2. QuikChange Site-Directed Mutagenesis 
 The QuikChange Site-Directed Mutageneis protocol was adapted from 
Stratagene. Complementary oligonucleotides were designed between 25 – 45 bases in 
length, containing unmodified bases flanking a central region of mutated sequence. 10 
X Pfu DNA polymerase buffer, dNTPs, complementary oligonucleotides, template 
DNA and Pfu DNA polymerase were pooled for amplfication. PCR reactions were 
denatured at 95oC for 5 minutes and underwent 16 cycles of: 95oC denaturation, primer 
annealing, and extension at 68oC. The extension time was determined based on the 
vector size and the rate of Pfu DNA polymerase extension at 0.5 kb / minute. The final 
PCR extension time was 7 minutes at 68oC. The optimal annealing temperature was 
determined using MacVector 7.2.3. Upon completion of amplification, the reaction 
mixtures were treated with restriction endonuclease using 15 units of DpnI at 37oC for 
90 minutes, to digest the parental DNA.  
 
3.5.3. Competent Bacterial Cells 
3.5.3.1. Preparation of TOP10 Cells 
 A culture of competent Escherichia coli TOP10 cells was grown overnight in 5 
mL LB media, shaking at 37oC. The entire overnight starter culture was used to 
inoculate 100 mL of LB, which was grown under identical conditions until the optical 
density (OD) 550 nm reached approximately 0.4. At this point, TOP10 cells were 
collected by centrifugation in a Sorvall RT6000D at 2000-3000 rpm and 4oC for 15 
minutes. The cell pellet was resuspended in 30 mL RF1 (100 mM rubidium chloride 
(RbCl), 50 mM manganese chloride tetrahydrate (MnCl2 – 4H2O), 30 mM potassium 
 89
acetate (C2H3O2K, BDH), 10 mM calcium chloride dihydrate (CaCl2 – 2H2O)), 15% 
(w/v) glycerol, and acetic acid to pH 5.8) and incubated on ice for 15 minutes. Cells 
were collected, as discussed above, and resuspended in 7.2 mL RF2 (10 mM 3-N-
morpholinopropanesulfonic acid (MOPS), 10 mM RbCl, 75 mM CaCl2 – 2H2O, 75 mM 
glycerol, and sodium hydroxide (NaOH) adjusted to pH 6.8). Following a second 15 
minute incubation on ice, TOP10 cells were aliquotted into 200 µL fractions, flash 
frozen and stored at -80oC. 
3.5.3.2. Transformation of Competent TOP10 Cells 
Transformation of bacteria with a ligation reaction was performed by adding 5 
µL of the ligation reaction to 100 µL of TOP10 cells. The mixture was incubated on ice 
for 30 minutes, heat shocked at 42oC for 30 seconds, and returned to ice for 2 minutes. 
Next, 500 µL of room temperature LB was added to the transformation reaction and the 
cells were allowed to grow in a shaking incubator at 37oC. After 1 hour, cells were 
spread on LB ampicillin plates, and positioned upside down at 37oC overnight. For the 
transformation of intact plasmids, 1 µL of plasmid was added directly to 100 µL of 
TOP10 cells, which were placed on ice for 5 minutes and plated directly onto LB 
ampicillin plates. 
 
3.5.4. Zero Blunt TOPO PCR Cloning and One Shot TOP10 Cell Transformation 
 Blunt end PCR products, generated by Pfu DNA polymerase, were inserted into 
a pCR-Blunt II-TOPO plasmid vector as described in the Zero Blunt TOPO PCR 
Cloning Kit manual. Briefly, 4 µL of PCR product was combined with a dilute salt 
solution and the pCR-Blunt II-TOPO plasmid and incubated at room temperature for 5 
minutes prior to transformation. Two µL of the TOPO cloning reaction were 
transformed into One Shot TOP10 chemically competent E. coli. The transformation 
was incubated on ice for 30 minutes, heat shocked at 42oC for 30 seconds, and returned 
to ice. 250 µL of S.O.C. media provided by the manufacturer was added to the 
transformation reaction, which was subsequently transferred to a shaking 37oC 





 Automated DNA sequencing to verify cloned genes, PCR products, or newly 
acquired DNA plasmids was performed by Annette Kerviche at the Saskatchewan 
Cancer Agency, Health Research Unit using an ABI Prism 310 Genetic Analyser or at 
the National Research Council Canada, Plant Biotechnology Institute using a 96-
capillary AB 3730x/DNA sequence analyser.  
 
3.5.6. Plasmid Isolation from E. coli Strains 
3.5.6.1. Small-Scale Plasmid Isolation 
 An isolated transformed colony from LB selective agar plates was grown 
overnight in 4 mL of LB ampicillin at 37oC in a shaking incubator. Two mL of the 
overnight culture was centrifuged in a tabletop Biofuge 13 microcentrifuge at 13,000 
rpm to collect the cells for small-scale plasmid isolation. The QIAprep Miniprep or the 
FastPlasmid Mini Kit was used as per the manufacturer’s recommendations for plasmid 
DNA isolation. The concentration of plasmid DNA was determined by assessing the 
absorbance at a wavelength of 260 nm with a SmartSpec 3000 Spectrophotometer, and 
by agarose gel electrophoresis comparative quantitative analysis. 
3.5.6.2. Mid-Scale Endofree Plasmid Isolation 
 A single transformed colony from a streaked LB ampicillin agar plate was used 
to inoculate 4 mL of LB ampicillin, which was then transferred to a 37oC shaking 
incubator. Following approximately 8 hours of incubation the plasmid DNA starter 
culture was diluted 1:500 or 1:1000 in 100 mL LB ampicillin, for low and high copy 
number plasmids, respectively, and the diluted culture was grown at 37oC overnight. 
Transformed cells were collected in a Beckman J2-MI highspeed centrifuge with a JA-
10 rotor at 6000 x g for 15 minutes at 4oC. Plasmid DNA purification was performed 
with a QIAfilter Plasmid Midi Kit, as suggested in the user manual, with a few 
modifications to ensure that plasmid DNA remained endotoxin-free. Modifications 
included adding 1.0 mL of Buffer ER to the filter lysate, followed by a 30 minute 
incubation on ice. Furthermore, DNA was eluted with Buffer QN rather than QF, 
endotoxin-free 70% ethanol was used to wash the DNA pellet and DNA was eluted in 
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endotoxin-free Buffer TE. The yield of plasmid DNA was determined as discussed 
above. 
3.5.6.3. Endofree Isolation of Large Scale Plasmid Preparations 
 Plasmid DNA starter cultures were initiated as explained above, although starter 
cultures were diluted in 250 mL of LB ampicillin. Large scale plasmid isolation was 
carried out with an EndoFree Plasmid Maxi Kit, exactly as recommended by the 
manufacturer. 
 
3.5.7. DNA Ladder Markers 
DNA size markers were generated by restriction endonuclease digestion of 
Lambda DNA with EcoRI, or pBluescript KS + DNA with HpaII. Alternatively, an 
O’GeneRuler 1 kb DNA Ladder or an O’GeneRuler 50 bp DNA Ladder was utilized. 
 
3.6. Information on Plasmids and Construction Details 
3.6.1. Expression Vectors and cDNAs 
The c-Src cDNA expression vector, Y530 wt c-Src pcDNA3.1 was obtained 
from Dr. Keith Bonham. Human c-Src Family Kinase (SFK) Expressed Sequence Tags 
(ESTs) corresponding to the mRNA sequence of Lck (GenBank Accession Number 
BG756533), Yes (BI560649), Fyn (BM920742) and Lyn (BE676457) were obtained 
from ATCC (ATCC Numbers: 6883710, 7497767, 7997662, and 5509761 
respectively). The HHCI89 clone, which contains a 1.1 kb β-actin cDNA insert in a 
pBluescript SK- vector was obtained from ATCC. The pCMV β-Gal expression vector 
was acquired from Dr. W. Roesler (University of Saskatchewan). pCMV hTAFII250 
was a gift from Dr. R. Tjian (Howard Hughes Medical Institute, University of 
California at Berkeley) and contains a 6 kb wt TAFII250 cDNA insert (Wang et al., 
1994). The TAF1 acetyltransferase (AT) mutants: pCS2+ HA-TAF1 ∆848-850 (∆Stu), 
pCS2+ HA-TAF1 ∆844-850 (∆MED), pCS2+ HA-TAF1 ∆574-590, and pCS2+ HA-
TAF1 G923/925D double mutant were acquired from Dr. E. Wang (University of 
Washington) and have been previously documented (Hilton et al., 2005).  The 
p21WAF1 expression vector, pCEP-WAF1, was obtained from Dr. B. Vogelstein 
 92
(Johns Hopkins Oncology Center) and contains a 2.1 kb p21WAF1 cDNA fragment 
including the 5’ untranslated, coding and 3’ untranslated regions (el-Deiry et al., 1993). 
 
3.6.2. c-Src Family Kinase CAT Reporter Constructs 
The 0.38SRC1A-chloramphenicol acetyltransferase (CAT) vector contains the 
pGEM2-CAT reporter vector backbone and has been previously described (Bonham 
and Fujita, 1993). The pCAT3-Basic backbone was used in the construction of the -
145SRC1α reporter vector and has also been described (Bonham et al., 2000). 
pYSCAT2 was obtained from Dr. T. Yamamoto (University of Tokyo) and contains a 
2.1kb YES promoter fragment (Matsuzawa et al., 1991). The -630LCK-CAT promoter 
construct was designed by amplifying an 808 bp fragment encompassing the LCK 
proximal promoter from Colo 205 genomic DNA (Takadera et al., 1989). A sense 
primer (Fwd LCK: 5’ CATGGTACCTTAAACTTTGAGGACAGCGCTTTCC 3’ 
introduced a 5’ KpnI restriction site, and an antisense primer (REV LCK: 5’ 
CTCCCTCGAGATCTGCTC-CCCCAACATCAG 3’ introduced a XhoI site at the 3’ 
end of the -630LCK promoter fragment. The -630LCK-CAT reporter construct was 
generated by digesting both pCAT3-Basic and the -630LCK PCR fragment with KpnI 
and XhoI, followed by ligation of the -630LCK fragment into the pCAT3-Basic vector.  
The -590LYN-CAT construct was constructed in a similar fashion by amplifying a 631 
bp fragment, encompassing the LYN promoter, from COLO 205 genomic DNA 
(Uchiumi et al., 1992). A sense primer (FWD LYN -593): 5’ CCCGGTACCGAAAGG 
TACACG 3’ was used to introduce a KpnI restriction site to the -590LYN fragment, 
and an antisense primer (REV LYN +14): 5’ CGGCTCGAGAGGAACTGGCTG 3’ a 
XhoI site.  
 
3.6.3. p21WAF1 Reporter Constructs 
The pWWP-luciferase (WAF1-Luc) vector was initially obtained from Dr. B. 
Vogelstein (Howard Hughes Medical Institute, Johns Hopkins Oncology Center) (el-
Deiry et al., 1993),  and further modified by Scott Dehm to generate the -2300WAF1-
CAT, -210WAF-CAT and -101WAF1-CAT reporter vectors (Dehm et al., 2004).  
 
 93
3.6.4. -210WAF1-CAT + p21WAF1 3’UTR Reporter Vectors 
 The -210WAF1-CAT reporter construct was digested with SpeI and SacII 
enzymes, blunt ends were created and the vector re-ligated to remove a 19 bp fragment, 
containing a XbaI restriction site immediately upstream of the -210WAF1 promoter. 
This vector, -210WAF1-CAT ∆XbaI, still contained one XbaI restriction site between 
the CAT coding gene and the SV40 late poly(A) region. The -210WAF1-CAT ∆XbaI 
vector was used as the parental vector for the majority of the subsequent -210WAF1-
CAT + p21WAF1 3’UTR plasmids. To generate the -210WAF1-CAT + p21WAF1 
3’UTR (591-2079) vector, the full length p21WAF1 3’UTR (591-2079) was amplified 
from the pCEP-WAF1 p21WAF1 cDNA expression vector. PCR was performed using 
Taq DNA polymerase, the forward primer (FWD p21WAF1 3’UTR 591): 5’ 
GGAAGTCTAGAGTCCTGGAAG 3’, and reverse primer (REV p21WAF1 3’UTR 
2079): 5’ CGTTTCTAGAGCACCTGCTG 3’, each containing built-in XbaI restriction 
endonuclease sites. The resultant PCR product was restriction digested with XbaI and 
ligated into a previously XbaI linearized -210WAF1-CAT ∆XbaI vector to create the -
210WAF1-CAT + p21WAF1 3’UTR (591-2079) plasmid.  
3.6.4.1. -210WAF1-CAT + p21WAF1 3’UTR 5’ Deletion Plasmids 
The -210WAF1-CAT + p21WAF1 3’UTR (712-2079) plasmid was constructed 
as described above for -210WAF1-CAT + p21WAF1 3’UTR (591-2079), but the 1367 
bp p21WAF1 3’UTR fragment was amplified with the FWD p21WAF1 3’UTR 712 
primer: 5’ CATACTCTAGACGCCCCCTGC 3’ and the REV p21WAF1 3’UTR 2079 
primer. Similarly, p21WAF1 3’UTR (788-2079) and p21WAF1 3’UTR (840-2079) 
sequences were amplified with the FWD p21WAF1 3’UTR 780 primer: 5’ 
GAGGTTTCTAGAAGTGCTGGGC 3’ and the FWD p21WAF1 3’UTR 840 primer: 5’ 
CCTCATCTAGAGTTCTCCTTTTCC 3’, respectively with the REV p21WAF1 
3’UTR 2079 primer. XbaI digested PCR products were individually ligated with the 
XbaI cut -210WAF1-CAT ∆XbaI vector to generate: -210WAF1-CAT + p21WAF1 
3’UTR (712-2079), -210WAF1-CAT + p21WAF1 3’UTR (788-2079), -210WAF1-
CAT + p21WAF1 3’UTR (840-2079) plasmids. The -210WAF1-CAT + p21WAF1 
3’UTR (591-840) vector was built in the same fashion by first performing PCR 
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amplification with the FWD p21WAF1 3’UTR 581 primer and REV p21WAF1 3’UTR 
833 primer: 5’ GAGAACTCTAGATGAGGAGGC 3’.  
3.6.4.2. -210WAF1-CAT + p21WAF1 3’UTR Internal Deletion Plasmids 
 Internal deletion constructs -210WAF1 + p21WAF1 3’UTR (932-2079), -
210WAF1 + p21WAF1 3’UTR (1045-2079), -210WAF1 + p21WAF1 3’UTR (1173-
2079), -210WAF1 + p21WAF1 3’UTR (1272-2079), and -210WAF1 + p21WAF1 
3’UTR (840-1470) were created exactly as described above. The REV p21WAF1 
3’UTR 2079 primer with the FWD p21WAF1 3’UTR 932: 5’ GTACCCTCTAGAGGG 
GTGTGGCTC 3’, FWD p21WAF1 3’UTR 1045: 5’ GGCATCTAGAAGGGGCCTCA 
C 3’,  FWD p21WAF1 3’UTR 1173: 5’ GTACCCTCTAGACTCTTGATACC 3’, or 
FWD p21WAF1 3’UTR 1272: 5’ CCTGCTCTAGAGAGCCCGTCTC 3’ primer was 
used to amplified the respective p21WAF1 3’UTR sequences. The FWD p21WAF1 
3’UTR 840 primer and a REV p21WAF1 3’UTR 1470 primer: 5’ CCCCTTCTAGACC 
ATTGAGCTGGG 3’ were used in the PCR reaction of the p21WAF1 3’UTR 840-1470 
region.  
3.6.4.3. -210WAF1-CAT + p21WAF1 3’UTR 3’ Deletion Plasmids 
 PCR amplification was performed to establish four different p21WAF1 3’UTR 
3’ deletions. The FWD p21WAF1 3’UTR 591 primer was used in all four reactions 
with either the REV p21WAF1 3’UTR 2063: 5’ CCTGCTCTAGATTCAGCATTG 3’, 
REV p21WAF1 3’UTR 2031: 5’ GAAAGATCTAGAACAGTACAGG 3’, REV 
p21WAF1 3’UTR 2000: 5’ GCCCTCTAGAGGTTTACAGTC 3’, or REV p21WAF1 
3’UTR 1979 primer: 5’ CTAGGTCTAGAAACGGGAACCAGG 3’. The p21WAF1 
3’UTR 1467-2079 fragment was amplified with the FWD p21WAF1 3’UTR 1467 
primer: 5’ CCCCATCTAGATGGACTGGAAGG 3’ and REV p21WAF1 3’UTR 2079 
primer. The PCR products were treated with restriction endonuclease XbaI and ligated 
into XbaI linearized -210WAF1-CAT ∆XbaI to create the -210WAF1 + p21WAF1 
3’UTR (591-2063), -210WAF1 + p21WAF1 3’UTR (591-2031), -210WAF1 + 
p21WAF1 3’UTR (591-2000), -210WAF1 + p21WAF1 3’UTR (591-1979), and -




3.6.4.4. -210WAF1-CAT + p21WAF1 3’UTR Mutant Constructs  
The -210WAF1-CAT + p21WAF1 3’UTR (591-2079) plasmid vector was 
altered via two mutagenesis reactions. First, the upstream XbaI restriction site between 
the CAT coding gene and p21WAF1 3’UTR was abolished using the complimentary 
sense (FWD -210WAF1 XbaI destroy):  5’GCGGGGCGTAATCTGCAGTCCTGGAA-
GCGCG 3’ and antisense (REV -210WAF1 XbaI destroy): 5’ CGCGCTTCCAGGAC-
TGCAGATTACGCCCCGC 3’ primers, to create -210WAF1-CAT + p21WAF1 3’UTR 
(591-2079) -XbaI. Second, an EcoRV restriction endonuclease site was created in the -
210WAF1-CAT + p21WAF1 3’UTR (591-2079) -XbaI vector at position 1991 of the 
p21WAF1 3’UTR with the respective primers, FWD p21WAF1 3’UTR EcoRV create: 
5’ CTCCACCTAGACTGATATCCTCTCGAGGGCAGG 3’ and REV p21WAF1 
3’UTR EcoRV create: 5’ CCTGCCCTCGAGAGGATATCAGTCTAGGTGGAG 3’. 
The vector generated from the above two mutagenesis reactions was named -
210WAF1-CAT + p21WAF1 3’UTR (591-2079) –XbaI / +EcoRV, and was used as the 
parental vector for the construction of the -210WAF1 + p21WAF1 3’UTR mutant 
vectors. Sixteen separate -210WAF1 + p21WAF1 3’UTR mutant constructs (mut #1 -
16) were created. Complementary mutant oligonucleotides were designed that contained 
the 1997 – 2077 region of the p21WAF1 3’UTR surrounded by EcoRV and XbaI 
adaptor nucleotides. The oligonucleotide pairs were annealed and individually ligated 
into an EcoRV / XbaI cut -210WAF1-CAT + p21WAF1 3’UTR (591-2079) –XbaI / 
+EcoRV vector to generate the mutant vectors, -210WAF1-CAT + p21WAF1 3’UTR 
mut #1 - #16. Each mutant oligonucleotide pair contained five consecutive base pair 
mutations, beginning at position 2000 of the p21WAF1 3’UTR, where pyrimidines 
were replaced with pyrimidines (C to T, or T to C) and purines for purines (A to G, G to 
A). Mutant # 16 oligonucleotides were the exception, where only two base pairs were 
mutated at 2076 and 2077 of the p21WAF1 3’UTR. The oligonucleotide pairs utilized 
in the above cloning experiments are listed in Table 3.5, with the mutated nucleotide 
sequence underlined. 
3.6.4.5. -210WAF1-CAT + p21WAF1 3’UTR + Poly(A) Signal Constructs  
The -210WAF1-CAT + p21WAF1 3’UTR (591-2079) –XbaI / +EcoRV vector 
SV40 late poly(A) signal was destroyed by QuikChange site directed mutagenesis, 
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creating a SpeI restriction endonuclease site in its place. Mutagenesis was carried out 
with the primers, FWD -210WAF1-CAT poly(A) destroy: 5’ CCATTATA 
AGCTGCACTAGTCAAGTTAACAAC 3’ and REV -210WAF1-CAT poly(A) destroy: 
5’ GTTGTTAACTTGACTAGTGCAGCTTATAATGG 3’ to generate -210WAF1-CAT 
+ p21WAF1 3’UTR (591-2079) –XbaI / +EcoRV / ∆poly(A) signal. New wt, mutant 
#15 and mutant #15/16 p21WAF1 3’UTR + poly(A) signal oligonucleotides were 
purchased from IDT that spanned 1997 – 2102 and contained the p21WAF1 3’UTR 
poly(A) signal (Table 3.5, mutated sequences are underlined and the poly(A) signals are 
identified in bold). Similar to the oligonucleotides discussed above, EcoRV and XbaI 
adaptor nucleotides were placed at the termini of these oligonucleotides for cloning 
purposes. The complementary oligonucleotides were annealed and ligated into an 
EcoRV / XbaI cut -210WAF1-CAT + p21WAF1 3’UTR (581-2079) –XbaI / +EcoRV / 
∆poly(A) signal plasmid. The positive clones were digested with XbaI / SpeI, to remove 
a 145 bp region encompassing the upstream SV40 late poly(A) region leading up to the 
late SV40 destroyed poly(A) signal. The vector backbone was ligated to re-circularize 
and create the -210WAF1-CAT + p21WAF1 3’UTR wt poly(A) signal, -210WAF1-
CAT + p21WAF1 3’UTR mut#15 poly(A) signal, and -210WAF1-CAT + p21WAF1 
3’UTR mut#15/16 poly(A) signal plasmids. 
 
3.7. Transient Transfections of Cultured Cells 
3.7.1. Standard Transfection Conditions 
 Confluent SW480, HepG2, HT29 cells were counted and seeded at 5.0 x 105, 2.5 
x 105, and 3.5 x 105 cells / 35 mm tissue culture plate, respectively. Following seeding, 
cells were allowed to proliferate under normal growth conditions for 24 hours prior to 
transient transfection. A standard transfection mixture contained: 1.0 µg of CAT 
reporter plasmid, 0.5 µg of CMV β-Gal, 0.5 µg pBlue, 85 µL of serum free DMEM 
media and 10 µL of the SuperFect Transfection Reagent. The mixture was incubated at 
room temperature for 20 minutes, and the cells were prepared for transfection by 
washing with PBS. After 20 minutes, 600 µL of DMEM containing 10% FBS was 
added to the transfection mixture. This transfection mix was then administered to the 
cells at 670 µL / 35 mm tissue culture plate and the cells were returned to 5% CO2 and 
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37oC. Three hours later, the cell transfection was supplemented with 2 mL of the cell 
type specific media containing 10% FBS. The transfected cells were incubated under 
standard growth conditions for 45 more hours prior to harvesting.  
p21WAF1 transfections were carried out in a similar manner with 0.5 µg of 
p21WAF1 promoter CAT construct, 0.5 µg CMV β-Gal, 1.0 µg of pBlue and 85 µL of 
serum free DMEM mixed together with 10 µL of SuperFect and incubated for 20 min. 
at room temperature. The transfection mix was diluted further with 600 µL DMEM 
containing 10% FCS and added to directly to HT29 or HepG2 cells seeded the previous 
day. Likewise, co-transfection mixtures were prepared containing 1.0 µg of WAF1 
promoter CAT construct, 1.0 µg CMV β-Gal, 1.0 µg of pBlue and 1.0 µg of CMV c-jun 
(ATTC). The plasmid preparations used in all transient transfections were endotoxin-
free, prepared with either a QIAfilter Plasmid Midi Kit or an EndoFree Plasmid Maxi 
Kit.  
 
3.7.2. Histone Deacetylase Inhibitor Transfection Procedure 
 Cells were transfected as described under standard transfection conditions, 
however 24 hours following the transfection, cell media was removed and replaced with 
either 2.5 mL of fresh cell culture media (untreated), media containing 5.0 mM of NaB 
or 1.0 µM of TSA. Following treatment, cells were grown under normal conditions for a 
6,12, or 24 hour time periods before harvesting. Untreated transfected cells were 
harvested 24 hours following media replacement. 
 
3.7.3. Transfection of BHK-21 and tsBN462 Cells 
3.7.3.1. BHK-21 and tsBN462 Transfections and Histone Deacetylase Inhibitors  
 BHK-21 and tsBN462 confluent cells were counted and seeded at 2.5 x 105 cells 
/ 35 mm tissue culture plate and placed at 32.6oC and 5% CO2 for 24 hours. One half µg 
of CAT reporter construct, 0.5 µg of CMV β-Gal, 1.0 µg of pBluescript, 85 µL of 
serum free DMEM media and 10 µL of the SuperFect Transfection Reagent were 
pooled to generate the transfection mixture. This mix was incubated at room 
temperature for 20 minutes and the cells were washed with PBS. 600 µL of DMEM 
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plus serum was added to the transfection components, and 670 µL of the diluted 
mixture was directly dispensed to the cells. The cells were returned to 32.6oC and 5% 
CO2 growth conditions. Following three hours, the transfection mix was removed from 
the cell tissue culture plate, the cells were washed with PBS, and fresh DMEM 
containing 10% FBS was added. The cells were allowed to proliferate at 32.6oC for an 
additional 21 hours, at which time their media was withdrawn again and replaced with 
5.0 mM NaB or 1.0 µM TSA treated media or fresh DMEM. The BHK-21 and tsBN462 
cells were either transferred to 39.5oC, their restrictive temperature, or maintained at 
32.6oC. All cells were harvested 24 hours later.   
3.7.3.2. tsBN462 Co-transfections 
 tsBN462 cells were seeded as discussed above. Co-transfections were performed 
with the c-Src family kinase (SFK) CAT reporter plasmids and TAF1 or TAF1 
acetyltransferase (AT) mutants. The transfection mix was comprised of 0.5 µg of the 
CAT reporter construct, 0.25 µg of TAF1 (or mutant TAF1), 0.5 µg CMV β-Gal, 0.75 
µg pBluescript, 85 µL of serum free DMEM media and 10 µL of the SuperFect 
Transfection Reagent. When TAF1 was not included in the transfection mix, an 
additional 0.25 µg of pBluescript was included. The tsBN462 cells were transfected 
with this mixture as discussed above and placed at 32.6oC or 39.5oC 24 hours following 
transfection initiation, however the cell culture media was not replenished at this time. 
Cells were harvested 24 hours after the temperature shift occurred.    
 
3.8. Determination of CAT Reporter Activity 
3.8.1. Chloramphenicol AcetylTransferase Assay 
 Chloramphenicol acetyltransferase (CAT) assays were performed on transiently 
transfected cells with a CAT Colorimetric Enzyme-Linked Immunosorbent Assay Kit, 
based on the instruction manual. Transiently transfected cells in 35 mm tissue culture 
plates were washed with PBS and harvested in 500 µL of 1 X CAT lysis buffer. Two 
hundred µL of each lysed cell sample was added to an anti-CAT coated microplate well 
and samples were incubated at 37oC for a minimum of 1 hour. The plates were 
subsequently washed five times with 1 X Washing Buffer. 200 µL of 1:100 digoxigenin 
labeled CAT antibody (Anti-CAT-DIG), diluted in Sample Buffer was aliquoted to the 
 99
wells, and the microplates were returned to 37oC. Following at least 1 hour at 37oC, the 
microplates were subject to five washes with 1 X Washing Buffer and 200 µL of an 
antibody DIG conjugated to peroxidase (Anti-DIG-POD), diluted 1:133 in Sample 
Buffer, was added to the wells. Samples were once again placed at 37οC for an hour, 
followed by a final set of five washes. Two hundred µL of POD substrate, without 
enhancer, was added to the wells and the color was allowed to develop at room 
temperature. The absorbance of the CAT samples was measured using a Microplate 
Reader Model 3550, at a measurement wavelength of 405 nm and reference wavelength 
of 490 nm.  
 
3.8.2. Beta-Galactosidase Assay 
 β-Galactosidase activity was monitored by adding 30 µL of 1 X CAT lysis 
buffer harvested transfected cell sample to 85.5 µL of 0.1M sodium phosphate (41 mL 
0.2 M Na2HPO4 ⋅ 2H20, 9 mL sodium dihydrogen phosphate (NaH2PO4 ⋅ 2H20), 50 mL 
H2O), 1.5 µL of 100 X Mg2+ solution (0.1 M MgCl2, 4.5 M β-mercaptoethanol), and 33 
µL of o-nitrophenyl-β-D-galactopyranoside (ONPG) (Hall et al., 1983). The reaction 
mixtures were placed at 37οC until a yellow color developed, and color development 
was halted by the addition of 120 µL of 1 M sodium carbonate (NaCO3) Stop solution. 
The sample absorbance, following the addition of Stop solution, was measured with a 
Microplate Reader at a wavelength of 415 nm.  
 
3.8.3. Bradford Protein Assay 
 Protein concentration analysis of transiently transfected cells was performed 
with a Bio-Rad Protein Assay Dye Reagent Concentrate diluted 1:10 in water. 15 µL of 
1 X CAT lysis buffer harvested cell sample was added directly to the diluted Protein 
Assay Dye Reagent and the absorbance, at 595 nm, was determined with a Microplate 
Reader. 




3.9. RNA Isolation from Cultured Cells 
Total RNA was isolated from cells based on the guanidinium thiocyanate 
method (Chomczynski et al., 1987). Cells were lysed and harvested in 500 µL of 
Solution D (4 M guanidinium thiocyanate, 25 mM sodium citrate (Na3C6H5O7), 0.5% 
(%w/v) N-lauroyl sarcosine). Fifty µL of 2 M sodium acetate (CH3COONa) pH 4.0, 
500 µL of water saturated phenol and 100 µL of chloroform:isoamyl alcohol mix (49 
mL chloroform:1 mL isoamyl alcohol) were added sequentially to each harvested 
sample, and mixed thoroughly after each addition. Samples were incubated on ice for 
15 minutes and centrifuged at 12, 000 x g for 2 minutes. The top, aqueous layer was 
collected in a fresh microcentrifuge tube and isopropanol was added to make up 75% of 
the total volume. Samples were placed at -20oC for a minimum of 1 hour. Upon 
removal from the freezer, samples were centrifuged at 12, 000 x g for 15 minutes, the 
liquid was removed and the resultant pellet was resuspended in Solution D including β-
mercaptoethanol and 400 mL of 95% Ethanol. The RNA preparation was placed on ice 
until precipitation was apparent, and centrifuged at 12, 000 x g for 15 minutes. The 
RNA pellet was washed once with 70 % ethanol and ultimately resuspended in 0.1 mM 
EDTA containing 0.1% (v/v) diethyl pyrocarbonate water. RNA concentration was 
determined by measuring the absorbance at a wavelength of 260 nm, where an A260 
reading of 1 = 40 µg/mL RNA. RNA purity was identified by the A260/A280 ratio, where 
a ratio of 1.6 – 2.1 was considered pure RNA. 
 
3.10. Northern Blot 
3.10.1. Northern Blot Electrophoresis and Gel Transfer 
The RNA denaturing gel was prepared by boiling and dissolving 0.8 g agarose 
in 8 mL of 10 X morpholinopropanesulfonic acid (MOPS) running buffer (0.2 M 
MOPS, 0.05 M sodium acetate, 0.01 M EDTA) and 72 mL H20. After cooling the 
agarose gel to 60oC, 6% (v/v) of formaldehyde was added and the gel was poured in an 
RNAase free gel tray. Samples were prepared by combining the volume equivalent of 
15 µg total RNA with 10 µL of Northern Juice (50.7 % (v/v) formamide, 11.3 % (v/v) 
10 X MOPS, 6.8 % (v/v) formaldehyde, 5.6 % (v/v) of glycerol, in diethyl 
pyrocarbonate treated H20 containing 0.1 mM EDTA) and H20 up to a total volume of 
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25 µL. These samples were heated at 65oC for 5 minutes and cooled on ice for 5 
minutes prior to the addition of 6 µL of a 6 X DNA gel loading buffer (10 µL) / 
ethidium bromide (10 µg) mix. Electrophoresis was performed in 1 x MOPS running 
buffer and the samples were separated on the RNA denaturing gel at 90 V. Following 
electrophoresis, the Gel Doc was used to photograph the RNA gel to ensure all the RNA 
samples had been evenly loaded. The gel was washed in H20, and denatured in 50 mM 
NaOH for 15 minutes. Subsequently, the gel was rinsed with H20, neutralized in 100 
mM Tris pH 8.0 for 15 minutes, and a final wash was carried out for 15 minutes in H20. 
The RNA gel was then transferred overnight in 50 mM sodium phosphate solution, pH 
7.0 onto a GeneScreen Plus Hybridization Transfer Membrane. Following gel transfer, 
the membrane was washed with 1 X SSC (150 mM NaCl, 15 mM sodium citrate) and 
auto-crosslinked in a UV Stratalinker 2400.  
 
3.10.2. Northern Probes 
Northern probes were generated by endonuclease restriction digestions, 
followed by gel extraction of the appropriately fractioned DNA fragment using the 
QIAquick Gel Extraction Kit. More specifically, the HHCI89 clone was treated with 
EcoRI to liberate a 1.1 kb β-actin cDNA fragment. KpnI and NcoI were used to isolate 
the 876 bp c-Src probe from the Src (wt) Y530 pcDNA 3.1 plasmid. A 500 bp cDNA 
probe specific for Lck was generated by digesting the Lck EST with RsrII and NcoI.  
Similarly SacI and HindIII were used to restrict a 523 bp cDNA fragment from the Lyn 
EST.  The Fyn EST was digested with KpnI to produce a 431bp probe, and c-Yes was 
treated with the BamHI and HincII restriction endonucleases to create a 560 bp cDNA. 
A 500 bp c-myc probe was generated by PstI digestion of the c-myc cDNA vector, pMI. 
p21WAF1 plasmid cDNA pCMV-Cip1 was obtained from ATCC and was digested 
with EcoRI and XhoI to liberate a 1 kb cDNA fragment. The ribosomal protein (RPPO) 
cDNA was obtained from Dr. W. Roesler (University of Saskatchewan). All cDNA 
probes were [α-32P] dCTP labeled with either the RediPrime II DNA Labeling System 
(GE Healthcare) or Ready-To-Go DNA Labeling Beads (-dCTP) as per manufacturer 
instructions. [α-32P] labeled probe reactions were further purified using a QIAquick 
Nucleotide Removal Kit to remove unincorporated radiolabeled nucleotides. 
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3.10.3. Northern Blot Hybridization  
 RNA crosslinked membranes were prehybridized in a hybridization tube with 
ExpressHyb Hybridization Solution for a minimum of 1 hour at 65oC in a Micro 
Hybridization Incubator Model 2000. [α-32P] dCTP-labeled cDNA probes of interest 
were added directly to the ExpressHyb solution in the tube and the hybridization 
reaction allowed to proceed overnight at 65oC. Subsequently, hybridized membranes 
were put through a series of 20 minute washes at 65oC in Wash Buffer 1 (0.3 M NaCl, 
30 mM sodium citrate, 1% dodecyl sodium sulfate (SDS), Wash Buffer 2 (75 mM 
NaCl, 7.5 mM sodium citrate, 1% SDS) and Wash Buffer 3 (30 mM NaCl, 3 mM 
sodium citrate, 1% SDS). Hybridization signals were acquired with the use of a 
Molecular Imager FX following exposure to an Imaging Screen K (Bio-Rad 
Laboratories) or by autoradiography at -80oC on BioMax XAR film with the aid of an 
intensifier screen. The Molecular Imager was used to quantify RNA signals in some 
instances.  
 
3.11. Western Blot 
3.11.1. Lowry Protein Assay 
Cells were harvested in a SDS sample buffer containing 10% (v/v) glycerol, 5% 
(v/v) β-mercaptoethanol, 2% (w/v) SDS, 65 mM Tris-HCl (pH 7.0), and 0.05% (w/v) 
bromophenol blue adjusted to pH 6.8. Lowry assays were performed using a Total 
Protein Kit, Micro Lowry to determine the protein concentration of the samples.  
 
3.11.2. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A 10% SDS-polyacrylamide resolving gel was prepared containing 10% 
acrylamide:bis acrylamide (29.2%:0.8%), 375 mM Tris-HCl pH 8.8, 0.1% (v/v) SDS, 
0.1% (w/v) ammonium persulfate and 0.04 % (w/v) N,N,N',N'-
tetramethylethylenediamine (TEMED) (Sambrook et al., 1989). The 10% acrylamide 
resolving gel was poured into the Mini-PROTEAN II gel apparatus and layered with 
water saturated butanol to prevent the gel from warping. Following polymerization, the 
butanol was removed and a 5% acrylamide stacking gel (29.2% acrylamide:0.8% bis 
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acrylamide), 130 mM Tris-HCl, 0.1 % (w/v) SDS, 0.1 % (w/v) ammonium persulfate 
and 0.04 % (w/v) TEMED) was added above the 10% acrylamide gel (Sambrook et al., 
1989).Commonly, 30 µg protein samples were resolved by SDS-PAGE in SDS gel 
running buffer (25 mM Tris-HCl, 200 mM glycine, 0.1% (w/v) SDS). Prior to loading, 
all protein samples were boiled for 2 minutes. Electrophoresis was carried out in a 
Mini-PROTEAN II Cell and allowed to proceed for 50 minutes at 180 volts. 
 
3.11.3. Western Blot Method and Antibodies 
Following electrophoresis, the resolved protein was transferred by semi dry 
electroblotting to Optitran Supported Nitrocellulose and briefly washed in TBST buffer 
(10 mM Tris, 15 mM NaCl, 0.5% (v/v) TWEEN-20. Subsequently, the membranes 
were blocked for 1 hour at room temperature in 5% (w/v) fat-free skim milk powder in 
TBST. Membranes were incubated with the Anti-v-Src (Ab-1) mouse monoclonal 
antibody at 1 µg/mL or p21WAF1 (187) sc-817 mouse monoclonal antibody at a final 
concentration of 200 ng/mL in blocking solution. The membrane was washed and 
incubated for a second time with goat anti-mouse IgG horseradish peroxidase 
conjugated antibody at 100 ng/mL, which was diluted 1:2000 in blocking buffer. A 
second wash was performed prior to blot treatment with Western Lightening 
Chemiluminescence Reagent Plus and exposure to X-OMAT Blue XB-1 film for 
detection.    
 
3.12. Isolation of Nuclear and Cytoplasmic Cellular Extracts 
 Cells were harvested in PBS containing 0.2 mM phenylmethylsulphonyl fluoride 
(PMSF), 1 X Protease Inhibitor Mix (PIM), 0.5 mM dithiothreitol (DTT) and collected 
by centrifugation at 450 x g at 4oC for 5 minutes. The cell pellet was resuspended in low 
salt cold Buffer A (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) pH 7.9 with potassium hydroxide (KOH), 1.5 mM MgCl2, 10 mM KCl, 0.5 
mM DTT, 0.2 mM PMSF, 1 X PIM) and incubated for 10 to 15 minutes on ice to allow 
the cells to swell. 10% Nonidet-P40 (NP-40) was added to each sample, which was 
vortexed and subsequently placed on ice for 2 to 5 minutes. Trypan blue was used to 
assess when the cell membrane had been lysed. The samples were centrifuged at 2500 x 
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g for 4 minute at 4oC. The resultant supernatant consisting of cytoplasmic extract was 
saved and the nuclei containing pellet was resuspended in cold hypertonic Buffer C (10 
mM HEPES KOH pH 7.9, 25% glycerol, 15 mM MgCl2, 420 mM NaCl, 0.5 mM DTT, 
0.2 mM PMSF, 1 X PIM) and placed on ice for 20 minutes. The samples were vortexed 
briefly, centrifuged at 12, 000 x g for 10 minutes to attain the nuclear extracts from the 
supernatant fraction and snap-frozen. The saved cytoplasmic supernatant was freeze-
thawed five times, centrifuged one final time for 10 minutes at 2500 x g, 4oC, aliquoted 
and snap-frozen (Wang et al., 2000).  
 
3.13. RNA Mobility Shift Assays (RMSAs) 
3.13.1. Preparation of the T7 Transcript 
 The template pCEP-WAF1 was used to amplify the three sections of the 
p21WAF1 3’ UTR, 586-840, 835-1470, 1459-2079. The extreme 5’ of each of the 
forward primers possessed the T7 promoter sequence 5’ CCAAGCTTCTAATACGAC 
TCACTATAGGGAGA (T7). The p21WAF1 3’UTR (T7)586-840 sequence was 
generated with the FWD p21WAF1 3’UTR (T7)586 primer: 5’ (T7) 5' CCTGCAGTCC 
TGGAAGCGCGAGG 3’and REV p21WAF1 3’UTR 840 primer: 5’ GAGAACTCTAG 
ATGAGGAGGC 3’. The (T7)835-1470 region of the 3’UTR was amplified with the 
FWD p21WAF1 3’UTR (T7)835 5’ (T7) CCCGTGTTCTCCTTTTCCTCTC 3’ and 
REV p21WAF1 3’UTR 1470 5’ CCCCTTCTAGACCATTGAGCTGGG 3’ primers. 
Similarly the (T7)1459-2079 fragment was amplified using the FWD p21WAF1 3’UTR 
(T7)1459 5’ (T7) CCAGCTCAATGGACTGGAAGGG 3’ and REV p21WAF1 3’UTR 
2079 5’ CGTTTCTAGAGCACCTGCTG 3’ primers. 
 
3.13.2. T7 Reaction and RNA Probe Isolation 
 RNA fragments corresponding to ribonucleotides 586-840, 840-1481 and 1467-
2079 of the p21WAF1 3’ UTR were synthesized by T7 polymerase using the Riboprobe 
in vitro Transcription System Kit as suggested by the manufacturer standard 
transcription protocol. Following in vitro transcription, the reactions were treated with 
RQ1 RNase-free DNase to remove the template DNA for 15 minutes at 37oC. 
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Afterward, [α-32P] rUTP-labeled RNA was extracted from the reactions using an 
RNeasy Mini Kit.  
 
3.13.3. RNA Mobility Shift Assay Method  
 Binding reactions between the p21WAF1 3’UTR ribonucletide sequences and 
cellular extracts were carried out with Binding Buffer (15 mM HEPES pH 7.9, 10 mM 
KCl, 10% glycerol, 0.2 mM DTT, 5 mM MgCl2), 1 µg tRNA, 30 µg of nuclear or 
cytoplasmic extract and 100, 000 cpm of p21WAF1 3’ UTR RNA probe and incubated 
at room temperature for 1 hour. RNase T1 was added to the binding reactions and 
incubated at 37oC for 15 minutes. A 6% acrylamide gel containing 2.5% glycerol was 
prepared in Tris-Glycine Buffer (25 mM Tris, 250 mM glycine, 0.1% SDS) for the 
RMSA. Binding complexes were resolved on the native gel at 120 volts for 
approximately 3 hours in a PROTEAN II xi Cell. The gel was dried in a Gel Dryer 








4. RESULTS  
4.1. THE EFFECT OF HISTONE DEACETYLASE INHIBITORS ON THE 
GENE EXPRESSION LEVELS OF C-SRC  
4.1.1. The Influence of Histone Deacetylase Inhibitors on Tumor Cell Growth 
HDIs have been shown to harbor potent anti-tumor activities in a range of 
human tumor cells and animal models, and as such, have promising therapeutic value 
(Marks et al., 2001, Vigushin and Coombes, 2002 and Arts et al., 2003). One HDI that 
inhibits cellular growth of tumor cells is sodium butyrate (NaB), a non-competitive HDI 
that exists at physiologically relevant concentrations within the colon as a byproduct of 
anaerobic bacterial fermentation of dietary fiber (Sealy and Chalkley, 1978, Roediger, 
1980 and Carey and La Thangue, 2006).  
Previous work performed in the Bonham Lab has identified differential SRC 
promoter usage and relative c-Src expression levels across a variety of tumor cell lines 
(Bonham et al., 2000, Dehm et al., 2001 and Dehm and Bonham, 2004b). To 
investigate the effect of HDIs on c-Src expression levels, four cell lines were chosen 
based on the criteria of cellular origin, SRC promoter usage and c-Src expression levels. 
Two colon cancer cell lines were selected (HT29 and SW480), as well as one breast 
cancer cell line (T-47D) and one hepatocellular carcinoma cell line (HepG2). HT29 
cells were chosen based on their utilization of both the SRC1A and SRC1α promoters, 
and relatively high c-Src mRNA and protein expression levels. In contrast, SW480 cells 
primarily synthesize mRNA transcripts from the SRC1A promoter and exhibit low c-
Src expression levels. T-47D cells also employ the SRC1A promoter but express c-Src 
at moderate levels, while HepG2 cells predominantly use the SRC1α promoter and 
display high c-Src expression levels.  
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To monitor the anti-proliferative effects of NaB, the growth kinetics of HT29 
and SW480 colon cancer cells were studied over 24, 48, 72 and 96 h time periods 
following exposure to NaB doses ranging from 0 - 10.0 mM (Figure 4.1.A, B). Growth 
curve analysis indicated that NaB represses colon tumor cell proliferation of HT29 and 
SW480 cells in a dose dependent manner and that a dose of 5.0 mM NaB was sufficient 
to completely inhibit colonic cell growth. Similarly, NaB affected cell growth of T-47D 
cells (Figure 4.1.C), however, a dose as low as 1.0 mM NaB caused a significant 
decrease in cell proliferation and 2.0 mM NaB prevented cell growth entirely.  
Given that NaB is quite dissimilar from other HDIs, including Trichostatin A 
(TSA), the anti-proliferative effects of NaB and TSA were studied side by side in 
HepG2 hepatocellular carcinoma cells (Figure 4.2.A, B). HepG2 cells were cultured 
alone or following treatment with NaB concentrations ranging from 0.5 mM – 10.0 mM 
or TSA from 0.5 µM – 10.0 µM for 24, 48, 72, and 96 h. Once again, cellular growth of 
HepG2 cells decreased in a dose dependent manner following exposure to both NaB 
and TSA. Similar to T-47D cells, a dose of 1.0 mM NaB was capable of inhibiting 
cellular proliferation and 2.0 mM NaB was optimal for stopping the growth of HepG2 
cells. TSA, on the other hand, inhibited cell growth at significantly lower 
concentrations, where 1.0 µM TSA was sufficient for the absence of HepG2 cellular 
proliferation. These results conform with the current literature, that TSA is a much more 
potent HDI than NaB and is capable of inducing cellular growth arrest at µM 
concentrations, instead of the mM concentrations that NaB requires (Rosato and Grant, 
2004). Furthermore, 5.0 mM NaB and 1.0 µM TSA appear to be the optimal doses 
required to convincingly abrogate tumor cell growth. The viability of HepG2 cells at the 
optimal NaB and TSA doses were confirmed following 96 hours of HDI treatment by 
trypan blue staining (results not shown). 
 
4.1.2. Histone Deacetylase Inhibitor Downregulation of c-Src Expression Levels  
Upon selecting a diverse panel of tumor cell lines, and establishing the 
concentration range required for the anti-proliferative effects of NaB and TSA in these 
cell lines, HDI dose response experiments were performed. Principally, the action of 
NaB was monitored in HT29 and SW480 human colon cancer cells (HCCLs), given that  











































































Figure 4.1. Sodium butyrate decreases cell growth in human colon and breast tumor
cells. Growth curve analysis of (A) HT29, (B) SW480, and (C) T-47D cells following
96 h of treatment with increasing concentrations of NaB ranging from 0 - 10.0 mM.
The data represent an average of two independent experiments performed in duplicate

















































































































Figure 4.2. Histone deacetylase inhibitors decrease cell growth in HepG2 cells.
Growth curve analysis of HepG2 cells treated with increasing doses of either (A) 0 -
10.0 mM NaB or (B) 0 - 10.0 M TSA for a 96 h time period. The data represent an
average of two independent experiments, each performed in duplicate and include




physiologically high butyrate concentrations are naturally produced in the colon and c-
Src protein levels and/or kinase activity is frequently elevated in malignant colonocytes 
compared to normal colonic mucosa (Roediger, 1980, Rosen et al., 1986, Bolen et al., 
1987, and Cartwright et al., 1989). Remarkably, NaB dose response experiments 
revealed that c-Src mRNA expression levels were repressed in a dose dependent manner 
by an effective dose of 2.0 – 10.0 mM NaB for 24 h in HT29, and SW480 cells (Figure 
4.3.A, B). c-Src mRNA levels of T-47D and HepG2 cells were also consistently 
downregulated within this optimal dose range (Figure 4.3.C, D). Since p21WAF1 is a 
well defined target of HDIs, all dose response Northern blots were re-probed with 
p21WAF1 as a positive control (Nakano et al., 1997, Sowa et al., 1997 and Huang et 
al., 2000). Accordingly, 2.0 – 10.0 mM NaB was observed to induce p21WAF1 mRNA 
expression levels in HT29, SW80, T-47D and HepG2 cells (Figure 4.3.).Taking these 
observations into account, an average dosage of 5.0 mM was chosen to further study 
NaB mediated c-Src downregulation.  
Time course experiments carried out with the HT29, SW480, T-47D and HepG2 
cell lines revealed that 5.0 mM NaB was capable of significantly repressing c-Src and 
elevating p21WAF1 mRNA levels as early as 6 h following treatment (Figure 4.4.A). In 
addition, NaB was also shown to suppress c-Src mRNA expression levels completely in 
the metastatic breast carcinoma cell lines MDA-MB-231 and MCF7 after 24 h of 
exposure (Figure 4.4.A). It was noted from both the dose response and time course 
experiments that NaB appeared to inversely regulate c-Src and p21WAF1, and often the 
RNA sample with the lowest level of c-Src also displayed the highest level of 
p21WAF1 mRNA expression.  
Subsequently, to establish if decreases in c-Src mRNA were matched by a drop 
in c-Src protein levels, Western blot analysis was performed with HT29, SW480, T-
47D and HepG2 cell NaB time course samples. Similar to c-Src mRNA, NaB 
downregulated c-Src protein levels in a time dependent fashion. However, suppression 
of c-Src protein expression levels was expectantly delayed as decreases in protein 
expression were not apparent until the cells had been exposed to NaB for a minimum of 
18 h (Figure 4.4.B). To ensure that the NaB mediated downregulation of c-Src levels 
was not a consequence of pleiotropic effects beyond inhibiting HDACs, the effect of  
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Figure 4.3. Sodium butyrate suppresses c-Src mRNA levels dose dependently in
human tumor cells. Northern blot analysis was performed on total RNA extracted
from (A) HT29, (B) SW480, (C) T-47D, and (D) HepG2 cells following treatment
with NaB doses ranging from 0 - 10.0 mM for a 24 hour time period. The mRNA
levels of c-Src and p21WAF1 were examined. The data shown are a representation
of three experiments.
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Figure 4.4. c-Src mRNA and protein levels are repressed by histone deacetylase
inhibitors in human tumor cells. A. Total RNA was extracted from HT29, SW480,
T-47D, HepG2, MDA-MB-231 and MCF-7 cells following treatment with 5.0 mM
NaB for 0 - 24 h and Northern blot analysis was performed with c-Src and p21WAF1
probes. B. Total cellular protein was harvested from HT29, SW480, T-47D and HepG2
cells after 0 - 24 h of NaB treatment and analyzed by Western blot for c-Src protein
(pp60 ). C. Western blots were performed on HT29 and SW480 cells treated with
1.0 M TSA for 0 - 24 h and analyzed for pp60 levels. The Northern blot data
shown are a representation from three independent experiments, while the Western














TSA, a competitive HDI, on c-Src protein levels was monitored. Clearly, 1.0 µM TSA 
also inhibited the expression of c-Src protein levels in HT29 and SW480 cells, 
over 24 h (Figure 4.4.C). Taken together, these observations suggest that HDIs may 
universally downregulate c-Src expression, regardless of tissue, SRC promoter usage or 
relative c-Src mRNA and protein levels.  
 
4.1.3. The Effect of Histone Deacetylase Inhibitors on SRC Transcription 
 In view of the observation that c-Src expression levels are inhibited by NaB in 
cell lines which display a preference for either the SRC1α promoter (HepG2) or 
SRC1A promoter (SW480), the potential of HDIs to suppress activity of both SRC 
promoters was assessed. For these experiments, the minimal SRC1α (-145SRC1α-
CAT) promoter plasmid, harboring the HNF-1 site, was transiently transfected into 
HepG2 cells and treated with NaB (5.0 mM) or left untreated for 24 h (Figure 4.5.A). 
Similarly, the minimal SRC1A (0.38SRC1A-CAT) promoter vector, containing the cis-
acting GC1, GA2, TC1, TC2 and TC3 sites, was transiently transfected into HepG2 
cells and exposed to NaB in the same manner (Figure 4.5.B). CAT levels were used to 
determine the activity of the -145SRC1α and 0.38SRC1A promoters in the absence and 
presence of NaB treatment. Interestingly, NaB repressed both the highly dissimilar 
SRC1α and SRC1A promoters by approximately 80%, in HepG2 cells. Furthermore, 
1.0 µM TSA inhibited the SRC1α and SRC1A promoters by 90% in HepG2 cells 
(Kostyniuk et al., 2002). Identical -145SRC1α−CAT and 0.38SRC1A-CAT plasmid 
transient transfections carried out in SW480 cells with NaB and TSA also displayed a 
respective 90% and 95% decrease in the activity of both promoters (Kostyniuk et al., 
2002). To ensure that the transient transfections were working correctly, the promoter 
activity of p21WAF1 was assessed. Three p21WAF1 promoter vectors were tested: the 
full length -2300WAF1-CAT vector, which possessed all six Sp binding sites and two 
distal p53 REs; the -210WAF1-CAT reporter plasmid, which lacked the p53 REs but 
still contained the Sp elements; and the -101WAF1-CAT vector, which harbored only 
Sp sites 3-6. Transient transfections with these reporter plasmids in HT29 cells revealed 
that -210WAF1-CAT displayed the highest basal promoter activity of the WAF1-CAT 
promoter vectors, and that both NaB and TSA were competent for promoter  













































Figure 4.5. Sodium butyrate mediated repression of the SRC1 and SRC1A promoters.
HepG2 cells were transfected with (A) 0.38SRC1A-CAT or (B) -145SRC1 promoter
constructs and treated with or without NaB (5.0 mM) for 24 h prior to assessing CAT
levels. C. The -2300, -210, or -101WAF1-CAT promoter constructs were transfected
into HT29 cells and treated with either NaB (5.0 mM) or TSA (1.0 M) for 24 h. Each
of these experiments was performed in duplicate a minimum of two times. The error


















































































































upregulation of all three WAF1-CAT reporter plasmids (Figure 4.5.C). Therefore, HDIs 
appear to inhibit c-Src expression levels by suppressing the SRC1α and SRC1A 
promoters and to elevate p21WAF1 expression levels by activating the WAF1 
promoter. 
 
4.1.4. p21WAF1 Activation of SRC Transcription 
 Given that c-Src downregulation inversely correlates with p21WAF1 
upregulation and HDIs have been shown to suppress activity of the SRC promoters, a 
role for p21WAF1 in HDI mediated repression of the SRC1α and SRC1A promoters 
was explored. Transient co-transfections were performed in SW480 and HepG2 cells 
with the reporter plasmid -145SRC1α-CAT and a p21WAF1 expression vector pCMV-
Cip1 to determine if p21WAF1 had the ability to suppress the SRC1α promoter. 
Contrary to this hypothesis, pCMV-Cip1 trans-activated the SRC1α promoter nearly 2-
fold in SW480 cells and 4-fold in HepG2 cells (Figure 4.6.A). When HDIs were added 
to the co-transfections, -145SRC1α promoter levels were subsequently repressed. 
Furthermore, the 0.38SRC1A promoter was stimulated by pCMV-Cip1 in HepG2 cells, 
but not in SW480 cells, and in every instance HDIs were still proficient at repressing 
the SRC1A promoter (Figure 4.6.B). Hence, p21WAF1 is not responsible for HDI 
facilitated downregulation of the SRC1α and SRC1A promoters. However, p21WAF1 
does appear to activate these promoters by a novel mechanism, which may be 
overridden by HDIs.   
 
4.1.5. Downregulation of c-Src Expression Levels by HDIs does not Require New 
Protein Synthesis  
 To investigate whether HDIs directly or indirectly inhibit c-Src expression 
levels, additional time course experiments were carried out with the protein synthesis 
inhibitor cycloheximide (CHX). Four selected cell lines were subjected to time course 
analysis with NaB (5.0 mM), CHX (50 µM), or NaB (5.0 mM) and CHX (50 µM) 
jointly. In HT29, SW480, T-47D, and HepG2 cells, NaB treatment alone repressed c-
Src mRNA levels, as previously reported, and CHX treatment induced c-Src mRNA 
expression (Figure 4.7.A-D). However, when the cells were exposed to both agents,  
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Figure 4.6. The SRC1 and SRC1A promoters are trans-activated by p21WAF1 in
SW480 and HepG2 cells. Cells were transiently transfected with (A) 0.38SRC1A-
CAT or (B) -145SRC1 promoter constructs in the absence or presence of co-
transfected pCMV Cip1 and left untreated (-) or exposed to NaB (5.0 mM) or TSA
(1.0 M) for 24 h These data are the average of two independent experiments, each





























Figure 4.7. c-Src mRNA levels are reduced by sodium butyrate independent of new
protein synthesis. Total RNA was extracted from HT29 (A), SW480 (B), T-47D (C)
and HepG2 (D) cells. Cells were treated for the allotted time frames with NaB
(5.0 mM), CHX (50 M), or both NaB (5.0 mM) and CHX (50 M) together. RNA
levels of c-Src and p21WAF1 were examined by Northern blot. Each experiment




CHX was unable to prevent HDI mediated repression of c-Src in all cell lines examined.  
Moreover, when Northern blots were re-probed with p21WAF1, NaB and CHX alone 
elevated p21WAF1 mRNA levels, while the combination of NaB and CHX stimulated 
p21WAF1 expression even further in HT29, SW480 and T-47D cells (Figure 4.7.A-C). 
In HepG2 cells, therefore, p21WAF1 mRNA expression was not upregulated by NaB in 
the presence of CHX (Figure 4.7.D). These results suggest that HDIs suppress c-Src 
expression independent of new protein synthesis. Furthermore, the observation that 
protein neo-synthesis is not necessary for HDIs to elevate of p21WAF1 mRNA levels in 
HT29, SW480 and T-47D cells conforms with the current literature (Nakano et al., 
1997 and Sowa et al., 1997). The need for new protein synthesis to enhance the mRNA 
expression levels of p21WAF1 in HepG2 cells, therefore, is a novel finding that will be 
discussed in greater detail in the third part of the results section. 
  
4.1.6. SUMMARY 
c-Src overexpression has been implicated in tumor development, growth and 
metastasis. Therefore, the potential of HDIs to affect c-Src gene expression in colon 
carcinoma cells was investigated. HDIs were capable of efficiently inhibiting c-Src 
mRNA and protein levels in a dose and/or time dependent manner, not only in HCCLs, 
but also in breast and hepatocellular carcinoma cell lines. Surprisingly, this repression 
of c-Src levels was suggested to be the result of HDI mediated downregulation of the 
SRC promoters, as both the dissimilar SRC1α and SRC1A promoters were repressed by 
HDIs to a similar degree. Furthermore, HDIs were observed to regulate c-Src 
expression independent of new protein synthesis. Therefore, these results suggest that c-
Src may be an important target of HDIs, and in particular of butyrate, which 
physiologically resides in the colon at equivalent dosages to those utilized in the above 







4.2. THE RESPONSE OF C-SRC FAMILY KINASE MEMBERS TO HISTONE  
      DEACETYLASE INHIBITORS 
4.2.1. The Relative Expression Patterns of c-Src Family Kinase Members in 
HCCLs. 
In addition to overexpression and/or activation of c-Src, elevated gene 
expression level and kinase activity of a number of the c-Src family kinase (SFK) 
members have been reported in tumor development, proliferation, motility, invasiveness 
and progression (Biscardi et al., 1999; Frame, 2002; Russello and Shore, 2003 and 
Summy and Gallick, 2003). Furthermore, experiments performed with SFK knockout 
mice have suggested SFKs may elicit compensatory effects for one another, likely due 
to their high amino acid sequence conservation (Lowell and Soriano, 1996 and Stein et 
al., 1994). Therefore, given the potential for functional redundancy among the 
members, and that acquired deregulation of a subset of SFK members appears to be 
implicated in colorectal carcinoma development and progression, the ability of NaB to 
inhibit the expression of other SFK members expressed in HCCLs was tested.  
Although a complete survey of the relative c-Src mRNA and protein expression 
levels in various HCCLs has been reported, a comprehensive analysis of the 
comparative expression patterns of the remaining SFK members had not been studied 
(Dehm et al., 2001). Nine representative HCCLs (Colo 201, Colo 205, Colo 320, 
SW480, SW620, HT29, DLD-1, WiDr and LS174T) were chosen to carry out this 
objective and establish the gene expression levels of the SFKs. mRNA levels of five 
SFKs, c-Src, Yes, Fyn, Lck and Lyn were expressed in at least four of the HCCLs 
examined, while expression of Hck, Fgr and Blk was not detected in any of the HCCLs 
(Figure 4.8. and data not shown). Interestingly, the cell lines displayed quite distinct 
SFK expression signatures, which could be grouped together based on similarities in 
mRNA expression levels. For example, the related cell lines Colo 201 and Colo 205 
exhibited relatively high levels of c-Src, Lck and Lyn gene expression, but had 
significantly lower levels of Yes and Fyn. Conversely, the isogenic SW480 and SW620 
cell lines expressed Lck, Fyn, and Lyn at high levels, but not c-Src or Yes. Furthermore, 
HT29, WiDr and LS174T cells displayed a similar pattern of high c-Src and Yes mRNA 




































Figure 4.8. Differential gene expression of c-Src family kinase members in human
colon cancer cell lines. harvested from nine colon tumor cell lines
and
Total RNA was
RNA was probed for the SFK members, c-Src,
Yes, Lck, Fyn and Lyn.
Northern blot analysis of total
120
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the other hand, had a uniquely high level of Yes mRNA expression, but did not express 
any other SFKs to the same degree. Generally speaking, the relative level of specific 
SFK mRNA expression was mirrored by its protein levels (Hirsch et al., 2006). Based 
on these similarities in the pattern of SFK member gene expression, four representative 
cell lines were chosen for further study: Colo 201, Colo 320, SW480 and HT29.  
 
4.2.2. Histone Deacetylase Inhibitors Decrease c-Src Family Kinase Expression 
Levels 
To begin examining HDI mediated effects on the SFK members, NaB dose 
response experiments were performed in HT29, Colo 320, SW480 and Colo 201 cells 
(Figure 4.9.A-D). The effect of NaB on the mRNA expression level of each SFK 
member was examined in at least two different HCCLs. For example, since c-Src is 
overexpressed in HT29 and Colo 201 cells, dose response experiments to examine HDI 
mediated effects on c-Src mRNA expression levels were carried out in both of these cell 
lines. As previously observed the presence of NaB suppressed c-Src mRNA levels in a 
dose dependent manner in HT29 and Colo201 cells. A repression of other SFKs was 
also observed upon examination. Lck mRNA expression levels were repressed in a dose 
dependent manner in both Colo 201 and SW480 cells. Similarly, Fyn mRNA levels 
were dose dependently repressed by NaB in SW480 cells and to a lesser extent in Colo 
320 cells, which express relatively low endogenous levels of Fyn to begin with (Figure 
4.8). Yes mRNA expression levels were also downregulated in HT29 cells, and less 
strikingly in Colo 320 cells, over the 24 h treatment period. However, a curious 
reproducible transient induction was noted in Yes mRNA levels, which was especially 
evident in the Colo 320 cells. Lyn mRNA levels were also transiently induced, 
particularly in Colo 201 cells, followed by an NaB mediated dose dependent repression 
over the remaining time course. In comparison, the NaB mediated downregulation of 
Lyn expression observed in SW480 cells was less dramatic. However, in contrast to the 
general repression of SFK members, the expression level of p21WAF1 was induced in 
all cell lines (Figure 4.9.B, C) (Kostyniuk et al., 2002). Therefore, these observations 
suggested that NaB may influence the mRNA expression of SFK members in somewhat 
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Figure 4.9. Sodium butyrate inhibits mRNA expression of the c-Src family kinase members
in human colon cancer cell lines. Northern blots were performed with total RNA harvested
from HCCLs (A) HT29, (B) Colo 320, (C) SW480 and (D) Colo 320 treated with either
2.5 mM, 5.0 mM, 10.0 mM, or 15.0 mM of NaB for 6 and 24 h or left untreated. Relative
induction of SFKs was analyzed with a Molecular Imager and normalized to the RNA gel.









expression levels of all SFK members expressed in HCCLs. 
As NaB exhibits pleiotrophic effects in addition to being a HDI, time course 
experiments were also performed with TSA (1.0 µM) in the four representative cell 
lines: SW480 (Figure 4.10.A), Colo 201 (Figure 4.10.B), HT29 (Figure 4.11.A), and 
Colo 320 (Figure 4.11.B) to evaluate changes in SFK mRNA expression. Once again, c-
Src and p21WAF1 were used as positive controls. As expected, TSA downregulated c-
Src and Lck mRNA levels in a time dependent manner in both SW480 and Colo 201 
cells (Figure 4.11.A, B). Furthermore, Fyn mRNA levels were suppressed by TSA in 
SW480 and Colo 320 cells. Consistent with our earlier observations, Lyn mRNA levels 
were downregulated by TSA 24 h following exposure in SW480, Colo 201 and HT29 
cells. However, the early transient induction in Lyn levels observed following NaB 
exposure was significantly less evident in HT29 cells treated with TSA. Yes mRNA 
expression levels still exhibited the same early transient induction followed by a sharp 
repression in mRNA levels after 24 h of incubation with TSA in Colo 320 colon tumor 
cells. However, TSA mediated a less convincing repression of Yes in HT29 cells, in 
contrast to NaB. Taken together, TSA appears to mimic the effects of the NaB dose 
response experiments over a 24 h treatment period, which further suggests that the HDI 
activity of NaB is responsible for the downregulation of SFK member mRNA 
expression.   
 
4.2.3. The Effect of Cycloheximide on Histone Deacetylase Inhibitor Mediated 
Repression of the c-Src Family Kinase Members 
Given that NaB was previously observed to repress c-Src mRNA levels 
independent of protein neo-synthesis, the requirement for new protein synthesis in HDI 
mediated downregulation of the remaining SFK members was examined (Kostyniuk et 
al., 2002). Cycloheximide (50 µM) time course experiments were carried out in the 
absence or presence of NaB (5.0 mM) in HT29 (A), Colo 320 (B), SW480 (C) and Colo 
201 (D) cells (Figure 4.12.). Initially, the mRNA levels of Lck were assessed since the 
HDI response displayed by Lck was most similar to that observed by c-Src. In SW480 
and Colo 201 cells, CHX alone induce a slight transient induction in Lck mRNA levels, 











































Figure 4.10. Trichostatin A represses the mRNA expression levels of the c-Src family
kinase members in HT29 and Colo 320 cells. Total RNA was harvested from HCCLs
treated with 1.0 M TSA for 6, 12 and 24 h or left untreated. Northern blots were
performed on (A) HT29 and (B) Colo 320 cells and analyzed with a Molecular Imager
to determine the mRNA expression levels of the SFK members and were normalized
to the RNA gel to produce the graph. The Northern blots, along with the representative

































































































Figure 4.11. TSA inhibits the mRNA expression of SFK members in SW480 and
Colo 201 cells. Total RNA was harvested from HCCLs treated with 1.0 M TSA for
6, 12 and 24 h or left untreated. Northern blots were performed on (A) SW480 and
(B) Colo 201 cells and analyzed with a Molecular Imager to determine the mRNA
expression levels of the SFK members and were normalized to the RNA gel to
produce the graph. The Northern blots, along with the representative RNA gel for















































































Figure 4.12. Sodium butyrate represses Lck and Lyn mRNA expression levels
independent of protein neo-synthesis. Total RNA was collected from (A) HT29, (B)
Colo 320, (C) SW480 and (D) Colo 201cells treated with NaB (5.0 mM) in the
presence or absence of a protein synthesis inhibitor, CHX (50 M) for 6, 12 and 24 h,
and analyzed by Northern blot. HT29 and Colo 320 Northern blots were probed for
c-Src, Yes and p21WAF1. SW480 and Colo 201 blots were probed for c-Src, Lck ,
Lyn and p21WAF1 levels.
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presence of CHX, suggesting new protein is not a requirement (Figure 4.12 and data not 
shown). Similarly, protein neo-synthesis was not a prerequisite for HDI mediated 
repression of Lyn in SW480 or Colo 201 cells. The results for HDI mediated 
downregulation of Yes were inconclusive in Colo 320 and HT29 cells, given that CHX 
treatment alone resulted in a slight induction in Yes mRNA levels (Figure 4.12 and data 
not shown). As a control, all Northern blots were re-probed for p21WAF1, which 
exhibited a significant upregulation in mRNA expression upon joint exposure to NaB 
and CHX, as previously documented (Nakano et al., 1997 and Sowa et al., 1997). 
Therefore, in parallel to c-Src, HDIs directly downregulate Lck and Lyn levels in 
SW480 and Colo 201 cells, however, Yes mRNA levels may be indirectly regulated by 
HDIs. 
 
4.2.4. Promoters of c-Src Family Kinase Members are Downregulated by Histone 
Deacetylase Inhibitors 
Since NaB directly represses SFK mRNA expression levels of Lck and Lyn, transient 
transfections were performed to examine the transcriptional activity of the LCK type 1 
and LYN promoters following treatment with HDIs. In addition, the effect of HDIs on 
the YES gene promoter was also monitored. The highly disparate SRC1A and SRC1α 
promoters have been previously shown to be directly repressed by NaB and TSA, and 
therefore the SRC1A promoter was used as a positive control for these experiments 
(Kostyniuk et al., 2002 and Dehm et al., 2004). Transient transfections were carried out 
in SW480 cells with the 0.38SRC1A-CAT (A), –630LCK CAT (B), -590LYN-CAT (C) 
or 2.1YES-CAT (D) promoter constructs followed by treatment with either NaB (5.0 
mM) or TSA (1.0 µM) for 6, 12 or 24 hours (Figure 4.13.). The activities of the 
0.38SRC1A, -630LCK and 2.1YES promoters were all repressed in a time dependent 
manner by as much as 80%. The -590LYN promoter was similarly suppressed in a time 
dependent fashion by TSA, however, while NaB downregulated the LYN promoter 6 h 
following treatment, the dramatic suppression that NaB imparted on the promoter was 
not maintained after 24 h of treatment. As a control, WAF1-CAT reporter plasmids 
were also upregulated in the presence of HDIs (data not shown). Taken together, these 
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Figure 4.13. Histone deacetylase inhibitors downregulate the activity of the SRC1A,
LCK type 1, LYN and YES promoters. SW480 cells were transfected with
(A) 0.38SRC1A -CAT, (B) -630LCK-CAT, (C) -590LYN-CAT or (D) pYSCAT2
constructs in the presence of NaB (5.0 mM) or TSA (1.0 M). Transfected cells were
harvested 6, 12 and 24 h following HDI treatment and CAT levels were measured. A
cartoon of the respective promoters is shown above the transfection results for each
subfigure. Each experiment was performed at least three times in duplicate and include
























4.2.5. TAF1 Dependency of the c-Src Family Kinase Member Promoters 
Approximately 46% of human genes contain an Inr core promoter element, 
which is localized near or encompasses the transcription start site (Yang et al., 2007). 
TAF1 and TAF2 are components of the TFIID multi-subunit complex which recognize 
and directly bind the Inr element to facilitate the assembly of the transcription pre-
initiation complex (Chalkley and Verrijzer, 1999). Indeed, given this role in 
transcription, TAF1 has been shown to be an essential regulator of approximately 30% 
of genes in yeast and 18% in hamster cells (Holstege et al., 1998 and O’Brien and 
Tjian, 2000). A ts hamster cell line tsBN462, derived from the parental BHK-21 cell 
line, which harbors a TAF1 mutation in the AT domain (G690A) has been an 
irreplaceable tool in the identification of TAF1 regulated genes, such as cyclin A and 
cyclin D1 (Sekiguchi et al., 1996, Rushton et al., 1997, Dunphy et al., 2000, Hilton and 
Wang, 2003 and Hilton et al., 2005). At a permissive temperature of 32.6oC, tsBN462 
cells exhibit normal growth and TAF1 function, while at the restrictive temperature of 
39.5oC, TAF1 AT activity and Inr binding are compromised and G1/S cell cycle arrest 
is induced (Hayashida et al., 1994, Sekiguchi et al., 1996, Wang et al., 1997, Dunphy et 
al., 2000). Previously, Dr. Scott Dehm from the Bonham lab reported that the 
SRC1α and SRC1A promoters were Inr driven and, using the tsBN462 cell line 
identified that the SRC1A promoter was also dependent on TAF1 for complete 
promoter activity (Dehm et al., 2004).  In addition, TAF1 AT activity was also 
suggested to play a role in HDI mediated repression of SRC, as HDIs were incapable of 
further inhibiting the activity of the SRC1A promoter in tsBN462 cells, at the non-
permissive temperature (Dehm et al., 2004). Therefore, a natural extension of this work 
was to identify if other SFK members also displayed a dependency on TAF1 and 
whether TAF1 was involved in HDI facilitated suppression of these SFKs.  
Transient transfections in parental BHK-21 and matched tsBN462 cells were 
carried out with 0.38SRC1A, pYSCAT2, -590LYN or -630LCK CAT reporter plasmids 
in the absence and presence of HDIs at the permissive (32.6oC) and restrictive  
temperatures (39.5oC) to confirm SRC1A TAF1 dependence and examine the other 
SFK member promoters (Figure 4.14.). The activity of the SRC1A promoter decreased 
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slightly in BHK-21 cells at the non-permissive temperature, but was suppressed by 
approximately 80% in tsBN462 cells at the restrictive temperature, verifying TAF1 
dependency of the SRC1A promoter (Figure 4.14.A) (Dehm et al., 2004). Furthermore, 
TSA (1.0 µM) was efficient at repressing the SRC1A promoter in tsBN462 cells at the 
permissive temperature, but could not further prevent transcription at the restrictive 
temperature. Interestingly, the YES (pYSCAT2) promoter exhibited a similar pattern to 
that of SRC1A. The promoter activity of pYSCAT2 was downregulated approximately 
30% in BHK-21 cells, while a more significant 60% reduction was observed in 
tsBN462 cells at the non-permissive temperature. However, HDI mediated repression of 
YES did not require functional TAF1, as pYSCAT2 activity was still inhibited by TSA 
at the restrictive temperature in tsBN462 cells (Figure 4.14.B). In comparison, the LYN 
promoter (-590LYN-CAT) itself was identified to be highly temperature sensitive, 
displaying an approximately 80% repression in promoter activity at the restrictive 
temperature in BHK-21 cells (Figure 4.14.C). Yet, the promoter activity of -590LYN-
CAT was suppressed 90% in tsBN462 cells at the non-permissive temperature, 
suggesting a possible role for TAF1 in LYN activation. Interestingly, the LYN promoter 
mimics the SRC1α promoter, which was previously reported to display temperature 
sensitive characteristics (Dehm et al., 2004). Also, it was curious to note that TSA was 
ineffective as an inhibitor of LYN promoter activity in both the BHK-21 and tsBN462 
cells, but has previously been effective in the SW480 cell line (Figure 4.13). TAF1 
dependency of the LCK type I promoter was also investigated, but minimal LCK 
promoter activity was evident in BHK-21 cells (data not shown). Taken together, these 
results suggested that similar to the SRC1A promoter, both the YES and LYN 
promoters may be TAF1 dependent. However, distinct from SRC1A promoter, TAF1 
does not appear to be involved in HDI mediated YES or LYN gene suppression. 
 
4.2.6. Activity of the TAF1 Acetyltransferase Domain is Required for c-Src Family 
Kinase Member Transcription 
Although the SRC1A promoter has been reported to display TAF1 reliance, 
these studies were unable to determine directly whether AT activity of TAF1 was 
required for SRC1A transcription, given that recombinant mutant TAF1 G690A was  


















































































































































































































































































































Figure 4.14. c-Src family kinase member promoters are TAF1 dependent. BHK-21
or BN462 cells were transiently transfected with (A) 0.38SRC1A, (B) pYSCAT2,
or (C) -590LYN-CAT and treated in the absence and presence of TSA (1.0 M) at
the permissive or restrictive temperature. Experiments were performed a minimum





also shown to have impaired binding ability to the SRC1A Inr element at the non- 
permissive temperature in vitro (Dehm et al., 2004). Therefore, SRC1A TAF1 
dependency may be based solely on the ability of TAF1 to interact with the SRC1A Inr 
element, rather than the impairment of TAF1 AT activity. To address the role of TAF1 
AT activity in transcription of the SRC1A promoter, a series of mutant TAF1 AT 
domain expression plasmids were obtained from a collaborator, Dr. Edith Wang, at the 
University of Washington: TAF1∆574-590, TAF1∆844-850 (∆Stu), TAF1∆848-850 
(∆MED) and TAF1G923/925D (Figure 4.15.) (Hilton et al., 2005). The TAF1∆574-590 
mutant contains a 16 amino acid deletion in the TAF1 AT domain, but the TAF1 AT 
activity remains intact. Mutants TAF1∆848-850 (∆Stu) and TAF1∆844-850 (∆MED) 
both exhibit severely compromised TAF1 AT activity. Finally, the TAF1G923/925D 
double mutant possesses AT activity comparable to wild-type TAF1 and was utilized as 
an experimental control.  
 Transient co-transfections were performed in tsBN462 cells with the 
0.38SRC1A-CAT reported plasmid and wild-type (wt) TAF1, TAF1G923/925D, 
TAF1∆574-590 TAF1∆Stu, or TAF1∆MED expression vectors to establish which 
TAF1 mutants could restore the SRC1A promoter activity at the restrictive temperature 
(Figure 4.16.A). As previously reported, promoter activity of SRC1A can be rescued by 
wt TAF1 (Dehm et al., 2004). Remarkably, TAF1G923/925D and TAF1∆574-590 
mutants also effectively reinstated SRC1A activity, however, neither the TAF1∆Stu nor 
TAF1∆MED mutants reconstituted SRC1A promoter activity at the non-permissive 
temperature. In addition, TAF1 dependency and the importance of TAF1 AT activity in 
YES and LYN promoter activation were studied. Activation of the YES promoter was 
partially restored by the TAF1 wt, TAF1G923/925D and TAF1∆574-590 expression 
plasmids, but once again TAF1∆Stu and TAF1∆MED mutants were deficient at 
rescuing YES promoter activity in tsBN462 cells at the restrictive temperature (Figure 
4.16.B). Furthermore, TAF1 wt and TAF1G923/925D and TAF1∆574-590 vectors 
marginally rescued LYN promoter activity at the restrictive temperature, while the 
TAF1∆Stu and TAF1∆MED plasmids were entirely incompetent at reactivating the 













Figure 4.15. Structural Domains of TAF1. The N-terminal and C-terminal kinase
domains are shown along with the bromodomains and acetyltransferase (AT) domain.
The AT domain is enlarged to highlight the positions of TAF1 AT deletions and
mutations.
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Figure 4.16. TAF1 acetyltransferase activity is required to restore SFK promoter activity.
Transient co-transfections were performed in BN462 cells with wt or various TAF1 AT
deletion and mutant expression vectors in the presence of
ts
(A) 0.38SRC1A, (B) pYSCAT2,
or (C) -590LYN-CAT at the permissive and restrictive temperatures. All experiments were
repeated twice in duplicate and include error bars for standard deviations.
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promoters are TAF1 dependent and suggest that SRC1A, YES and LYN basal 
transcription requires TAF1 AT activity.  
 
4.2.7. SUMMARY 
c-Src and a number of the SFK members have been shown to play a role in 
colon neoplasias (Biscardi et al., 1999, Frame, 2002, Russello and Shore, 2003 and 
Summy and Gallick, 2003). Prior studies demonstrated that HDIs downregulates c-Src 
expression in human colon, breast and hepatocellular carcinoma cells (Kostyniuk et al., 
2002). Therefore, given that SFK members are exceedingly alike and have been 
suggested to compensate for one another, the response of SFK members to HDIs, in 
particular butyrate, was undertaken (Lowell and Soriano, 1996 and Stein et al., 1994). 
First, the relative expression patterns of SFKs were investigated in a panel of HCCLs 
and it was determined that most of these cell lines expressed relatively high levels of at 
least two SFKs. Furthermore, when the effects of NaB were monitored on SFK 
members in HCCLs, downregulation of the SFK members was observed following 24 h 
of NaB (5.0 mM) or TSA (1.0 µM) exposure. Similar to c-Src, NaB directly repressed 
Lck and Lyn mRNA expression levels, independent of new protein synthesis. However, 
HDI mediated inhibition of Yes gene expression could be either directly or indirectly 
mediated by HDIs, as these results were inconclusive. HDIs were sufficient inhibitors of 
LCK type I, LYN and YES promoter activities. In addition, the YES and LYN 
promoters were characterized to be TAF1 dependent, and TAF1 AT was determined to 
be a requirement for SRC1A, YES and LYN basal transcription activity. Impairment of 
TAF1 AT activity did not, therefore, prevent HDI facilitated suppression of YES. Taken 








4.3. HISTONE DEACETYLASE INHIBITOR REGULATION OF P21WAF1 IN 
HEPG2 CELLS 
4.3.1. New Protein Synthesis is Required for HDI Induction of p21WAF1 in 
HepG2 cells 
HDI mediated activation of p21WAF1 has been intimately linked to cellular 
G1/S growth arrest, and reported to be a necessary factor in HDI prevention of tumor 
cell growth (Archer et al., 1998, Rosato et al., 2001 and Rosato et al., 2003). A number 
of previous reports have demonstrated that HDIs stimulate p21WAF1 gene expression 
independent of p53 and protein neo-synthesis (Nakano et al., 1997, Sowa et al., 1997 
and Huang et al., 2000). Furthermore, HDIs have been documented to induce histone 
hyperacetylation of the p21WAF1 gene promoter and downstream nucleosomes, and to 
activate the promoter primarily through the third Sp site (Nakano et al., 1997 and Sowa 
et al., 1997, Saito et al., 1999, Han et al., 2000 Richon et al., 2000, Han et al., 2001 and 
Kim et al., 2001). However, material presented in the first results section of this thesis 
noted a surprising observation; HDIs required new protein synthesis to upregulate 
p21WAF1 mRNA expression levels in HepG2 cells (Figure 4.7.D) (shown again in 
Figure 4.17.A). Given these curious data, the effects of HDIs on p21WAF1 gene 
expression were more thoroughly studied in HepG2 cells.  
Since NaB (5.0 mM) enhanced p21WAF1 mRNA expression levels in HepG2 
cells in the absence of the protein synthesis inhibitor CHX (50 µM), but not in its 
presence, time course studies were performed with HepG2 cells exposed to either NaB 
(5.0 mM) or TSA (1.0 µM) to assess p21WAF1 protein levels. In agreement with 
p21WAF1 mRNA levels, Western blots demonstrated a dramatic time dependent 
increase in p21WAF1 protein expression, cumulatively suggesting that HDIs indirectly 
upregulated p21WAF1 mRNA in HepG2 cells (Figure 4.17.B, C). Furthermore, basal 
p21WAF1 expression levels were detectable in HepG2 cells, unlike most cell lines.  
 
4.3.2. Histone Deacetylase Inhibitors Cannot Activate the p21WAF1 Promoter in 
HepG2 Cells 
Since NaB stimulation of p21WAF1 gene expression appears to be dependent 
on de novo protein synthesis, the ability of HDIs to indirectly activate the p21WAF1  
c-Src
p21WAF1
0 6 12 24 0 6 12 24 Time (h)
NaB NaB/CHX
HepG2
0 6 12 24 Time (h) 0 6 12 24 Time (h)
NaB TSA
p21WAF1 p21WAF1
Figure 4.17. Histone deacetylase inhibitor upregulation of p21WAF1 gene expression
in HepG2 cells requires protein neo synthesis. A. Total RNA was extracted from
HepG2 cells following various periods of exposure to NaB (5.0 mM), CHX (50 M),
or a combination of the two. RNA was examined by Northern blot analysis for
p21WAF1 and c-Src. B, C. Total cellular extracts were isolated from HepG2 cells
following incubation with NaB (5.0 mM) or TSA (1.0 M) for varying time points and
analyzed by Western blot for p21WAF1 protein expression. Representative Northern







promoter in HepG2 cells was monitored. Transient transfection assays were performed 
in HepG2 cells with WAF1-CAT reporter plasmids in the absence or presence of HDIs. 
Two different WAF1-CAT promoter constructs that have previously been shown to be 
inducible by HDIs were utilized to determine if the WAF1 promoter could be activated 
by HDIs in HepG2 cells (Nakano et al., 1997, Archer et al., 1998 and Han et al., 2001). 
HT29 or HepG2 cells were transiently transfected with -210WAF1 or -101WAF1 CAT 
promoter constructs and treated with either NaB (5.0 mM) or TSA (1.0 µM) (Figure 
4.18.). Transient transfections performed in HT29 cells verified that the WAF1 
promoter constructs were activated as expected (Figure 4.18. B). In these cells, the 
promoter activity of -210WAF1 CAT was increased 15 and 30-fold by NaB and TSA, 
respectively. Similarly, the -101WAF1 CAT promoter construct was also activated 
approximately 6 and 4-fold by NaB and TSA, respectively. However, in HepG2 cells 
neither the -210WAF1 and -101WAF1 promoters were activated by TSA, and were 
only marginally upregulated by NaB (Figure 4.18.C). The larger –2300WAF1 CAT 
reporter plasmid, which harbors two p53 REs was similarly unresponsive to HDIs in 
HepG2 cells (results not shown). Since p21WAF1 is constitutively expressed at 
relatively high levels in HepG2 cells, it was important to determine if the WAF1 
promoter could realistically benefit from supplemental transcriptional activation. Co-
transfection experiments were therefore performed with the WAF1 promoter vectors in 
the presence of c-jun, a known p21WAF1 trans-activator (Kardassis et al., 1999). Co-
transfection data confirmed that the WAF1 promoter was capable of further activation, 
being upregulated by c-jun in HepG2 cells approximately 2.5-fold and 6.0-fold in -
210WAF1 CAT and -101WAF1 CAT activity, respectively (Figure 4.18.C). These 
observations indicated that the p21WAF1 promoter is unresponsive to HDIs, and 
suggested that HDIs induce p21WAF1 gene expression by post-transcriptional 
mechanisms in HepG2 cells.  
 
4.3.3 p21WAF1 mRNA is Regulated Post-transcriptionally by Histone Deacetylase 
Inhibitors 
 A series of mRNA half-life studies were executed in HepG2 cells. Actinomycin 




























































































































































Figure 4.18. The WAF1 promoter is not activated by histone deacetylase inhibitors in
HepG2 cells. A. Diagram representing various WAF1-CAT constructs used in this
study, showing the positions of critical Sp sites. HT29 (B) or HepG2 (C) cells were
transiently transfected with WAF1-CAT promoter constructs; -210WAF1-CAT and
-101WAF1-CAT. B, C. Co-transfections were performed with the WAF1 promoter
constructs and exposed to NaB (5.0 mM), TSA (1.0 M), or left untreated. A second
set of co-transfections were performed with the WAF1 promoter constructs and c-jun.
The CAT levels were determined relative to the untreated WAF1 co-transfected HT29
(B) and HepG2 cells (C). Results represent two independent experiments performed in
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period in the presence or absence of either, NaB (5.0 mM) or TSA (1.0 µM). Northern 
blot analysis was then performed to examine p21WAF1 mRNA levels (Figure 4.19.A). 
Ribosomal Protein PO (RPPO) was used as a control to normalize the data. The half-life 
of p21WAF1 mRNA in untreated HepG2 cells was calculated to be approximately 85 
min. However, in HepG2 cells exposed to either NaB or TSA the p21WAF1 mRNA 
half-life increased approximately 3.1-fold (270min) and 5.4-fold (460min), respectively 
(Figure 4.19.B). Taken together, these data show that NaB and TSA upregulate 
p21WAF1 mRNA and protein levels by post-transcriptional mechanisms in HepG2 
cells. These results represented the first reported example of HDI mediated mRNA 
stabilization (Hirsch and Bonham, 2004).   
 
4.3.4. The Role of the p21WAF1 3’ Untranslated Region in Histone Deacetylase 
Inhibitor Mediated Stabilization of p21WAF1 mRNA 
Post-transcriptional regulation is an important regulatory mechanism in the 
control of gene expression. mRNA levels can be stabilized by numerous mechanisms, 
including the association of trans-RNA binding proteins with cis-acting elements in the 
3’ UTR of many mRNAs (Ross, 1995). One of the most well defined 3’ UTR cis-acting 
stability determinants is the ARE. AREs are inherently destabilizing elements that 
mediate deadenylation of the mRNA poly (A) tail (Chen and Shyu, 1995). The 
interaction of trans-associated factors such as AUF1 and members of the ELAV and 
TTP families with AREs may either enhance or suppress mRNA decay rates (Barreau et 
al., 2005 and Lai et al., 2006). The 3’ UTR of the p21WAF1 mRNA contains an ELAV 
binding element recognized by HuD, and three well characterized AREs (A, B and C) 
that have been documented to mediate UVC-induced stabilization of p21WAF1 mRNA 
levels (Figure 4.20.) (Figure 4.21.A) (el-Deiry et al., 1993, Joseph et al., 1998 and 
Wang et al., 2000). Given that new protein synthesis is necessary for HDI mediated 
upregulation of p21WAF1 gene expression levels, the interaction of key cis-acting 
p21WAF1 3’ UTR mRNA stability determinants with a newly synthesized trans-
associated RNA binding protein was hypothesized to alter the p21WAF1 mRNA decay 
rate in HepG2 cells exposed to HDIs.  
To study this hypothesis, a transient transfection system was employed to look 
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Figure 4.19. Histone deacetylase inhibitors increase the stability of p21WAF1 mRNA
in HepG2 cells. A. Total RNA was isolated from HepG2 cells treated with Act. D in
the presence or absence of NaB (5.0 mM) or TSA (1.0 M) and examined by Northern
blot analysis for p21WAF1 and RPPO. B. The p21WAF1 mRNA signal was determined
by a Molecular Imager and normalized to the RPPO mRNA signal. Data were plotted on







571  TCCGCCCACA GGAAGCCTGC AGTCCTGGAA GCGCGAGGGC CTCAAAGGCC CGCTCTACAT 
631  CTTCTGCCTT AGTCTCAGTT TGTGTGTCTT AATTATTATT TGTGTTTTAA TTTAAACACC  
         HuD 
691  TCCTCATGTA CATACCCTGG CCGCCCCCTG CCCCCCAGCC TCTGGCATTA GAATTATTTA  
         ARE (A) 
751  AACAAAAACT AGGCGGTTGA ATGAGAGGTT CCTAAGAGTG CTGGGCATTT TTATTTTATG  
            ARE (B) 
811  AAATACTATT TAAAGCCTCC TCATCCCGTG TTCTCCTTTT CCTCTCTCCC GGAGGTTGGG  
   ARE (C) 
871  TGGGCCGGCT TCATGCCAGC TACTTCCTCC TCCCCACTTG TCCGCTGGGT GGTACCCTCT 
931  GGAGGGGTGT GGCTCCTTCC CATCGCTGTC ACAGGCGGTT ATGAAATTCA CCCCCTTTCC 
991  TGGACACTCA GACCTGAATT CTTTTTCATT TGAGAAGTAA ACAGATGGCA CTTTGAAGGG 
1051 GCCTCACCGA GTGGGGGCAT CATCAAAAAC TTTGGAGTCC CCTCACCTCC TCTAAGGTTG 
1111 GGCAGGGTGA CCCTGAAGTG AGCACAGCCT AGGGCTGAGC TGGGGACCTG GTACCCTCCT 
1171 GGCTCTTGAT ACCCCCCTCT GTCTTGTGAA GGCAGGGGGA AGGTGGGGTA CTGGAGCAGA 
1231 CCACCCCGCC TGCCCTCATG GCCCCTCTGA CCTGCACTGG GGAGCCCGTC TCAGTGTTGA 
1291 GCCTTTTCCC TCTTTGGCTC CCCTGTACCT TTTGAGGAGC CCCAGCTTAC CCTTCTTCTC 
1351 CAGCTGGGCT CTGCAATTCC CCTCTGCTGC TGTCCCTCCC CCTTGTCTTT CCCTTCAGTA 
1411 CCCTCTCATG CTCCAGGTGG CTCTGAGGTG CCTGTCCCAC CCCCACCCCC AGCTCAATGG 
1471 ACTGGAAGGG GAAGGGACAC ACAAGAAGAA GGGCACCCTA GTTCTACCTC AGGCAGCTCA 
1531 AGCAGCGACC GCCCCCTCCT CTAGCTGTGG GGGTGAGGGT CCCATGTGGT GGCACAGGCC 
1591 CCCTTGAGTG GGGTTATCTC TGTGTTAGGG GTATATGATG GGGGAGTAGA TCTTTCTAGG 
1651 AGGGAGACAC TGGCCCCTCA AATCGTCCAG CGACCTTCCT CATCCACCCC ATCCCTCCCC 
1711 AGTTCATTGC ACTTTGATTA GCAGCGGAAC AAGGAGTCAG ACATTTTAAG ATGGTGGCAG 
1771 TAGAGGCTAT GGACAGGGCA TGCCACGTGG GCTCATATGG GGCTGGGAGT AGTTGTCTTT 
1831 CCTGGCACTA ACGTTGAGCC CCTGGAGGCA CTGAAGTGCT TAGTGTACTT GGAGTATTGG 
1891 GGTCTGACCC CAAACACCTT CCAGCTCCTG TAACATACTG GCCTGGACTG TTTTCTCTCG 
1951 GCTCCCCATG TGTCCTGGTT CCCGTTTCTC CACCTAGACT GTAAACCTCT CGAGGGCAGG 
2011 GACCACACCC TGTACTGTTC TGTGTCTTTC ACAGCTCCTC CCACAATGCT GAATATACAG 
2071 CAGGTGCTCA ATAAATGATT CTTAGTGACT TT 
  poly (A) site hexamer 
 
Figure 4.20. The sequence of the p21WAF1 3’ untranslated region. The 3’ UTR 
corresponds to nucleotides 571-2102 of the p21WAF1 mRNA. The sequence of the 
HuD site and AREs (A-C) are underlined and shown in blue. The poly (A) site hexamer 
is highlighted in red.  
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Figure 4.21. The p21WAF1 3' UTR plays a role in histone deacetylase inhibitor
mediated mRNA stabilization in HepG2 cells. (A) The p21WAF1 mRNA is shown
containing the 5' UTR, coding region and 3' UTR. Key cis acting 3' UTR elements are
denoted by the HuD element and three AU-rich elements (AREs - A, B, C). (B) A
cartoon of the -210WAF1-CAT + p21WAF1 3'UTR 591-2079 (FL) vector is displayed.
-210WAF1-CAT + p21WAF1 3'UTR (FL) and empty -210WAF1CAT vectors were
transiently transfected in HepG2 cells treated in the absence or presence of TSA
(1.0 M) (C) or NaB (5.0 mM) (D). An empty SV40 driven pCAT3 promoter vector or
a pCAT3 promoter vector + p21WAF1 3'UTR (FL) were transiently transfected and
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for relevant p21WAF1 mRNA cis-acting stability elements influenced by HDIs. First, 
an appropriate vector was constructed. The p21WAF1 mRNA 3’UTR 591-2079, 
lacking the original p21WAF1 poly(A) signal hexamer motif AATAAA, was cloned 
into the -210WAF1 CAT promoter construct downstream of the CAT reporter but 
upstream of the vector’s SV40 late poly(A) region and signal to generate a -210WAF1-
CAT + p21WAF1 3’UTR 591-2079 (FL) plasmid (Figure 4.21.B). Transient 
transfections were performed with the -210WAF1-CAT or -210WAF1-CAT + 
p21WAF1 3’UTR (FL) vector in the absence and presence of TSA in HepG2 cells and 
CAT levels determined to assess whether addition of the p21WAF1 3’UTR influenced 
mRNA stability and subsequent CAT synthesis. Interestingly, addition of the p21WAF1 
3’ UTR significantly decreased basal activity of the -210WAF1-CAT + p21WAF1 
3’UTR (FL) plasmid compared to -210WAF1-CAT transfected cells (Figure 4.21.C, D). 
Furthermore, the -210WAF1-CAT vector was not significantly upregulated by TSA (1.0 
µM) nor NaB (5.0 mM), while the -210WAF1-CAT + p21WAF1 3’ UTR (FL) plasmid 
exhibited an elevation in CAT activity following TSA and NaB treatment in HepG2 
cells: 6.9 and 11.7- fold, respectively. As a control, the p21WAF1 3’UTR (FL) was also 
cloned into a pCAT3 promoter vector downstream of a SV40 promoter and upstream of 
the SV40 late poly(A) region and signal to generate a pCAT3 + p21WAF1 3’UTR (FL) 
plasmid (vector not shown). Similar to the initial observations, neither TSA nor NaB 
could activate the SV40 driven pCAT3 promoter vector (Figure 4.21.E, F). However, 
the presence of the p21WAF1 3’UTR, downstream of the SV40 promoter in the pCAT3 
vector increased HDI responsiveness in HepG2 cells. Therefore, these observations 
suggested that the p21WAF1 3’ UTR plays an important role in HDI mediated 
p21WAF1 mRNA stabilization, even out of the context of its own promoter. 
Furthermore, transient transfections of -210WAF1-CAT + p21WAF1 3’UTR vectors, 
followed by CAT assays, appeared to be an effective method to monitor the status of 
p21WAF1 mRNA stability. The -210WAF1-CAT vector provided the ideal backdrop 
for these experiments as this promoter was shown to be relatively non-responsive to 
HDIs, sequence from the -210WAF1 promoter did not indirectly influence p21WAF1 
mRNA stability levels and the p21WAF1 promoter was allowed to be paired with its 3’ 
UTR adding a level of physiological relevance to these experiments.  
 145
4.3.4.1. Proximal p21WAF1 3’Untranslated Region Deletions 
To further assess the role of the p21WAF1 mRNA 3’ UTR in HDI induction of 
mRNA stability, it was sought to identify cis-acting elements within the 3’ UTR that 
may be responsible for this effect. Deletions were made in the proximal  
region of the p21WAF1 3’ UTR, given the presence of well characterized destabilizing 
elements within the 591-840 region (el-Deiry et al., 1993, and Joseph et al., 1998). Four 
vectors were generated exactly as described in the previous section, where a deleted 
version of the p21WAF1 3’ UTR was cloned downstream of the -210WAF1-CAT, but 
upstream of the SV40 late poly(A) region and signal: -210WAF1-CAT + p21WAF1 
3’UTR 712-2079 (∆HuD), -210WAF1-CAT + p21WAF1 3’UTR 788-2079 
(∆HuD/∆ARE(A)), -210WAF1-CAT + p21WAF1 3’UTR 840-2079 
(∆HuD/∆ARE(sites)), and -210WAF1-CAT + p21WAF1 3’UTR 591-840 (Figure 
4.22.). HepG2 cells were transiently transfected with these deletion plasmids 
individually and the basal CAT activity of the -210WAF1-CAT + p21WAF1 3’UTR 
deletion vectors compared, relative to that of the -210WAF1-CAT vector lacking a 
p21WAF1 3’UTR (Figure 4.23.). Surprisingly, all of the deletion plasmids examined 
lacking the HuD site and AREs between 591-840 of the p21WAF1 3’UTR had 
destabilizing potential, compared to the reporter plasmid containing only the p21WAF1 
3’UTR 591-840 region (Figure 4.23.A). These results are a direct contradiction to 
numerous reports stating that AREs boost mRNA decay and suggest that the nucleotides 
encompassing 840-2079 of the 3’ UTR contain a powerful, and yet uncharacterized, 
destabilizing element.  
In addition to elucidating the relative CAT levels of the -210WAF1-CAT + 
p21WAF1 3’UTR deletion plasmids, the ability of TSA (1.0 µM) and NaB (5.0 mM) to 
mediate p21WAF1 mRNA stability was examined (Figure 4.23.B, C). The data 
revealed that p21WAF1 mRNA levels remained stabilized upon deletion of the HuD 
site and AREs, following exposure to HDIs. However, HDIs failed to stabilize the -
210WAF1-CAT + p21WAF1 3’UTR (591-840) deletion vector, indicating that the 
nucleotide sequence between 840-2079 of the p21WAF1 3’ UTR may harbor an 
important cis-acting element that is required to mediate HDI stabilization of p21WAF1 
mRNA levels.  
-210WAF1-CAT + p21WAF1 3'UTR 591-2079 (FL)
712-2079 ( HuD)
788-2079
( HuD/ AU(A)) 
840-2079

















Figure 4.22. The -210WAF1-CAT + p21WAF1 3'UTR proximal deletion constructs.
The p21WAF1 3'UTRs were cloned downstream of the -210WAF1promoter and CAT
coding region, but upstream of the late SV40 poly(A) region and signal as shown for
the 591-2079 (FL) vector. 5' deletions of the p21WAF1 3' UTR that were cloned into
the -210WAF1-CAT vector are shown.
Fold Induction of -210WAF1 Cip1 3'UTR constructs following NaB in HepG2
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Figure 4.23. The p21WAF1 3' UTR, HuD and AU-rich elements do not play a role in
histone deacetylase inhibitor mediated p21WAF1 mRNA stabilization. (A) HepG2 cells
were transiently transfected with empty -210WAF1-CAT or -210WAF1-CAT + p21WAF1
3'UTR deletion vectors and basal CAT levels were used to determine mRNA stabilization
relative to -210WAF1-CAT. Transfections were also carried out in the absence and
presence of TSA (1.0 M) (B) or NaB (5.0 mM) (C). CAT values are represented as fold
induction relative to untreated cells. The results represent two independent experiments




4.3.4.2. Further 5’ Deletions of the p21WAF1 3’ Untranslated Region 
A second set of p21WAF1 3’ UTR deletion vectors were constructed, as 
discussed above, to focus on the nucleotides between 840-1272 of the p21WAF1 
3’UTR. Five deletion plasmids were created: -210WAF1-CAT + p21WAF1 3’UTR 
932-2079, 210WAF1-CAT + p21WAF1 3’UTR 1045-2079, 210WAF1-CAT + 
p21WAF1 3’UTR 1173-2079, 210WAF1-CAT + p21WAF1 3’UTR 1272-2079, and -
210WAF1-CAT + p21WAF1 3’UTR 840-1470 (Figure 4.24.). CAT levels of these 
deletion vectors were directly compared to those of -210WAF1-CAT, and results 
suggested that an instability determinant existed between nucleotides 1045-1272 of the 
p21WAF1 mRNA 3’ UTR (Figure 4.25.A). Furthermore, p21WAF1 mRNA was 
radically stabilized by TSA (1.0 µM) and NaB (5.0 mM) in cells transiently transfected 
with the full length -210WAF1-CAT + p21WAF1 3’UTR (591-2079) or truncated 932-
2079 p21WAF1 3’UTR vectors (Figure 4.25.B, C). However, HDIs were impaired in 
their ability to stabilize p21WAF1 mRNA in cells transfected with -210WAF1-CAT + 
p21WAF1 3’UTR 1045-2079, p21WAF1 3’UTR 1173-2079 and, in particular, 
p21WAF1 3’UTR 1272-2079. These results suggested that the p21WAF1 mRNA 
contains a cis-acting HDI responsive element between nucleotides 932-1272 of the 3’ 
UTR. Although when the -210WAF1-CAT + p21WAF1 3’UTR 840-1470 vector was 
transfected into HepG2 cells, mRNA stabilization could also not be restored in the 
presence of TSA or NaB. However, while TSA could not elevate the CAT level of the -
210WAF1-CAT + p21WAF1 3’UTR 840-1470 vector, CAT levels were enhanced 3-
fold by NaB, suggesting that pleitotropic effects, rather than inhibition of HDACs, may 
influence NaB mediated mRNA stabilization of p21WAF1. Taken together, these data 
implicate a potential instability determinant between 1045-2079 of the 3’ UTR. Yet an 
additional cis-acting instability element clearly resides within nucleotides 1272-2079 of 
the p21WAF1 3’ UTR mRNA species. In addition, a cis-acting HDI responsive element 
may be located within the 932-1272 region of the p21WAF1 3’UTR, although this 
element likely cooperates with another cis-acting element within the 1470-2079 region 























Figure 4.24. Further -210WAF1-CAT + p21WAF1 3'UTR 5' deletions. The highlighted
p21WAF1 3'UTRs were cloned into the -210WAF1-CAT vector downstream of the
CAT coding region and upstream of the late SV40 poly(A) region and signal, as
illustrated for the 591-2079 (FL) vector.
Fold Induction of -210WAF1 Cip1 3'UTR following TSA in HepG2
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Fold Induction of -210WAF1 Cip1 3'UTR following NaB in HepG2
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Figure 4.25. 5' Deletions of the p21WAF1 3' UTR highlight a potential acting
sequence (A) Transient transfections were performed in HepG2 cells with empty
-210WAF1-CAT or -210WAF1-CAT + p21WAF1 3'UTR deletion vectors and the
relative fold induction of CAT levels was determined. Transfected cells treated with
TSA (1.0 M) (B) or NaB (5.0 mM) (C) are represented as fold induction relative to
untreated self. Average values of at least two transfections performed in duplicate are
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4.3.4.3. Deletions of the p21WAF1 3’ Untranslated Region at the Extreme 3’ End 
In an attempt to search for other cis-acting instability determinants and HDI 
responsive elements within the p21WAF1 3’ UTR, an additional series of vectors were 
produced that contained 3’ deletions. The plasmids -210WAF1 + p21WAF1 3’UTR 
591-1470, -210WAF1 + p21WAF1 3’UTR 591-1777, -210WAF1 + p21WAF1 3’UTR 
591-1885, and -210WAF1 + p21WAF1 3’UTR 591-1779 were created. Interestingly, 
when transfected into HepG2 cells, each of these plasmids displayed similar basal CAT 
levels, approximately 5-fold higher than full length -210WAF1 + p21WAF1 3’UTR 
591-2079 reporter plasmid (data not shown). In addition, TSA failed to stabilize the 
mRNA products of these vectors, suggesting that a HDI responsive element may exist at 
the extreme 3’-end of p21WAF1 mRNA (data not shown). To address this possibility, 
vectors were produced that harbored deletions in the extreme 3’ region of the p21WAF1 
3’UTR: -210WAF1 + p21WAF1 3’UTR 591-2064, -210WAF1 + p21WAF1 3’UTR 
591-2031, -210WAF1 + p21WAF1 3’UTR 591-2000, and -210WAF1 + p21WAF1 
3’UTR 591-1979 (Figure 4.26.). Remarkably, transient transfections demonstrated that 
deletions within as little as 79 base pairs from the 3’ end of the p21WAF1 mRNA 3’ 
UTR had a marked effect on basal mRNA stability (Figure 4.27.A). Nucleotides 2000-
2079 appeared to possess significant destabilizing ability. Moreover, TSA (1.0 µM) and 
NaB (5.0 mM) failed to enhance CAT levels of vectors with extreme 3’ deletions to the 
same degree as the full length p21WAF1 3’UTR (FL), suggesting that a second cis-
acting HDI responsive sequence may reside between nucleotides 2000-2079 (Figure 
4.27.B, C). In spite of these observations, a -210WAF1-CAT + p21WAF1 3’UTR 1468-
2079 vector was unable to reinstate HDI mediated mRNA stabilization of p21WAF1. 
Therefore, in accordance with our previous results, at least two cis-acting elements, 
located between 932-1272 and 2000-2079 of the p21WAF1 3’ UTR are important 
sequence determinants of basal p21WAF1 mRNA stability and HDI induced p21WAF1 
mRNA stability.  
4.3.4.4. p21WAF1 3’Untranslated Region Mutants 
A sequence alignment of the human p21WAF1 3’ UTR 2001-2079 performed 
with corresponding rat and mouse p21WAF1 3’ UTR sequences demonstrated a high  





















Figure 4.26. The -210WAF1-CAT + p21WAF1 3' UTR extreme 3' deletions. The
p21WAF1 3' UTR sequence deletions were cloned into the -210WAF1-CAT
vector downstream of the CAT coding region and upstream of the late SV40
poly(A) region and signal, as illustrated for the 591-2079 (FL) vector.
Fold Induction of -210WAF1 Cip1 3'UTR constructs following NaB in HepG2
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Figure 4.27. 3' Deletions of the p21WAF1 3' UTR suggest the presence of a second
acting element. (A) Transient transfection of HepG2 cells with empty -210WAF1-
CAT or -210WAF1 + p21WAF1 3'UTR 3' deletions were performed and the basal
relative fold induction of CAT levels determined. HepG2 transfected cells treated with
TSA (1.0 M) (B) or NaB (5.0 mM) (C) are shown as fold induction relative to
untreated self. Transfections are represented as the average of a minimum of two




the notion that this region of the 3’ UTR may be critical for mRNA stabilization (Figure 
4.28.A). Therefore, to precisely pinpoint the identity of the HDI responsive element 
between nucleotide positions 2001-2079 of the 3’ UTR, sixteen p21WAF1 mutant 
sequences were generated within this region. The wt base pairs 2001-2077 were 
replaced, in the -210WAF1 + p21WAF1 3’UTR (FL) vector, with p21WAF1 3’ UTR 
sequence mutated at five consecutive base pairs per mutant plasmid, where pyrimidines 
were replaced with pyrimidines (C to T, or T to C) and purines with purines (A to G, G 
to A) (Figure 4.28.B, C). For example, p21WAF1 3’UTR mutant #1 (mut#1) had 
mutated sequence from 2001-2005, but 2006-2077 nucleotide pairs corresponded to wt 
p21WAF1 3’ UTR sequence.  
Transient transfections were initially performed with mut #1 through mut #8 
reporter vectors, and compared to the empty -210WAF1-CAT vector in HepG2 cells. 
Furthermore, HepG2 cells were also transiently transfected with -210WAF1-CAT + 
p21WAF1 3’UTR (FL) and -210WAF1-CAT + p21WAF1 3’UTR 591-2000 to serve as 
benchmarks for depleted and elevated p21WAF1 basal mRNA stability, respectively. 
Each mutant exhibited low basal CAT levels that most closely resembled the CAT 
levels produced by the -210WAF1-CAT + p21WAF1 3’UTR 591-2079 (FL) plasmid 
(Figure 4.29.A). In addition, treatment with either TSA (1.0 µM) or NaB (5.0 mM), did 
not compromise the mRNA stabilization of any of these mutants when judged against 
the -210WAF-CAT and -210WAF1 + p21WAF1 3’UTR 591-2000 vectors (Figure 
4.29.B, C). Therefore, the nucleotide sequence between 2001-2040 of the p21WAF1 3’ 
UTR does not appear to contain either a mRNA instability determinant, nor an HDI 
responsive element.  
When -210WAF1-CAT + p21WAF1 3’UTR mut#9 through mut#16 were 
investigated in HepG2 transient transfections followed by CAT assays, however, a 
slight increase in the basal CAT levels of mut#15 and mut#16 plasmids was detected 
(Figure 4.30.A). Furthermore, following treatment with TSA (1.0 µM) or NaB (5.0 
mM), a reduction in mRNA stability was observed in HepG2 cells transiently 
transfected with the -210WAF1-CAT + p21WAF1 3’UTR mut#15, when compared to 
the -210WAF1 + p21WAF1 3’UTR 591-2000 vector (Figure 4.30.B, C). mRNA 













































CGAGGGCAGG GACCACACCC TGTACTGTTC TGTGTCTTTC
GCTCCCGTCC CTGGTGTGGG ACATGACAAG ACACAGAAAG
ACAGCTCCTC CCACAATGCT GAATATACAG CAGGTGCTC
TGTCGAGGAG GGTGTTACGA CTTATATGTC GTCCACGAG
Figure 4.28. High sequence conservation exists within the extreme 3' region of the
p21WAF1 3' UTR. (A) Sequence alignment results of rat (U24174), mouse (U24173)
and human (U03106) p21WAF1 3' UTRs 85 base pairs upstream of their poly(A)
hexamer signals. The hexamer signals are shown in red. (B) p21WAF1 3' UTR mutant
design, where pyrimidines were replaced with pyrimidines and purines with purines.
Starting at 2001 of the p21WAF1 3'UTR with mutant #1 (mut#1), five bases were
mutated per p21WAF1 3'UTR mutant. The sequence to be altered for mut#1 is
underlined and the other subsequent 5 bp mutations are denoted by color, leading up to
mut#16 where only 2 bp are modified (underlined). (C) A representation of wt p21WAF1
3'UTR sequence 2001-2079 ligated into a -210WAF1-CAT + p21WAF1 3'UTR
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Figure 4.29. p21WAF1 3’ UTR mutants #1 through # 8 are still capable of enhancing
mRNA stability. Transient transfections were performed in HepG2 cells with empty
-210WAF1-CAT, -210WAF1-CAT + p21WAF1 3'UTR 591-2079, 591-2000, or mutants
(mut) #1 through #8. The basal relative fold induction of CAT levels were determined
(A), as well as the fold induction relative to untreated self following TSA (1.0 M) (B)
or NaB (5.0 mM) (C) treatment of the transfected cells. These experiments are an
average of at least two independent experiments performed in duplicate and include
error bars for standard deviations.
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Figure 4.30. The p21WAF1 3’ UTR m
The average of a minimum of two transfection
experiments, performed in duplicate, are displayed. Standard deviations are shown as
error bars.
utants #15 and #16 have compromised mRNA
stabilization ability in the presence of histone deacetylase inhibitors. HepG2 transient
transfections were carried out with empty -210WAF1-CAT, -210WAF1-CAT +
p21WAF1 3'UTR 591-2079, 591-2000, or mutants (mut) #9 through #16. The basal
relative fold induction of CAT levels were determined (A), as well as the fold
induction relative to untreated self following TSA (1.0 M) (B) or NaB (5.0 mM)





respectively, compared to a 1.5-fold and 3-fold increase following TSA and NaB 
exposure to -210WAF1 + p21 3’UTR 591- 2000 transfections. A decrease in mRNA 
stability was also evident in mut#16 transfections, but not to the same degree as in 
mut#15 transfections. Cumulatively, these data suggest that the region between 
nucleotides 2071-2077 of the p21WAF1 3’ UTR, contain an instability determinant and 
a responsive element that may be responsible for HDI mediated stabilization of the 
p21WAF1 mRNA in HepG2 cells.  
The poly(A) signal hexamer sequence of the p21WAF1 mRNA resides between 
nucleotides 2080-2085, which falls adjacent to the 2071-2077 cis-acting element 
implicated in p21WAF1 mRNA stability. Given that all of the previous -210WAF1-
CAT + p21WAF1 3’UTR plasmids were missing the endogenous p21WAF1 poly(A) 
signal hexamer motif, but utilized the CAT vector SV40 late poly(A) region and signal, 
it was vital to exclude the possibility that the changes in p21WAF1 mRNA stability 
observed in mut#15 and mut#16 HepG2 transfections were the result of the absence of 
the endogenous p21WAF1 poly(A) signal hexamer. Three vectors containing the 
original p21WAF1 poly(A) AATAAA hexamer, rather than the downstream SV40 late 
poly(A) signal, were generated: -210WAF1-CAT + p21WAF1 3’UTR wt poly(A) 
(Figure 4.31.), -210WAF1-CAT + p21WAF1 3’UTR mut#15 poly(A), and -210WAF1-
CAT + p21WAF1 3’UTR mut #15/#16 poly(A). In contrast to the previous 
experiments, mut #15/#16 poly(A) contained nine mutated base pairs, from 2071-2079. 
Transient transfections were carried out with these vectors in HepG2 cells, exactly as in 
earlier experiments. The basal CAT levels and relative fold induction following TSA 
(1.0 µM) and NaB (5.0 mM) exposure were compared to the original plasmids lacking 
the p21WAF1 poly(A) signal hexamer sequence. Indeed the relative CAT levels of 
untreated wt poly(A) and mut#15 poly(A) vectors matched those of the -210WAF1-
CAT + p21WAF1 3’UTR 591-2079 (FL) and -210WAF1-CAT + p21WAF1 3’UTR 
mut#15 first series plasmids, respectively (Figure 4.32.A). In addition, wt poly(A) CAT 
levels were induced by TSA (B) and NaB (C), although to a lesser extent than the -
210WAF1-CAT + p21WAF1 3’UTR 591-2079 (FL) vector (Figure 4.32.). Also, CAT 
levels of mut#15 poly(A) and -210WAF1-CAT + p21WAF1 3’UTR mut#15 reporter 











Figure 4.31. A diagram of the -210WAF1-CAT + p21WAF1 3'UTR wt + poly(A)
hexamer vector. An enlarged fragment of the p21WAF1 3' UTR was cloned into the
-210WAF1-CAT plasmid downstream of the CAT coding region and upstream of the
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Figure 4.32. Nucleotides 2071-2079 of the p21WAF1 3' UTR contain an instability
determinant and a histone deacetylase inhibitor responsive element.
Constructs containing
the p21WAF1 poly(A) hexamer are denoted by poly(A). The average of three
transfection experiments, performed in duplicate are displayed with error bars for
standard deviations.
HepG2 transient
transfections were performed and the relative fold basal induction of CAT levels were
determined (A), in addition to the fold induction relative to untreated self upon TSA
(1.0 M) (B) or NaB (5.0 mM) (C) exposure to transfected cells.
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#15/#16 poly(A) CAT levels were induced approximately 1.5-fold following TSA 
treatment, analogous to what was observed with the -210WAF1-CAT and  -210WAF1-
CAT + p21WAF1 3’UTR 591-2000 control vectors (Figure 4.32.B, C). NaB 
upregulated both -210WAF1-CAT + p21WAF1 3’UTR 591-2000 and mut#15/#16 
poly(A) roughly 3-fold, while the activity of the parental -210WAF1-CAT reporter 
plasmid was not induced by NaB. An ongoing observation throughout the course of 
these experiments has been that NaB produces higher CAT gene expression levels than 
TSA in HepG2 cells, suggesting that NaB may elicit other effects to influence 
p21WAF1 mRNA decay beyond its activity as a HDI. Taken as a whole, these 
observations indicate that inclusion of the p21WAF1 poly(A) signal hexamer does not 
influence p21WAF1 mRNA stability levels in the absence or presence of HDIs. 
Furthermore, the region directly adjacent to the p21WAF1 poly(A) hexamer, between 
2071 and 2079 of the p21WAF1 3’ UTR, contains a stability determinant that is 
responsive to HDIs in HepG2 cells.   
Cumulatively, this work strongly suggests that there are multiple cis-acting 
elements in the p21WAF1 3’ UTR that influence mRNA decay; one between 932-1272 
and another encompassing 2071-2077 have been characterized. mRNA stability is 
known to be regulated by trans-acting factors that bind cis-acting stability determinants 
within the 3’ UTR of mRNAs. In an effort to identify differences in trans-RNA binding 
factors across the length of the p21WAF1 mRNA 3’ UTR, RMSAs were performed. 
HepG2 cytoplasmic (A) and nuclear (B) extracts isolated in the absence or presence of 
TSA (1.0 µM) were incubated with three RNA probes equivalent to sections of the 
p21WAF1 3’ UTR: ribonucleotides 586-840, 840-1481 and 1476-2079 (Figure 4.33.). 
Trans-proteins were shown to associate with the p21WAF1 3’ UTR; however, this 
method failed to consistently recognize changes in trans-factors interacting with the 
p21WAF1 3’ UTR following HDI treatment. Therefore, in combination with earlier 
results, mRNA secondary structure may play an important role in this HDI mediated 
mRNA stabilization effect, and likely requires the entire context of nucleotides 932-
2079 of the p21WAF1 3’ UTR. 
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Figure 4.33. A change in -binding factors to the 3' UTR of p21WAF1 mRNA does
not occur following histone deacetylase inhibitor treatment. (A)
trans
Three RNA probes
corresponding to the p21WAF1 mRNA 3' UTR were generated for RMSAs; 586-840,
840-1481, and 1467-2079. Cytoplasmic (B) and (C) nuclear extracts were isolated from
either untreated HepG2 cells or those treated with TSA (1.0 M), incubated with P-











HDIs have been well documented to directly enhance p21WAF1 gene 
expression at the transcriptional level (Nakano et al., 1997, Sowa et al., 1997). 
However, for the first time, new protein synthesis has been elucidated as a requirement 
for HDI mediated upregulation of p21WAF1 mRNA levels in HepG2 cells. In addition, 
it was shown that HDIs are incapable of activating the p21WAF1 promoter while 
p21WAF1 mRNA levels are stabilized by both NaB and TSA in HepG2 cells. These 
studies represent the first example of HDI mediated mRNA stabilization (Hirsch and 
Bonham, 2004). The 3’ UTR of the p21WAF1 mRNA has been extensively implicated 
in mRNA stabilization (el-Deiry et al., 1993, Li et al., 1996, Joseph et al., 1998, Liu et 
al., 2000, Wang et al., 2000, Giles et al., 2003, Lal et al.,2004 and Yang et al., 2004). 
By linking the p21WAF1 3’ UTR to the downstream end of a p21WAF1-CAT reporter 
gene, the p21WAF1 mRNA 3’ UTR was demonstrated to be an important contributor to 
mRNA stability in the absence and presence of HDIs. Many 3’ UTR deletion and 
mutant plasmids were generated, which identified two previously unreported cis-acting 
stability elements between 932-1272 and 2071-2079 in the p21WAF1 3’UTR that 




















Basal CAT Activity 
(%) 
TSA - Fold 
Induction CAT 
Activity 
NaB - Fold 
Induction CAT 
Activity 
-210WAF1-CAT ↑↑ ↓ ↓ 
591-2079 (FL) ↓ ↑↑ ↑↑ 
712-2079 ↓ ↑↑ ↑↑ 
788-2079 ↓ ↑↑ ↑↑ 
840-2079 ↓ ↑ ↑↑ 
591-840 ↑↑ ↓ ↓ 
932-2079 ↓ ↑↑ ↑↑ 
1045-2079 ↓ ↓ ↑↑ 
1173-2079 ↑ ↓ ↑↑ 
1272-2079 ↑ ↓ ↑↑ 
840-2079 ↑ ↓ ↑ 
591-2063 ↑ ↓ ↑↑ 
591-2031 ↑ ↓ ↑ 
591-2000 ↑ ↓ ↓ 
591-1979 ↑ ↓ ↓ 
1467-2079 ↑ ↓ ↓ 
mut#1 ↓ ↑↑ ↑↑ 
mut#2 ↓ ↑↑ ↑↑ 
mut#3 ↓ ↑↑ ↑↑ 
mut#4 ↓ ↑↑ ↑↑ 
mut#5 ↓ ↑↑ ↑↑ 
mut#6 ↓ ↑↑ ↑↑ 
mut#7 ↓ ↑↑ ↑↑ 
mut#8 ↓ ↑↑ ↑↑ 
mut#9 ↓ ↑↑ ↑↑ 
mut#10 ↓ ↑↑ ↑↑ 
mut#11 ↓ ↑↑ ↑↑ 
mut#12 ↓ ↑↑ ↑↑ 
mut#13 ↓ ↑↑ ↑↑ 
mut#14 ↓ ↑↑ ↑↑ 
mut#15 ↑ ↓ ↑ 
mut#16 ↑ ↑ ↑↑ 
wt poly(A) ↓ ↑ ↑↑ 
mut#15 poly(A) ↑ ↓ ↑ 
mut#15/#16 poly(A) ↑ ↓ ↑ 
 
Table 4.1.  A summary table comparing relative basal CAT activities and CAT fold 
induction following HDI exposure in HepG2 transfected cells with the -210WAF1-CAT 
+ p21WAF1 3’ UTR deletion and mutation plasmids. Basal CAT activity; ↑↑ ≥ 50%, ↑ ≥ 









5. GENERAL DISCUSSION  
5.1. Histone Deacetylase Inhibitors Function as Anti-neoplastic Agents 
 A considerable amount of effort has been invested in clinical trials of the anti-
tumor HDI compounds. Due to their ability to selectively induce cell cycle arrest, 
differentiation and/or apoptosis of tumor cells in vitro and in vivo, while showing little 
toxicity to normal cells, these compounds make attractive chemo-therapeutic agents 
(Marks et al., 2001; Vigushin and Coombes, 2002 and Arts et al., 2003). Three HDIs 
have currently been approved for clinical use: butyrate, valproic acid and the 
hydroxamic acid SAHA. Interestingly, both butyrate and valproic acid were originally 
approved by the FDA for the treatment of urea cycle disorders and epilepsy, 
respectively (Rosato and Grant, 2004). However, in the past year SAHA became the 
first HDI approved for clinical use in the treatment of a human malignancy, cutaneous 
T-cell lymphoma (CTCL) (Garber, 2007 and Marks and Breslow, 2007). In addition, an 
application for FDA approval of the HDI depsipeptide, as a therapeutic agent for CTCL 
and peripheral T-cell lymphoma (PTCL), is anticipated within the year (Garber, 2007). 
Currently, at least eight HDIs are the focus of multiple Phase I and Phase II clinical 
trials, either as primary or combinatorial treatments for various hematological and solid 
tumors. Given the promising collection of clinical trial data and the recent clinical 
recognition of SAHA, HDIs are rapidly proving themselves as worthy anti-cancer 
agents.  
Although the study of HDIs appears to be gaining momentum in the clinical 
setting, the comprehension of how HDIs direct tumor cells to undergo growth arrest, as 
well as enhance cellular differentiation and apoptosis is lagging behind considerably. 
Various signaling pathways involved in eliciting HDI mediated effects have become 
more clearly understood, such as HDI activation of the mitochondrial apoptotic pathway 
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and stimulation of cell cycle arrest, but the molecular mechanisms which underlie such 
signaling cascades and achieve these anti-tumor effects are poorly understood (Bolden 
et al., 2006). The cyclin dependent kinase inhibitor gene, p21WAF1, is both 
transcriptionally activated by HDIs and an absolute requirement for HDI induced cell 
cycle arrest in human tumor cells (Nakano et al., 1997 and Archer et al., 1998). Given 
these observations, p21WAF1 has been typecast as the model gene studied to 
understand the mechanisms of HDI action. 
 
5.2. The Mechanisms of Histone Deacetylase Inhibitor Action 
HDIs have been proposed to carry out their chemotherapeutic actions by altering 
the expression levels of genes associated with the cell cycle, differentiation and 
apoptosis. As inhibitors of the histone modifying enzymes, HDACs, HDIs are primarily 
thought to regulate the gene expression pattern of tumor cells by interfering with the 
overall balance of histone acetylation levels. Direct inhibition of HDAC activity shifts 
the histone acetylation status towards hyperacetylation, which is anticipated to activate 
transcription and enhance gene expression by relaxing the chromatin structure and 
allowing PIC and transcription factor access to the DNA promoter. This theory not only 
fits well with the observation that a number of HATs, such as PCAF and p300, behave 
as co-activators while HDACs function as co-repressors, but a global elevation in H4 
and H3 acetylation levels following HDI exposure correlates with growth arrest at the 
G1 and G2/M phases of the cell cycle in tumor cells (Sowa et al., 1997; Saito et al., 
1999; Han et al., 2000 and Han et al., 2001). Furthermore, examination of the 
p21WAF1 gene also initially corroborated this theory when it was reported that HDIs 
directly enhanced the overall H3 and H4 acetylation levels in chromatin associated with 
the p21WAF1 promoter and downstream gene, and that the p21WAF1 promoter was 
activated in a p53 independent manner that required the presence of at least one of the 
Sp family binding sites (Nakano et al., 1997; Sowa et al., 1997; Huang et al., 2000; 
Richon et al., 2000 and Kim et al., 2001). In addition, the HAT p300 was identified as 
an activator of the p21WAF1 promoter, while HDAC1, HDAC2 and HDAC3 were 
implicated as repressors (Xiao et al., 2000; Lagger et al., 2003; Gui et al., 2004; Huang 
et al., 2005 and Wilson et al., 2006). Taken together, these observations strongly 
 167
suggest that the anti-tumor effects carried out by HDIs are the result of increased 
histone acetylation and transcriptional upregulation of genes.  
However, when microarray profiling was performed to identify genes affected 
by HDIs, only a small and selective subset of genes (2-20%) were found to be altered. 
Moreover, genes were both activated and suppressed by HDIs in equivalent proportions 
(Van Lint et al., 1996; Mariadason et al., 2000 and Peart et al., 2005). If HDIs purely 
elicited their anti-tumor effects by histone hyperacetylation and subsequent gene 
activation, a far greater percentage of expression profiles would be expected to be 
affected by exposure to HDIs. Since these observations, the p21WAF1 model gene, 
used to study the molecular mechanism of HDIs, has also undergone some revision. An 
upstream signaling pathway involving PI 3-kinase and PKCε isoform has now been 
implicated in HDI mediated upregulation of the p21WAF1 promoter through the Sp1-3 
site (Han et al., 2001 and Kim et al., 2003). Furthermore, H3 acetylation alone was 
determined to be an insufficient means of stimulating the p21WAF1 promoter in the 
absence of PKC activity (Kim et al., 2003). In addition, histone acetylation has been 
proposed to be a secondary effect of HDIs, as the alteration of H3 and H4 acetylation 
levels and chromatin rearrangement of the mouse mammary tumor virus (MMTV) 
promoter does not correlate with the massive transcriptional defect imposed by TSA 
(Mulholland et al., 2004). Also, PKCε and PKCδ isoforms have recently been reported 
as essential proteins in HDI mediated downregulation of gelsolin gene expression and 
upregulation of cyclin D3 transcription, respectively (Eun et al., 2007 and Kim et al., 
2007). Therefore, it is apparent that the underlying mechanisms of HDI action need to 
be revisited to account for HDI mediated gene repression and upregulation in the 
absence of histone acetylation. This thesis has focused specifically on elucidating the 
effects of HDIs on the expression of the c-Src proto-oncogene, the SFK members and 
p21WAF1, outside of the context of gene activation mediated by histone 
hyperacetylation and chromatin rearrangement. Simply, the data within demonstrates 
that HDIs repress the mRNA and protein expression levels of c-Src and the SFK 
members in HCCLs, and can enhance p21WAF1 mRNA levels at the post-
transcriptional level in HepG2 cells. 
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5.3. Histone Deacetylase Inhibitor Repression of c-Src and the c-Src Family Kinase 
Members 
5.3.1. c-Src Gene Expression is Suppressed by Histone Deacetylase Inhibitors 
As reported in this thesis, HDIs were determined to be proficient inhibitors of c-
Src gene mRNA and protein expression levels in a variety of human tumor cell lines, 
including colon, breast and hepatocellular carcinoma cells. This HDI mediated effect on 
c-Src expression, which has been observed in all tumor cell lines examined to date, 
occurred independently of new protein synthesis and directly inhibited SRC 
transcription. Surprisingly, HDIs independently and similarly repressed expression from 
both the highly dissimilar SRC1α and SRC1A promoters by approximately 80-95%. 
Both TSA and butyrate, a noncompetitive HDI, comparably suppressed these promoters 
and activated the p21WAF1 promoter, indicating that inhibition of HDAC activity was 
responsible for the downregulation of c-Src expression. Gene expression analysis drew 
attention to the fact that a tight correlation existed between HDI increases in p21WAF1 
expression and deceases in c-Src expression levels. However, p21WAF1 was not 
responsible for HDI mediated inactivation of the SRC1α or SRC1A promoter. In fact, 
p21WAF1 activated both SRC promoters in HepG2 cells, which is a particularly 
interesting observation given that p21WAF1 has previously been reported to behave as 
a transcriptional cofactor and transcriptional regulator of genes including c-myc, cdc25 
and IGF-I (Perkins, 2002; Devgan et al., 2006 and Vigneron et al., 2006).  
5.3.2. c-Src Family Kinase Member Expression is Downregulated by Histone 
Deacetylase Inhibitors  
In addition to c-Src, expression levels of the ubiquitously expressed SFK 
members, Yes and Fyn, and the more tissue specific Lck and Lyn were also shown to be 
repressed by HDIs in various HCCLs. Both butyrate and TSA suppressed the mRNA 
levels of these SFKs after 24 h of HDI exposure. As a rule, Src, Fyn and Lck expression 
levels were downregulated by butyrate in a dose dependent manner, while Yes and Lyn 
often displayed a transient increase in mRNA levels approximately 6 h after butyrate 
exposure. Yes and Lyn were consistently also repressed by 24 h, however, TSA time 
course experiments verified that the HDI activity of butyrate was responsible for both 
the transient upregulation and ultimate decrease of SFK mRNA expression levels. 
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Furthermore, as observed with c-Src, butyrate directly downregulated Lck and Lyn 
mRNA levels in HCCLs, independently of protein neosynthesis. HDI mediated 
suppression of Yes mRNA expression could not conclusively be reported to occur in the 
absence of protein synthesis, however, remarkably, the LCK type I promoter utilized in 
colon cancer tissues, LYN and YES promoters were all downregulated by butyrate and 
TSA in transient transfections. HDI mediated repression of the SFK member promoters 
was observed as early as 6 h following HDI treatment and was maintained for the full 
24 h period. Although the LYN promoter was consistently inhibited by HDIs, butyrate 
mediated suppression of this promoter was not as striking after 12 and 24 h when 
compared to transfected cells treated with butyrate for only 6 h. It is important to note 
that the transcriptional activity of the YES and LYN promoters were not transiently 
stimulated by butyrate or TSA. Therefore, the temporary induction observed in Yes and 
Lyn mRNA levels may be the result of two HDI mediated processes. Firstly, HDIs may 
increase histone hyperacetylation of the chromatin template to facilitate chromatin 
rearrangement and transcriptional upregulation. However, this increase in 
transcriptional activity may not be detected in transient transfections given that complex 
chromatin structure is not readily formed in this experimental system. Alternatively, 
HDIs may enhance mRNA stabilization of these SFK members, since three separate 
reports have now indicated that HDIs harbor the ability to post-transcriptionally 
regulate gene expression (Hirsch and Bonham, 2004; Xiong et al., 2005 and 
Januchowski et al., 2007). 
5.3.3. The Mechanism of Histone Deacetylase Inhibitor Directed Inhibition of c-Src 
and the c-Src Family Kinase Members 
The molecular mechanism of HDI mediated suppression of c-Src and SFK 
member expression levels has been most thoroughly investigated using SRC as the 
model gene. First, proximal promoter mutants and deletions were made to the SRC1α 
and SRC1A-CAT promoter vectors, to assess the importance of proximal promoter 
elements in this effect. Reports studying the response of the p21WAF1 promoter to 
HDIs have suggested that at least one of the Sp sites in the proximal promoter region is 
necessary to facilitate HDI activation (Nakano et al., 1997; Sowa et al., 1997 and Xiao 
et al., 2000). Interestingly, the SRC1A, LYN and YES promoters also harbor at least 
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three Sp sites (Matsuzawa et al., 1991; Uchiumi et al., 1992; Bonham and Fujita, 1997 
and Ritchie et al., 2000). While mutations in the Sp binding sites GC1 and GA2 of the 
0.38SRC1A-CAT reporter plasmid decreased promoter activity, HDIs always further 
repressed the SRC1A promoter (Kostyniuk et al., 2002). Furthermore, extensive core 
and proximal promoter deletions were made to the 0.38SRC1A-CAT and -145SR1α-
CAT vectors in order to search for the presence of HDI responsive elements (Dehm et 
al., 2004). However, HDIs still consistently downregulated SRC gene expression in 
every deletion plasmid examined (Dehm et al., 2004). In addition to this, 
electrophoretic mobility shift assays demonstrated that HDI transcriptional inhibition of 
the SRC1α and SRC1A promoters was not associated with either an increase or 
decrease in factors bound to their proximal promoter regions (Kostyniuk et al., 2002). 
In vivo, ChIPs also verified that the presence of HDIs did not change the levels of Sp1 
and Sp3 associated with the SRC1A promoter (Ellis and Bonham, unpublished results). 
Taken together, these results suggest that it is unlikely that a proximal promoter element 
exclusively mediates the effects of HDIs on c-Src expression levels. 
5.3.3.1. The Involvement of TAF1  
When the SRC gene and the SFK member gene promoters were examined more 
closely, two major similarities were noted: all of the SFK core promoters, SRC1A, 
SRC1α, YES, LYN, and LCK type I, are TATA-less and all contain multiple 
transcription start sites (Matsuzawa et al., 1991; Uchiumi et al., 1992; Leung et al., 
1993 and Bonham and Fujita, 1997). Interestingly, a consensus sequence resembling an 
Inr element was identified and mapped to a major transcription start site in both the 
SRC1A and SRC1α promoters (Dehm et al., 2004). A characteristic of Inr element 
driven promoters is their ability to interact with TAF1-TAF2 heterodimers in order to 
nucleate assembly of the transcriptional PIC (Chalkley and Verrijzer, 1999). In vitro, 
both of the proposed SRC1A and SRC1α Inr elements successfully bound to TAF1-
TAF2 heterodimers (Dehm et al., 2004). Furthermore, utilization of the matched cell 
lines BHK-21 and tsBN462, which contains a G690D temperature sensitive mutant of 
TAF1, demonstrated that the SRC1A promoter was TAF1 dependent in nature (Dehm et 
al., 2004). In addition, at the restrictive temperature, HDIs were incapable of repressing 
the SRC1A promoter in tsBN462 cells transiently transfected with 0.38SRC1A-CAT, 
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suggesting that TAF1 may also be responsible for HDI mediated repression of the 
SRC1A promoter (Dehm et al., 2004). Similar experiments were performed with the 
SRC1α promoter, however, the high restrictive temperature was shown to significantly 
lower the trans-activation of the promoter, making these results difficult to interpret 
(Dehm et al., 2004). Yet, a chimeric promoter construct of the -210WAF1 proximal 
promoter fused to the SRC1α Inr core promoter element conferred TAF1 dependence 
on the previously TAF1 independent p21WAF1 promoter (Dehm et al., 2004). In vitro 
binding assays more specifically demonstrated that association of the G690D mutant 
TAF1-TAF2 heterodimer with the SRC1A and SRC1α promoters diminished at the 
non-permissive temperature, while wt TAF1 binding remained consistent (Dehm et al., 
2004). Therefore, these results suggest that both the SRC1A and SRC1α promoters are 
TAF1 dependent and hint that HDI mediated repression of SRC may involve TAF1.  
 Core promoter Inr elements have not yet been defined in the YES, LYN and 
LCK type I promoters, though potential consensus sequences suggest that Inr elements 
may be present in the core promoter regions of these SFKs. The identification of Inr 
elements in SFK member promoters is out of the scope of this thesis; however, given 
that TAF1 has been implicated in basal transcription of the SRC1A promoter and that 
SRC1A transcription is repressed by HDIs, TAF1 dependency on the YES, LYN and 
LCK type I gene promoters was assessed to establish the commonality of TAF1 
function across the family of c-Src kinases. By performing transient transfection 
experiments in the parental BHK-21 and matched tsBN462 cells with 0.38SRC1A, 
pYSCAT2, or -590LYN-CAT reporter plasmids, it was observed that both the SRC1A 
and YES promoters displayed a dependency on TAF1. The activity of each of these 
reporter plasmids was suppressed to some degree in parental BHK-21 cells at the 
restrictive temperature, although in every instance SFK promoter activity was even 
further inhibited in tsBN462 cells at the same restrictive temperature which triggers 
both impaired TAF1 AT activity and SRC1A Inr element binding capacity. Overall, 
reductions of approximately 50% and 30% were observed in SRC1A and YES basal 
transcription, respectively, which accounts purely for compromised TAF1 AT activity 
and/or DNA binding ability. However, only a general 10% decrease in LYN promoter 
activity was observed. Although each of the SFK promoters examined displayed some 
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degree of temperature sensitivity, activity of the LYN promoter was inhibited over 80% 
at the restrictive temperature in BHK-21 cells, which may explain the minimal decrease 
observed in LYN transcription following TAF1 impairment. Furthermore, these data 
suggest that activity of the LYN promoter is temperature dependent, similar to the 
SRC1α promoter (Dehm et al., 2004). In addition, results from transient co-transfection 
experiments carried out with wt TAF1 indicated that SRC1A, YES and LYN promoter 
activity could be restored at the restrictive temperature in tsBN462 cells, at least to 
levels previously observed for matched BHK-21 transfected cells exposed to the non-
permissive temperature. Further co-transfections performed with various TAF1 
deletions and mutants demonstrated that only those TAF1 expression plasmids that 
retained TAF1 AT activity were capable of rescuing SRC1A, YES and LYN promoter 
activity, while those TAF1 deletion vectors that lacked AT activity could not re-
stimulate transcription. Therefore, each of these SFK member promoters is TAF1 
dependent and requires TAF1 AT activity for basal transcription. To ensure that TAF1 
AT activity was effectively separated from TAF1 Inr element binding, however, it must 
be demonstrated that each of the TAF1 deletions impaired in AT activity (TAF1 ∆Stu, 
TAF1 ∆MED) maintains their competence for binding the Inr element. A collaborator, 
Dr. Edith Wang, is currently performing binding experiments to verify that the TAF1 
AT mutants remain able to bind the SRC1A Inr element at the restrictive temperature. 
Taken together, these data strongly suggest that TAF1 AT activity is necessary for basal 
SRC1A, YES and LYN transcription. While TAF1 is known to display relatively weak 
HAT activity towards histones H3 and H4, when compared to PCAF and p300, it is also 
capable of acetylating non-histone proteins such as the β-subunit of TFIIE (Imhof et al., 
1997). Therefore, TAF1 may negotiate SRC, YES and LYN transcription by modifying 
the chromatin structure associated with these genes and/or an unknown component of 
the transcriptional machinery. 
Although relatively little work has been performed to uncover the potential 
molecular mechanisms of HDI mediated gene repression, one of the major proposals 
stipulates that HDIs may exert their anti-tumor effects by permitting HAT acetylation of 
non-histone proteins such as p53, GATA-1, E2F, YY1, Ku70 and STAT3 (Gu and 
Roeder, 1997; Boyes et al., 1998; Kouzarides, 2000; Martinez-Balbas et al., 2000; Yao 
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et al., 2001; Cohen et al., 2004; Glozak et al., 2005; Yuan et al., 2005 and Minucci and 
Pelicci, 2006). Acetylation of non-histone proteins has been reported to influence gene 
expression by affecting such factors as the DNA binding affinity of transcription 
factors, protein stabilization, protein dimerization and protein localization (Drummond 
et al., 2005, Lin et al., 2006 and Minucci and Pelicci, 2006). For example, acetylation 
of p53 by HDIs increases cell cycle arrest by stabilizing p53 protein levels and 
promoting activation of the p21WAF1 promoter (Zhao et al., 2006). Additionally, such 
a mechanism of HDI mediated acetylation of non-histone proteins has been proposed to 
explain TSA repression of the MMTV promoter (Mulholland et al., 2003). 
Changes in the acetylation status of the histones H3 and H4 associated with the 
SRC1A promoter do not effectively correspond with HDI mediated SRC gene 
repression. This suggests that a shift in the balance between HAT and HDAC activity 
may be responsible for decreased SRC1A transcription through the acetylation of a non-
histone protein linked to the SRC1A promoter (Ellis and Bonham, unpublished data). 
Previously, Dr. Scott Dehm had shown that TAF1 may be required for HDI mediated 
downregulation of the SRC1A promoter, which implies that TAF1 may be the HAT 
responsible for acetylating an as yet unrevealed non-histone substrate (Dehm et al., 
2004). However, given that the AT activity of TAF1 is imperative for basal 
transcription, it is counterintuitive that TAF1 may also be required to mediate SRC1A 
transcriptional repression in the presence of HDIs, particularly if the loss of TAF1 AT 
activity is responsible for preventing HDI downregulation of the SRC1A promoter. In 
accordance with this thought, a common role for TAF1 in HDI mediated inhibition of 
SFK member transcription does not appear to be prevalent, as three separate responses 
were generated by the SRC1A, YES and LYN SFK promoters upon TSA treatment in 
tsBN462 cells exposed to the restrictive temperature. First, TAF1 seemed to be an 
important contributor to SRC1A downregulation, as inactivation of TAF1 binding and 
AT activity prevented further inhibition of SRC1A transcription. Second, functional 
TAF1 AT or binding activity was not required to negate YES transcription in the 
presence of HDIs. Third, LYN transcription was strangely stimulated by TSA in both 
BHK-21 and tsBN462 cells. This was the first such observation of SFK member gene 
activation following HDI exposure. In SW480 cells, LYN promoter activity is 
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decreased by butyrate and TSA; therefore HDI mediated LYN promoter activation may 
be explained by the absence or presence of a particular factor in BHK-21 cells, 
compared to SW480 cells. As a whole these data suggest that the AT activity of TAF1 
is not universally responsible for suppressing transcription of the SFK members in the 
presence of HDIs, and therefore likely does not acetylate a non-histone protein at the 
SRC1A promoter to mediate transcriptional repression. However, it cannot be ruled out 
that another HAT or AT may still acetylate a non-histone substrate associated with 
transcription, to suppress the promoter activity of any or all of the SFKs examined.  
5.3.3.2. Other Potential Mechanisms of Histone Deacetylase Inhibitor Mediated 
SRC Repression 
 Another possible mechanism of HDI action has focused on the role of HDACs 
in HDI mediated gene repression. A collection of recent observations have identified a 
role for HDACs in the activation of particular genes. The yeast HDACs Hos2 and Rpd3 
have both been implicated in selective gene activation (Wang et al., 2002 and De Nadal 
et al., 2004). Trans-activation of STAT5 has also been reported to require HDAC 
activity for the recruitment of TBP and RNA polymerase II (Rascle et al., 2003). 
Furthermore, HDAC activity has been shown to be necessary for a number of interferon 
stimulated response genes (Nusinzon and Horvath, 2003; Klampfer et al., 2004; 
Sakamoto et al., 2004 and Nusinzon and Horvath, 2005). Therefore, HDIs may suppress 
the expression levels of genes that require HDAC activity for basal transcription by 
purely inhibiting the activity of HDACs associated with the gene promoter. Such an 
observation has been reported for the STAT5 and interferon responsive genes (Rascle et 
al., 2003 and Nusinzon et al., 2005). Consequently, localization of the Class I and Class 
II HDACs and their ability to activate the SRC1A promoter has been studied (Ellis and 
Bonham unpublished data). However, none of the Class I HDACs (HDAC1, HDAC2, 
HDAC3 and HDAC8) or Class II HDACs (HDAC5, HDAC6, HDAC7 and HDAC10) 
examined have been found to reside at the SRC1A or SRC1α promoters either prior to 
or following HDI exposure, although this may be due to poor quality ChIP antibodies. 
Encouragingly, siRNA mediated inhibition of Class IIb HDAC member expression 
resulted in a decrease in c-Src gene expression levels; however, this effect was not 
mediated by suppression of SRC1A or SRC1α promoter activity. Furthermore, siRNA 
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knockdown of the Class I HDACs led to an upregulation in c-Src expression. Also, 
overexpression of the Class I and Class II HDACs either had little effect on SRC1A and 
SRC1α transcription, or decreased promoter activity slightly. Therefore, HDAC activity 
of neither the Class I nor Class II HDACs appears to be a necessary component of 
SRC1A or SRC1α basal transcription and hence cannot play a subsequent direct role in 
HDI transcriptional repression of this gene. 
Other HDI molecular mechanisms suggest that HDIs may affect gene expression 
levels by disrupting HDAC-PP1 complexes associated with gene promoter regions, as 
in the case of CREB responsive genes (Canettieri et al., 2003 and Brush et al., 2004). 
PP1 has been shown to form complexes with HDAC1, HDAC6 and HDAC10; HDIs are 
capable of disturbing these HDAC-PP1 complexes (Brush et al., 2004). Specifically, the 
dissociation of HDAC-PP1 components from one another has been suggested to permit 
CREB transcription factor phosphorylation, HAT recruitment, histone acetylation and 
transcription (Canettieri et al., 2003 and Brush et al., 2004). PP1 dissociation from the 
HDACs also initiates an interaction between PP1 and Akt, which leads to Akt 
inactivation (Canettieri et al., 2003 and Chen et al., 2005). In addition to this, butyrate 
and valproic acid have been shown to decrease the gene expression levels of two 
kinases, Akt1 and Akt2 (Chen et al., 2006). Importantly, Akt interacts with and 
phosphorylates the co-activator p300 to stimulate its HAT activity (Chen et al., 2004 
and Huang and Chen, 2005). Therefore, HDIs have the capability to affect acetylation 
as well as phosphorylation levels in the cell by either disturbing PP1-HDAC complexes 
or by inhibiting Akt expression. Cumulatively, these data suggest that HDIs have the 
potential to selectively regulate gene expression levels and signaling pathways by 
altering the phosphorylation patterns of yet unidentified proteins, including additional 
transcription factors, signaling molecules, histones, transcriptional co-activators, and 
components of the general transcription machinery (Alao et al., 2006). 
 In the course of studying the molecular mechanism behind HDI mediated 
repression of c-Src gene expression levels, the presence of actively transcribing Pol II 
along the SRC gene, from Exon1α and Exon1A to the 3’ UTR, was investigated (Ellis 
and Bonham, unpublished data). A previous report has documented that the loss of Pol 
II at the transcription start site of the STAT5 promoter is responsible for 
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downregulation of STAT5 gene expression in the presence of HDIs (Rascle et al., 
2003). Under normal cellular conditions, Pol II was readily detected at the SRC1α and 
SRC1A promoters, coding region, intronic region and the 3’ UTR (Ellis and Bonham, 
unpublished data). Furthermore, Pol II was detected at Exon 1α and Exon 1A following 
exposure to TSA, however, an intermittent drop in Pol II occupancy was observed 
within the coding region and the 3’ UTR after as little as 15 minutes of TSA exposure, 
and after 1 h of TSA treatment Pol II was barely detectable at the SRC 3’ UTR.  
In addition to tracking Pol II down the SRC gene, the phosphorylation status of 
the Pol II unstructured CTD was monitored (Ellis and Bonham, unpublished data). 
Phosphorylation of the Pol II CTD has been proposed to delineate two important events. 
The hypophosphorylated form of the Pol II CTD is integrated into the PIC. Upon proper 
assembly of the PIC, TFIIH phosphorylates Ser 5 residues on the CTD, to facilitate 
promoter clearance and trigger early elongation (Svejstrup, 2004 and Meinhart et al., 
2005). Phosphorylated Ser 5 also acts as a platform for the recruitment of mRNA 
capping enzymes (Phatnani and Greenleaf, 2006). In addition, the active phosphorylated 
form of P-TEFb phosphorylates Ser 2 on the Pol II CTD to overcome an early pause in 
elongation after the nascent mRNA chain has been properly capped (Peterlin and Price, 
2006). Therefore, Ser 5 phosphorylation serves as a rough marker for promoter 
clearance and Ser 2 phosphorylation of the CTD behaves as a marker for productive 
elongation (Shilatifard, 2004 and Sims et al., 2004). When the phosphorylation status of 
Pol II CTD along the SRC gene was examined, Ser 5 phosphorylation of the CTD was 
detected both prior to and following TSA treatment; however, in the presence of TSA a 
drop in Ser 5 phosphorylation was noted in the 3’ UTR, which corresponded with the 
decrease in Pol II occupancy. Furthermore, similar observations were observed for Ser 2 
CTD phosphorylation along the SRC gene, although Ser 2 phosphorylation levels were 
comparatively much lower than Ser 5 phosphorylation levels at the SRC1α and SRC1A 
promoters. As a whole, these data suggest that while SRC1α and SRC1A transcriptional 
initiation occurs in the presence of HDIs, productive elongation may not, as a gradual 
loss of Pol II at the 3’ UTR of SRC indicates that formation of incomplete transcripts 
may be the reason for c-Src gene repression  
 
 177
5.3.3.3. The Working Model of Histone Deacetylase Inhibitor Mediated 
Downregulation of c-Src Gene Expression 
It is known that c-Src and SFK member gene expression is inhibited by HDIs 
and that HDIs directly suppress the promoter activity of SFK members in transient 
transfections assays performed with human tumor cells. However, the mechanism of 
HDI mediated SRC gene repression is still under investigation. Over the past five years, 
a number of possible mechanisms have been discounted, including the involvement of 
cis-acting DNA promoter sequences and trans-acting DNA binding factors with either 
of the SRC proximal promoters. In addition, HDI mediated changes in the histone 
acetylation levels of the SRC promoters do not correspond to the decrease observed in 
c-Src gene expression levels. Cumulatively, the data collected to date suggest that an 
event downstream of transcription factor and PIC assembly at the SRC1α and SRC1A 
promoters may be targeted by HDIs. A model of HDI control over c-Src expression 
levels has endured after intensive study; a representation of this mechanism is illustrated 
for the SRC1A promoter (Figure 5.1.).  
This model stipulates that TAF1 and components of the PIC associate via the Inr 
element of the SRC1A promoter during normal basal transcription and that HDAC-PP1 
complexes are present within close proximity to the SRC gene. HDAC-PP1 complexes 
may maintain an unknown substrate (X) at the SRC1A promoter in a 
hypophosphorylated and/or hypoacetylated state during formation of the PIC complex. 
In addition, PP1 has been documented to dephosphorylate residues Ser 5 and Ser 2 of 
the Pol II CTD, as well as the elongation factor P-TEFb (Washington et al., 2002 and 
Ammosova et al., 2005).  Therefore, HDAC-PP1 complexes may preserve the 
dephosphorylated form of the Pol II CTD until the PIC has been correctly assembled 
and loaded with the machinery necessary to properly synthesize and co-transcriptionally 
process the nascent mRNA transcript. In addition, HDAC-PP1 may inhibit kinase 
activation of P-TEFb, which phosphorylates Ser 2 residues on the CTD, by preventing 
the phosphorylation of this factor until the Pol II complex is adequately equipped for 
productive elongation. Following proper formation of the PIC, TFIIH triggers DNA 
melting and phosphorylates Ser 5 residues of the CTD to generate an early elongation 















































































































































Figure 5.1. The model of histone deacetylase inhibitor mediated SRC gene repression.
HDIs alter the phosphorylation and acetylation pattern of non-histone substrates within






(CEs). Furthermore, NELF, DSIF and TFIIS associate with Pol II to facilitate an early 
elongation pause which allows capping of the nascent mRNA transcript to proceed. 
After a 5’ 7-methyl-guanosine cap has been added to the pre-mRNA, activated P-TEFb 
phosphorylates both Ser 2 amino acids on the CTD and DSIF to promote NELF 
dissociation and re-stimulate Pol II elongation. Productive elongation ensues after 
further recruitment of elongation factors such as TFIIF, ELL and Elongin.  
Here it is proposed that HDIs alter c-Src expression levels by inhibiting HDAC  
activity and promoting the dissociation of HDAC-PP1 complexes from the SRC1A 
promoter. In this manner, HDIs may shift the overall equilibrium toward acetylation and 
facilitate HAT acetylation of an unknown non-histone protein (X) which renders a 
repressive effect on such events as SRC promoter clearance, nascent mRNA capping or 
elongation. Although, if acetylation of a non-histone protein contributes to the 
downregulation of c-Src expression levels, it is unlikely that TAF1 would be the HAT 
responsible for this acetylation event. In addition to enhancing acetylation levels upon 
PP1 dissociation from the SRC1A promoter, HDIs may also permit phosphorylation of 
an unidentified protein substrate (X) which negatively regulates transcript synthesis. 
Furthermore, loss of PP1 may indirectly allow TFIIH to prematurely phosphorylate Ser 
5 residues of the Pol II CTD, before all of the components of the PIC have been 
correctly assembled. Early phosphorylation of P-TEFb may also stimulate impulsive 
phosphorylation of Ser 2 on the CTD and ultimately abrogate the early elongation 
pause, preventing mRNA capping from occurring and opening up the pre-mRNA to 
exonuclease attack. Alternatively, the processivity of Pol II may be decreased if various 
elongation factors do not have time to associate with the early elongation complex, 
motivating Pol II dissociation from the gene. Given that HDI disruption of HDAC-PP1 
complexes has previously been reported to stimulate CREB transcription factor 
phosphorylation, it is plausible that dissociation of HDAC-PP1 components from the 
SRC1α and SRC1A promoters may enhance the phosphorylation levels of proteins 
associated with SRC transcription (Canettieri et al., 2003 and Brush et al., 2004). Taken 
together, the current evidence suggests that HDIs repress c-Src gene expression by 
altering the acetylation and/or phosphorylation status of an unidentified non-histone 
substrate(s) associated with events downstream of transcriptional initiation, such as Pol 
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II promoter clearance, early elongation, proximal pausing, productive elongation and/or 
mRNA processing.    
 
5.3.4. The Importance of c-Src Family Kinase Member Gene Repression by 
Histone Deacetylase Inhibitors 
While the work presented in this thesis primarily focuses on the ability of HDIs 
to regulate gene expression irrespective of histone hyperacetylation, it is important to 
comment on the significance of HDI downregulation of SFK gene expression levels. 
Members of the c-Src family of kinases have highly conserved amino acid sequences 
and have been suggested to exhibit compensatory effects for one another. SFKs have 
been extensively implicated in a number of cellular signaling pathways associated with 
proliferation, differentiation, adhesion, migration, invasion, survival angiogenesis and 
immune development (Thomas and Brugge, 1997; Biscardi et al., 1999; Frame, 2002 
and Yeatman, 2004). Therefore, it is not surprising that overexpression and/or activation 
of a number of these SFKs have been associated with tumor cell transformation, 
progression and metastasis (Summy and Gallick, 2003). In particular, high c-Src gene 
expression levels and/or kinase activity have been reported in colon carcinoma cells, 
and c-Src kinase activity has been suggested to increase as colon cancer cells progress 
from a pre-malignant state to primary and metastatic phenotypes (Rosen et al., 1986; 
Bolen et al., 1987; Cartwright et al., 1989; Cartwright et al., 1990; Talamonti et al., 
1993; Cartwright et al., 1994; Han et al.1996 and Mao et al., 1997). Furthermore, an 
enhancement in c-Src kinase activity has been proposed to be prognostic for poor 
clinical outcome in patients with colorectal carcinoma (Aligayer et al., 2002). The 
elevation in c-Src levels may be caused by protein deregulation, a rare Y531 mutation at 
the C-terminal end of the c-Src protein, or an upregulation in SRC promoter 
transcription (Irby et al., 1999, Dehm et al., 2001).  
Given that c-Src kinase levels are noticeably elevated in human colon cancer 
cells, studies have been performed to determine if c-Src is an important anti-tumor 
target. Indeed, antisense experiments have shown that suppression of c-Src expression 
decreases tumor growth and downregulates levels of the angiogenic factor vascular 
endothelial growth factor (VEGF) (Staley et al., 1997 and Ellis et al., 1998).  
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Furthermore, various inhibitors of c-Src kinase activity have been shown to reduce 
growth, survival, adhesion, migration, invasion and metastasis of tumor cells and a 
number of these drugs are entering clinical trails (Alvarez et al., 2006 and Summy and 
Gallick, 2006). Therefore, it was particularly exciting to observe that HDIs effectively 
downregulated the expression levels of c-Src as well as the SFKs in HCCLs, a finding 
that further suggests HDIs may be relevant therapeutic agents for the treatment of colon 
tumors expressing high levels of SFK members (Kostyniuk et al., 2003 and Hirsch et 
al., 2006). In addition, butyrate is a well established chemo-preventive colon cancer 
agent that exists at high concentrations in the colon as a result of eating a high fiber diet 
(Roediger, 1980). Currently it is unclear whether inhibition of the SFK members 
contributes to the chemo-preventive nature of butyrate, although it would be interesting 
to decipher if the downregulation in SFK gene expression levels contributes directly to 
the chemo-preventive and anti-tumor effects observed upon HDI exposure to malignant 
cells. 
 
5.4. Histone Deacetylase Inhibitor Post-transcriptional Regulation of p21WAF1  
An alternative and previously unreported form of HDI mediated gene regulation 
was serendipitously discovered as experiments were carried out to investigate the 
effects of HDIs on c-Src expression levels. Interestingly, p21WAF1, the model gene 
used as the definitive example to explain the mechanism of HDIs, was the target. As 
described earlier, the current literature indicates that HDIs directly facilitate p21WAF1 
gene activation through Sp family binding sites located within the proximal region of 
the p21WAF1 promoter. Indeed, it was noted in HepG2 cells that HDIs dramatically 
induced p21WAF1 mRNA and protein levels, however, new protein synthesis was 
required in order for this to occur. Furthermore, HDIs could not stimulate p21WAF1 
promoter activation in HepG2 cells to anywhere near the extent observed in HT29 cells. 
Specifically, a very minor butyrate mediated increase (< 2-fold) in p21WAF1 activity 
was observed, although the more specific HDI, TSA, did not activate the promoter at all 
in HepG2 cells. Such an indirect effect on p21WAF1 gene expression levels had not 
been previously reported to be elicited by HDIs. At first, it was hypothesized that HDIs 
may be incapable of further trans-activating the p21WAF1 promoter in the HepG2 cell 
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line, given that these cells already display high p21WAF1 promoter activity and 
constitutively high p21WAF1 expression levels. However, p21WAF1 promoter activity 
was sufficiently stimulated in HepG2 cells by c-jun, a known super-activator of 
p21WAF1 transcription, to suggest that the p21WAF1 promoter was still theoretically 
open to HDI mediated gene activation. Further investigation into the indirect effect that 
HDIs exert on p21WAF1 expression led to the discovery that HDIs regulate p21WAF1 
gene expression at the post-transcriptional level. Interestingly, butyrate and TSA 
enhanced p21WAF1 mRNA stability 3.1 and 5.4-fold respectively, in HepG2 cells. This 
was the first reported example of HDI post-transcriptional gene regulation, however, 
HDI mediated p21WAF1 mRNA stabilization has only been observed in HepG2 cells 
(Hirsch and Bonham, 2004). Since this time, HDIs have also been shown to reduce the 
mRNA stability of DMT3B and DMT1, indicating that regulation of mRNA stability 
may be a more universal action of HDIs than previously anticipated (Xiong et al., 2005 
and Januchowski et al., 2007).     
5.4.1. The Mechanism of Histone Deacetylase Inhibitor Mediated p21WAF1 
mRNA Stabilization 
 mRNA cis-acting stability elements and the trans-acting RNA binding proteins 
that interact with these sequence determinants have been extensively implicated as 
powerful regulators of mRNA stability. Stability determinants have been elucidated in 
the 5’ UTR, coding region and 3’ UTR of various mRNA species. The p21WAF1 
mRNA contains three cis-acting destabilizing ARE elements and a HuD binding 
element within the first 300 nucleotides of its 3’ UTR that have been reported to control 
mRNA decay (el-Deiry et al., 1993 and Joseph et al., 1998). AUF1 and the ELAV 
family members HuR and HuD are three known trans-acting factors that bind to these 
cis- nucleotide sequences of the 3’ UTR to regulate p21WAF1 mRNA stability (Wang 
et al., 2000; Giles et al., 2003 and Lal et al., 2004). The interaction of AUF1 with the 
p21WAF1 3’ UTR has been shown to decrease mRNA stability, however, HuR 
interaction with the proximal region of the 3’ UTR causes an increase in the mRNA 
stability of p21WAF1 following UVC or prostaglandin A2 exposure (Wang et al., 2000; 
Lal et al., 2004 and Yang et al., 2004). In our hands, the p21WAF1 3’ UTR was also 
shown to possess strong destabilizing potential when it was inserted into a -210WAF1-
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CAT or pCAT3 promoter vector downstream of the vector CAT coding region, when 
used in a HepG2 transient transfection system. Furthermore, the presence of the 
p21WAF1 3’ UTR downstream of the -210WAF1-CAT increased CAT expression 
levels 6.9 and 11.7-fold in transfected HepG2 cells upon TSA and butyrate exposure, 
respectively. Taken together, these observations verified that p21WAF1 mRNA 
stability could be effectively monitored at the level of CAT activity and suggested that a 
cis-acting element within the p21WAF1 3’ UTR may be responsible for mediating basal 
mRNA stability as well as the effect of HDIs on p21WAF1 mRNA stabilization. Given 
that HDIs were previously shown to indirectly stimulate mRNA stability of p21WAF1 
and that this required new protein synthesis, it was proposed that a newly synthesized 
trans-acting RNA binding protein may interact with a cis-acting element in the 3’ UTR 
to facilitate stabilization of the mRNA species. 
5.4.1.1. Histone Deacetylase Inhibitors Mediated Stabilization of p21WAF1 mRNA 
by Two cis-acting Sequences in the p21WAF1 3’ Untranslated Region  
The search for a HDI responsive cis-acting element was initialized by systematic 
deletion of p21WAF1 3’ UTR proximal nucleotides from the -210WAF1-CAT + 
p21WAF1 3’UTR reporter plasmid. Removal of the HuD element and all of the ARE 
sites from the p21WAF1 3’ UTR had neither a considerable effect on the overall basal 
mRNA stability of p21WAF1, nor prevented the increase observed in p21WAF1 
mRNA stability upon exposure to HDIs. Surprisingly, the reporter plasmid lacking the 
HuD site and all three AREs displayed only a very minor increase in basal mRNA 
stability, and an approximate 50% reduction in p21WAF1 mRNA stability in the 
presence of HDIs. However, when just the 250 proximal nucleotides of the 3’ UTR  that 
contain the HuD and ARE elements were inserted into a -210WAF1-CAT + p21WAF1 
3’UTR vector, a massive stabilization in basal p21WAF1 mRNA levels was observed 
and neither TSA nor butyrate were able to boost mRNA stability. Although the most 
influential cis-acting stability elements have been reported to reside within the proximal 
300 nucleotides of the p21WAF1 3’ UTR, these results suggest that the remaining distal 
nucleotides of the p21WAF1 3’ UTR, between nucleotides 840 and 2079, contain a cis-
acting sequence stability determinant responsive to HDIs. This was not the first time 
that sequence downstream from the HuD site and AREs have been suggested to contain 
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additional instability determinants. Other groups have also shown that exclusion of the 
proximal portion of the 3’ UTR still leads to prompt p21WAF1 mRNA decay (Li et al., 
1996 and Giles et al., 2003). In addition to this, EGF has been reported to mediate 
p21WAF1 mRNA stabilization through multiple cis-acting determinants in the distal 
portion of the 3’ UTR (Giles et al., 2003).  
Further deletions were made to search the distal region of the p21WAF1 3’ UTR 
for this cis-acting element. The exclusion of large segments of the 3’ UTR between 
nucleotides 591-1272 identified that nucleotides 1045-1272 of the p21WAF1 3’ UTR 
harbor an instability determinant and that nucleotides 932-1272 contain a cis-acting 
HDI response element. However, when a p21WAF1 3’ UTR fragment (840-1470) 
containing sequence corresponding to these regions was inserted into the -210WAF1-
CAT vector and transiently transfected into HepG2 cells, the inherent instability of the 
p21WAF1 full length 3’ UTR was not recovered and the HDI response was not rescued. 
These results hint at the presence of an additional cis-acting element between 
nucleotides 1272 and 2079 of the p21WAF1 3’ UTR, a region which also mediates 
p21WAF1 basal mRNA stability and HDI induced mRNA stabilization.  
Indeed, further examination of the p21WAF1 3’ UTR identified the presence of 
a second cis-acting element within the extreme 3’ end of the p21WAF1 3’ UTR. 
Located between nucleotides 2000 and 2079, this element controls both basal and HDI 
responsive p21WAF1 mRNA stability. However, in accordance with the previous data, 
a fragment of the p21WAF1 3’ UTR (1468-2079) containing the extreme 3’ nucleotides 
was unable to return basal p21WAF1 mRNA to low stability levels, nor enhance 
p21WAF1 mRNA stability when exposed to HDIs. This suggests that at least two cis-
acting elements are required to mediate mRNA stabilization. An alignment of the 
human, rat and mouse p21WAF1 3’ UTRs revealed high sequence similarity across all 
three species, particularly within the region immediately upstream of the poly (A) site 
hexamer that housed the most distal cis-acting element. Accordingly, the most distal 
element of the p21WAF1 3’ UTR was further characterized by methodically mutating 
the nucleotides between 2001-2079 of the 3’ UTR, five consecutive base pairs at a time. 
Surprisingly, the nine nucleotides immediately upstream of the poly (A) site hexamer 
2071-2079 were found to encompass the distal cis–acting element, as the consecutive 
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mutation of these nucleotides resulted in an increase in p21WAF1 basal mRNA stability 
and a reduction in HDI induced p21WAF1 mRNA stabilization. Given the immediate 
proximity of the p21WAF1 poly (A) site hexamer sequence, it is also interesting to note 
that this distal cis-acting element did not require the context of the p21WAF1 poly (A) 
site hexamer directly neighboring it to mediate an effect on mRNA stabilization.  
Of further mention is the observation that -210WAF1-CAT + p21WAF1 3’UTR 
vectors which generated low basal levels p21WAF1 mRNA stability such as 591-2079 
often directly corresponded to high HDI mediated stabilization of p21WAF1 mRNA 
levels. Furthermore, plasmids, such as -210WAF1-CAT + p21WAF1 3’UTR 591-840 
and -210WAF1-CAT + p21WAF1 3’UTR 591-2000 had a higher basal stabilization 
level, but were releatively defective enhancers of p21WAF1 mRNA stability in the 
presence of HDIs. Therefore, common cis-acting elements that mediate both basal 
p21WAF1 mRNA stability and HDI responsive stabilization may exist and changes in 
trans-factor binding to these cis-acting elements may ultimately dictate the mRNA 
stability of p21WAF1. 
In traversing the entire p21WAF1 3’ UTR, both 5’ and 3’ deletions were made 
to the 3’ UTR, and two distinct fragments were identified as important cis-acting 
regulators of mRNA stability in the absence and presence of HDIs. One cis-acting 
fragment was discovered between nucleotides 932-1272 and the other between 
nucleotides 2071-2079 of the p21WAF1 3’ UTR. Given the previous hypothesis that 
HDIs regulate p21WAF1 mRNA stability via cis-acting elements and the trans-factors 
that bind them, RNA binding assays were completed in order to elucidate changes in 
protein binding after HDI treatment. However, an alteration in trans-factor binding was 
not observed across the length of the entire p21WAF1 3’ UTR when RNA fragments of 
the 3’ UTR corresponding to nucleotides 586-840, 840-1481, and 467-2079 were 
examined. These data, in correlation with earlier transfection data, suggest once again 
that the cis-acting elements found between nucleotides 932-1272 and 2071-2079 are 




5.4.2. The Model of Histone Deacetylase Inhibitor Regulation of p21WAF1 mRNA 
Stability 
 Histone deacetylase inhibitors have been shown to require protein neo-synthesis 
to mediate HDI p21WAF1 mRNA stabilization in HepG2 cells. Two novel cis-acting 
elements within the p21WAF1 3’ UTR have also been identified as critical determinants 
of basal and HDI mediated mRNA stability, however, the presence of neither of these 
elements alone is sufficient to control mRNA decay; this likely requires the entire 
context of p21WAF1 3’ UTR nucleotides 932-2079. Therefore, the secondary and/or 
tertiary structure of the p21WAF1 mRNA may also be an important factor in p21WAF1 
mRNA stabilization. Interestingly, the predicted secondary structure of the p21WAF1 
mRNA as determined by MFOLD, a program that creates thermo-dynamically 
favorable mRNA secondary structures, suggests that the two newly identified cis-acting 
elements 932-1272 and 2071-2079 fold within close proximity to one another (Zuker et 
al., 1999) (http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html) (Figure 5.2.). 
This model proposes that inhibition of HDAC activity leads to an upregulation in the 
expression of an unidentified protein that binds the p21WAF1 mRNA within the 
vicinity of both cis-acting elements. In order for these cis-elements to facilitate an 
interaction, either directly or indirectly, with this unknown protein, nucleotides 932 to 
2079 of the 3’ UTR must be present to ensure correct folding of the mRNA. However, 
proper folding of the mRNA ensures trans-protein binding to p21WAF1 mRNA, which 
may subsequently enhance p21WAF1 mRNA stability by preventing destabilizing 
proteins or alternatively microRNAs (miRNAs) from accessing the 3’ UTR in the 
presence of HDIs. Although, in the absence of HDIs, destabilizing proteins and/or 
miRNAs are able to access the p21WAF1 3’ UTR and lower p21WAF1 basal mRNA 
stability levels are maintained.  
miRNAs are some of the most recently recognized contributors to post-
transcriptional mRNA regulation. These RNAs are approximately 21-26 nucleotides in 
length and have been reported to stimulate mRNA decay via deadenylation, 
endonucleolytic cleavage or repression in protein synthesis following the formation of 
double stranded RNA duplexes by antisense binding with precise 3’ UTR sequences of 






















































































































































































































































































































































































































































































2006 and Wu et al., 2006). The p21WAF1 3’ UTR is a potential target of fourteen 
different miRNAs, as determined by the Sanger miRBase. Interestingly, ten of these 
miRNA target sequences fall between nucleotides 932 and 2079 of the p21WAF1 3’ 
UTR and four of these (miR-525 and miR 526a: target nucleotides 918-934, miR-423: 
1048-1062, miR-409-5p: 1101-1122, miR-505: 1269-1290) reside in close proximity to 
both cis-acting stability determinants when the p21WAF1 mRNA is folded into its 
secondary structure. In addition, nucleotides 1508 to 1529 of the p21WAF1 3’ UTR are 
proposed to interact with the miRNA miR-22, the expression of which has been noted 
in the liver. This may provide a plausible explanation for why HDI induced p21WAF1 
mRNA stabilization has only been observed in the hepatocellular carcinoma HepG2 cell 
line (Rodriguez et al., 2004). Furthermore, HDIs have been shown to downregulate the  
expression levels of miR-22 and 21 other miRNAs, and to upregulate the expression of 
5 additional miRNAs (Scott et al., 2006). Therefore, HDIs may post-transcriptionally 
regulate p21WAF1 mRNA stability at multiple levels, however, the presence of two cis-
acting elements between nucleotides 932-1272 and 2071-2079, as well as the secondary 
structure of the 3’ UTR, appear to be central to mediating p21WAF1 mRNA 
stabilization in HepG2 cells. 
 
5.5. Scope and Significance 
HDIs are complex chemo-therapeutic compounds that selectively regulate the 
expression levels of genes, such as p21WAF1, to ultimately prevent tumor cell growth 
and encourage cellular differentiation and/or apoptosis. However, the molecular 
mechanism of HDI action is not as simplistic as previously proposed. In fact, HDIs are 
capable of controlling multiple facets of gene expression, aside from mediating histone 
hyperacetylation and activating gene transcription. Given that HDIs have quickly 
become realistic therapeutic agents, it is increasingly apparent that the actions of HDIs 
need to be elucidated. Here, two additional modes of HDI gene regulation were 
discussed. HDIs were shown to repress the gene expression levels of c-Src and the SFK 
members in HCCLs, and were documented to enhance p21WAF1 mRNA expression at 









6. CONCLUSIONS AND FUTURE STUDIES 
 HDIs are exciting anti-tumor drugs that have received a great deal of attention in 
clinical trials, due to their ability to specifically stimulate cell cycle arrest, 
differentiation and/or apoptosis of tumor cells, without affecting normal cells (Marks et 
al., 2001; Burgess et al., 2004 and Carey and La Thangue, 2006). SAHA is a HDI from 
the hydroxamic acid family that has rapidly gone through clinical trials and has recently 
become the first HDI accepted as a therapeutic agent for the treatment of a human 
malignancy, CTCL (Garber, 2007 and Marks and Breslow, 2007). The study of HDIs is 
gaining momentum in the clinic and it is almost ensured that additional HDIs will also 
be accepted for clinical use, either as monotherapies or in combination with other 
chemotherapies. Therefore, it is imperative that the molecular actions of HDIs are 
clearly understood. For decades HDIs have been thought to mediate their anti-cancer 
effects through the regulation of gene expression patterns. HDIs have been proposed to 
control gene expression primarily by inhibiting the activity of HDACs and thereby 
shifting the overall balance between HATs and HDACs in the cell to promote histone 
hyperacetylation. Enhanced histone acetylation of lysine residues negates the positive 
charge of the amino terminal histone tails, reducing the electrostatic interaction between 
these histone tails and the negatively charged DNA backbone. Accordingly, this 
hyperacetylated histone state presents an open and accessible DNA backbone for the 
transcriptional machinery to interact with, and thus encourages the activation of gene 
transcription. However, HDIs have been reported to alter the expression levels of only a 
small percentage of genes and are able to both activate and repress genes (Van Lint et 
al., 1996; Mariadason et al., 2000 and Peart et al., 2005). In addition, a number of 
reports have surfaced documenting a requirement for PKC isoforms ε and δ in HDI 
mediated gene regulation (Han et al., 2001 and Kim et al., 2003, Eun et al., 2007 and 
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Kim et al., 2007). Therefore, it has become increasingly apparent that HDIs regulate 
gene expression by additional molecular mechanisms, irrespective of histone 
hyperacetylation.  
 In this thesis, the HDIs butyrate and TSA were shown to suppress the gene 
expression levels of the c-Src proto-oncogene in a dose and time dependent manner in a 
variety of human tumor cell lines including colon, breast and hepatocellular carcinoma 
cells. Specifically, independent of de novo protein synthesis, HDIs directly inhibited 
transcription from both highly disparate SRC promoters, SRC1α and SRC1A, in 
transient transfection assays. In addition to inhibiting c-Src gene expression, HDIs also 
downregulated the expression levels of the SFK members Yes, Fyn, Lyn and Lck in 
HCCLs. Analogous to what was found with c-Src, new protein synthesis was not 
required to facilitate HDI repression of Lyn and Lck mRNA expression. HDIs also 
impaired the activity of the LCK type I, LYN and YES promoters in transient 
transfections.  
A direct comparison of the SFK member promoters revealed that all the 
promoters were TATA-less and contained multiple transcription start sites (Matsuzawa 
et al., 1991; Uchiumi et al., 1992; Leung et al., 1993 and Bonham and Fujita, 1997). As 
Dr. Scott Dehm reported that both the SRC1A and SRC1α promoters were driven by an 
Inr element that required TAF1 to facilitate basal transcription, and further suggested 
that TAF1 may be a necessary factor for HDI mediated repression of the SRC1A 
promoter, TAF1 dependency of the other SFKs was also examined (Dehm et al., 2004). 
Fittingly, the YES and LYN promoters were identified to be TAF1 dependent in nature. 
However, neither HDI mediated downregulation of YES nor LYN required TAF1. 
Results obtained from transient co-transfections with TAF1 and TAF1 mutant AT 
activity expression vectors, also strongly suggested that functional AT activity of TAF1 
was required to stimulate SRC1A, YES and LYN transcription. However to 
conclusively show that TAF1 AT activity is required for basal SFK member 
transcription, in vitro binding assays must be performed to ensure that TAF1 AT 
mutants still retain their ability to interact with the SRC1A Inr element. These 
experiments are currently being carried by Dr. Edith Wang at the University of 
Washington. The mechanism of HDI mediated repression of the SFK members is still 
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unclear, however, work performed by Dr. Scott Dehm and Danielle Ellis cumulatively 
suggests that HDIs decrease c-Src gene expression levels by preventing complete 
synthesis of SRC transcripts. While the mechanism of SRC gene repression is currently 
being studied, it will be of future interest to establish if HDIs mechanistically regulate 
SFK members in a similar manner, and to investigate if HDIs commonly downregulate 
the expression of other genes through the same mechanism.  
 It is known that HDIs exhibit powerful anti-cancer effects and that butyrate is a 
well described naturally produced chemo-preventive agent in the colon. Furthermore, 
overexpression and/or kinase activation of c-Src and the SFK members has been 
frequently described in colorectal carcinoma, and downregulation of c-Src expression 
has been shown to decrease tumor cell growth. This suggests that HDI downregulation 
of SFK members may be of clinical significance; however, it is currently uncertain 
whether HDI mediated inhibition of c-Src and/or SFK gene expression levels directly 
accounts for the anti-tumor or chemo-preventive nature of HDIs. To establish if a 
potential link exists between SFK gene repression and the anti-tumor effects of HDIs, 
such as butyrate in colon cancer, stable cell lines could be created in HT29 cells 
containing the SRC gene fused to a promoter known to be transactivated by HDIs, such 
as p21WAF1. A direct comparison between untransfected and stably transfected HT29 
cells following HDI treatment would offer a perspective on whether the prevention of 
HDI mediated c-Src inhibition alters the ability of HDIs to induce cell cycle arrest, 
differentiation and/or apoptosis in a HCCL.  
 In addition to presenting the finding that HDIs suppress SFK member 
expression levels in HCCLs in a non-conventional manner, this thesis also reports that 
HDIs upregulate p21WAF1 expression at the post-transcriptional level in HepG2 cells. 
HDIs are well known activators of p21WAF1 gene transcription, and p21WAF1 
expression has been documented to be a prerequisite for HDI stimulated cell cycle 
arrest (Nakano et al., 1997; Sowa et al., 1997; Archer et al., 1998 and Huang et al., 
2000). However, while HDIs were shown to be incapable of trans-activating the 
p21WAF1 promoter in HepG2 cells, they remained proficient at upregulating 
p21WAF1 mRNA and protein levels. In a unique manner, HDIs indirectly enhanced 
p21WAF1 expression levels by stabilizing p21WAF1 mRNA levels in HepG2 cells.  
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p21WAF1 mRNA stability has been reported to be regulated by cis –acting 
stability determinants in the 3’ UTR and the trans-acting factors that bind them. In 
particular, a HuD site and three AREs are important cis-acting elements within the 
proximal region of the p21WAF1 3’ UTR that have been extensively documented to 
interact with trans-associated factors and elicit an effect on the mRNA stabilization of 
p21WAF1. As presented in this thesis, two novel cis-acting elements in the 3’ UTR of 
the p21WAF1 mRNA were also identified as critical regulators of basal and HDI 
induced p21WAF1 mRNA stability. These cis-acting fragments of the p21WAF1 
mRNA were initially localized to nucleotides 932-1272 and 2000-2079 of the 3’ UTR. 
Further characterization narrowed down a region between nucleotides 2071 to 2079 of 
the p21WAF1 3’ UTR as the distal cis-acting element. Although both of these cis-acting 
elements, 932-1272 and 2071-2079, were independent critical mediators of p21WAF1 
stability, neither of these elements alone was sufficient to induce p21WAF1 mRNA 
stabilization in the presence of HDIs. Furthermore, a change in trans-binding factors 
was not detected at individual cis-acting elements before and after HDI exposure, 
further suggesting that these cis-acting elements are not mutually exclusive. 
Investigation of the predicted p21WAF1 mRNA secondary structure identified that both 
cis-acting elements reside in close proximity. Therefore, the cis-acting elements 
between 932-1272 and 2071-2079, as well as proper folding of the p21WAF1 mRNA, 
may collaboratively mediate p21WAF1 mRNA stabilization in the absence and 
presence of HDIs in HepG2 cells.  
To investigate the validity of this hypothesis, RNA binding assays should be 
performed with fragments of the p21WAF1 mRNA containing the entire 932-2079 
stretch of 3’ UTR ribonucleotides. This length of the 3’ UTR sequence should allow 
proper folding of the RNA and provide a theoretically receptive template to observe 
changes in trans-factor binding in the absence and presence of HDIs. However, the in 
vitro synthesis of a RNA template greater than 500 nucleotides is quite difficult to 
generate. Also, it would be of benefit to identify the precise nucleotides of the 932-1272 
cis-acting element responsible for p21WAF1 mRNA stability in HepG2 cells. 
Sequential mutation of the bases between 932 and 1272 of the 3’ UTR could serve as a 
method for elucidation, just as the 2071-2079 cis-acting sequence was detected. In 
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addition, given that the p21WAF1 3’ UTR possesses a large number of potential 
miRNA target sequences it would also be interesting to determine whether mutation of 
any of these sequences affects p21WAF1 mRNA stability or prevents HDI induced 
p21WAF1 mRNA stabilization. Furthermore, as HDIs have only been observed to 
stabilize p21WAF1 mRNA levels in HepG2 cells, it is important to determine whether 
this effect is cell specific or more universal. To start, liver cell lines and other cell lines 
which express relatively high levels of p21WAF1 could be investigated. 
The field of HDI research has undergone a great deal of evolution over the past 
ten years and will continue to develop with an improved perspective on the mechanisms 
of HDI action. Dogmatically, HDIs have been thought to mediate their anti-tumor 
effects by inducing changes in the pattern of gene expression by causing histone 
hyperacetylation and transcriptional activation. However, the observations presented in 
this thesis highlight that HDIs are more complex chemo-therapeutic compounds than 
previously anticipated and that they selectively control multiple facets of gene 
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